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Preface 
The present thesis is the result of a PhD project carried out from June 2013 to October 2016 under 
the supervision of Associate professor Susanne Brix Pedersen from the Technical University of 
Denmark, Kim Henriksen and Morten Asser Karsdal from Nordic Bioscience A/S and Professor 
Henning Beck-Nielsen from Odense University Hospital.  
 
The work leading up to this PhD thesis can be divided into three parts; clinical study-set up, 
data collection, and data analysis. I was responsible for the study set-up, protocol approval, along 
with hiring and training of all staff involved in the study. This initial step was followed by 
enrolment of 2,103 elderly Danish women within 16 months, meaning 4-6 daily visits in their 
own home. Alongside data collection the application for register-linkage was approved, and after 
data cleaning the longitudinal data analysis could be initiated.  
 
The Technical University of Denmark (DTU) has funded the PhD in collaboration with the 
Danish Research Foundation (Den Danske Forskningsfond).  
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Abstract 
The world’s population is ageing. With an increased life expectancy across the globe, more 
people will live into old age. Women outlive men averagely by four years, warranting an 
increased focus on healthy ageing in women. The demographic shift resulting in an increased 
fraction of elder individuals has given rise to concerns about whether the extra life years added 
are spent in good health or with disease conditions resulting in high impacts on health care 
systems, socioeconomic relations and on the individual level. The World Health Organization 
predicts the burden of non-communicable diseases such as type 2 diabetes mellitus (T2DM) and 
cardiovascular diseases (CVD) to account for more than three-fourths of the total disease burden 
in middle and high-income countries before year 2030. Despite the identification of many risk 
factors for non-communicable diseases within the last decades, these risk factors remain the 
leading contributors to decreased healthy life expectancy in late-life, necessitating an increased 
focus on risk factors and non-communicable diseases specifically in elderly.  
The studies constituting the foundation of this thesis aim to explore hypotheses focusing 
on known and novel risk factors and their relation to ageing, disease, and mortality in elderly 
Danish women. The studies are epidemiological in their character and based on data from the 
Prospective Epidemiological Risk Factor (PERF) study, a community-based cohort study on 
5,855 elderly Danish women enrolled in year 2000 with a follow-up examination of 2,103 of the 
women in year 2013 (study I).   
Data from the PERF cohort was used to evaluate whether the metabolic syndrome (MetS), 
a cluster definition of cardio-metabolic risk factors, is a valid and useful tool for prediction of 
future T2DM and CVD specifically in elderly women (study II). The study described how women 
fulfilling the current MetS criteria set by the International Diabetes Federation revealed an 
increased risk of future T2DM or CVD diagnosis. However, subjects who did not fulfil the 
definition criteria for MetS, but presented one or more of the MetS risk factors were likewise at 
increased risk. A further subdivision of the control group showed to increase the risk of T2DM 
to 6.3-fold (from 3.6-fold) and 1.7-fold for CVD (from 1.3-fold) for MetS-defined women when 
compared specifically to a control group solely including women with no MetS risk factors. 
Based on these risk estimates, it was concluded that employment of the MetS in elderly women 
should be focused only as a tool for identifying subjects with metabolic high-risk profiles. 
Further, the sum of risk factors was proposed to be equally considered, as elderly women holding 
only a few MetS risk factors, were also at increased risk of T2DM and CVD.  
ix 
The cohort was further used to explore how weight and weight change in late-life affected 
the risk of hyperglycaemia in elderly women (study III). The study presented a 2-fold increased 
risk of hyperglycaemia in overweight and obese elderly women compared to normalweight 
women after 13 years. In women who gained weight, the risk of hyperglycaemia in late-life was 
most profound for overweight and obese women resulting in a 2.7-fold increased risk of 
hyperglycaemia in overweight weight gainers and a 3.2-fold increased risk in obese weight 
gainers compared to normalweight weight-stable women. Contrarily, overweight and obese 
women who lost weight during the follow-up period decreased their risk of hyperglycaemia to a 
level comparable to women who stayed normalweight during the follow-up period.  
The thesis rounds off by introducing a novel risk factor; matrix metalloproteinase (MMP)-
mediated degradation of collagen type I (C1M) that was used in the description of mortality in 
elderly women (study IV). The study showed how increased MMP-mediated tissue degradation, 
as an independent risk factor, was associated with a 2-fold increase in all-cause mortality within 
three years of follow-up and a 1.5-fold increase in all-cause mortality up to nine years prior to 
death.  
Overall, these studies contribute to the knowledge specifically demanded on women’s 
health in late-life by describing associations between known risk factors of the MetS and 
subsequent risk of T2DM and CVD. Further, by highlighting associations between 
hyperglycaemia, weight and weight change in late-life, and lastly by the evaluation of collagen 
type I degradation possibly being an important predisposition for increased mortality in elderly 
women. 
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Dansk Resumé 
Verdens befolkning bliver ældre. Den globale forøgelse i middellevetid gør, at flere mennesker 
vil leve til de bliver gamle. Kvinder lever i gennemsnit fire år længere end mænd, hvorfor et øget 
fokus på netop kvinders aldring er specielt berettiget. Ændringen i den demografiske fordeling, 
med en større andel af ældre, har ledt til bekymring om, hvorvidt de ekstra leveår vil være 
sygdomsfrie eller om aldring vil være ledsaget af sygdom. Hvis de ekstra leveår resulterer i en 
øget sygdomsbyrde, vil det have store konsekvenser for sundhedssystemer og socioøkonomiske 
forhold, men også specifikt for den ældre borger. Verdenssundhedsorganisationen, WHO, 
estimerer, at andelen af ikke-smitsomme livsstilssygdomme såsom type 2 diabetes mellitus 
(T2DM) og hjertekarsygdomme (CVD) vil udgøre tre fjerdedele af den totale sygdomsbyrde i 
middel- og højindkomstlande inden år 2030. På trods af omfattende kortlægning af mange af de 
risikofaktorer, som har vist sig at lede til livsstilssygdomme, er disse fortsat medvirkende til at 
aldring ikke er en sygdomsfri proces. Dette nødvendiggør et øget fokus på risikofaktorer og 
livsstilssygdomme specielt hos ældre mennesker.  
Studierne, der udgør grundlaget for denne afhandling, har til formål at undersøge 
risikofaktorer og deres relation til aldring, sygdom og dødelighed i ældre danske kvinder. 
Arbejdet udgøres af epidemiologiske studier og er baseret på data fra det Prospektive 
Epidemiologiske Risikofaktor (PERF) studie, et kohortestudie af 5855 ældre danske kvinder, 
inkluderet i år 2000, med et opfølgende besøg for 2103 af kvinderne i år 2014 (studie I).  
Data fra PERF kohorten er i denne afhandling blevet brugt til at undersøge, om det 
metaboliske syndrom (MetS), en definition, der bruges til at beskrive de største kardio-
metaboliske risikofaktorer, er et brugbart værktøj til at forudsige risikoen for T2DM og CVD i 
ældre kvinder (studie II). Studiet beskriver, hvordan de kvinder, der opfylder det nuværende 
kriterie for MetS, som er fastsat af den Internationale Diabetes Føderation, viste sig at have en 
øget risiko for fremtidig T2DM eller CVD. Det viste sig dog også, at kvinder, der ikke opfyldte 
kriterierne for MetS, men som stadig havde en eller flere af de metaboliske risikofaktorer, 
ligeledes viste sig at have en øget risiko for T2DM og CVD. En yderligere opdeling af 
kontrolgruppen viste, at risikoen for T2DM hos kvinder med MetS blev øget til 6,3 fold (fra 3,6 
fold) og 1,7 fold for CVD (fra 1,3 fold) sammenlignet med kontrolgruppen, hvis denne gruppe 
udelukkende bestod af kvinder uden nogle MetS risikofaktorer. Baseret på disse fund, blev det 
konkluderet, at brugen af MetS udelukkende bør bruges som et redskab til at identificere kvinder 
med metaboliske højrisikoprofiler. Ydermere blev det konkluderet, at summen af risikofaktorer 
xi 
ligeledes skulle vurderes hos kvinder, der ikke falder ind under det nuværende MetS-kriterie, 
men som stadig har én eller flere risikofaktorer for MetS, da disse kvinder ligeledes blev 
identificeret til at være i øget risiko for T2DM og CVD.  
Kohorten blev yderligere anvendt til at undersøge, hvorledes vægt og vægtændring sent i 
livet påvirkede risikoen for hyperglykæmi hos ældre kvinder (studie III). Studiet viste en 2-fold 
forøget risiko for hyperglykæmi hos overvægtige og svært overvægtige ældre kvinder 
sammenlignet med normalvægtige kvinder ved opfølgning efter 13 år. Risikoen for hyperglykæmi 
sent i livet var størst for overvægtige og svært overvægtige ældre kvinder, som havde taget på i 
opfølgningsperioden. Vægtøgning resulterede i en 2.7-fold øget risiko for hyperglykæmi hos 
overvægtige kvinder og en 3,2-fold øget risiko hos svært overvægtige kvinder sammenlignet med 
normalvægtige kvinder med stabil vægt. Modsat fandt vi, at overvægtige og svært overvægtige 
kvinder, der tabte sig i perioden mellem første og andet besøg, havde en nedsat risiko for 
hyperglykæmi, svarende til niveauet set i kvinder, der forblev normalvægtige i 
opfølgningsperioden.  
Afhandlingen afrundes med introduktionen af en hidtil ukendt risikofaktor, matrix-
metalloproteinase (MMP)-medieret nedbrydning af kollagen type I (C1M), i beskrivelsen af 
dødelighed hos ældre kvinder (studie IV). Studiet viste, hvordan øget MMP-medieret 
vævsnedbrydning, som en uafhængig risikofaktor, var forbundet med en fordobling i risiko for 
død inden for tre års opfølgning og en 1,5 fold stigning i risiko for død op til ni år før døden 
indtraf.  
Samlet set bidrager studierne i denne afhandling til at afdække kravet om specifik viden inden 
for ældre kvinders sundhed ved at beskrive associationer mellem kendte risikofaktorer for MetS 
og deraf øget risiko for T2DM og CVD. Endvidere fremhæves risikoen for hyperglykæmi sent i 
livet som et resultat af vægt og vægtændring, og endelig ved evalueringen af MMP-medieret 
nedbrydning af kollagen type I som en mulig risikofaktor for øget dødelighed hos ældre kvinder. 
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1 PROLOGUE 
Every generation grows older than the previous, and this increased probability of survival 
into old age is one of humanity’s major achievements in global health (1). It is anticipated, 
that the worldwide population will encompass more old people than children before the 
year 2030 and this demographic shift is majorly a result of decreasing fertility, advances in 
medicine, and socioeconomic development (2). As both the length of life but also the 
proportion of elderly people will increase, key concerns arise. Will the increased life span 
lead to increased longevity and a longer life in good health, or be accompanied by illness, 
frailty, and increased dependency? The health of the elderly population and the term 
‘healthy ageing’, is consequently of greater interest than ever. 
Knowledge of disease and health is largely built upon population-based studies of the 
distribution and determinants of disease outcomes (3). The scientific discipline of 
epidemiology is used to assess if obtained data is consistent with current scientific 
knowledge and hypotheses, and to describe the natural history of diseases (3,4). The studies 
in this thesis are based on observational non-experimental epidemiology assessing risk 
factors associated with distortion of healthy ageing in elderly women. More specifically, the 
focus of this thesis is both on well-known and novel risk factors associated with increased 
risk of type 2 diabetes mellitus (T2DM), cardiovascular diseases (CVD) and mortality 
analysed in a cohort of elderly Danish women. The women were enrolled in the Prospective 
Epidemiological Risk Factor (PERF) study in year 2000 with a follow-up visit in year 2013.   
  
4 
2 INTRODUCTION 
The world’s population aged ³65 years is estimated to increase from currently 524 million 
to 1.5 billion by year 2050 (5,6). The rising life expectancy within the older population is 
increasing the number and proportion of people at old ages, which has resulted in a global 
population where 12% are ³65 years (7). If focusing specifically on the industrialized parts 
of the world, Europe has the largest percentage of elderly people, with 24% of the total 
population being ³65 years (8).  Further, within the industrialized countries, the oldest old, 
which account people aged ≥85 years, constitute 12% of the elderly population and they are 
now the fastest growing segment of the population. On a global scale, the oldest old are 
projected to increase by 351% before year 2050, followed by the ³65 segment increasing 188% 
between year 2010 and 2050. In comparison, the population aged <65 will merely increase 
with 22% (5,9). This demographic shift has given rise to concerns regarding the decrease in 
eligible workforces, demands for later retirement age, and costs of poor health of the elderly 
population (7). 
Traditionally, a decline in mortality reflected an equal decline in morbidity. However, 
in the industrialized parts of the world, where mortality rates have been continuously 
decreasing throughout the decades, the advances in life expectancy are largely caused by 
mortality reductions from chronic diseases at older age. This has raised doubts on whether 
a longer life also means better health for the surviving elderly population (10). The study of 
ageing as a discipline thus largely focuses on chronic diseases in late-life, and how the 
population of study is affected as a result of modifiable risk factors, e.g. obesity, physical 
inactivity, diet, smoking etc. together with non-modifiable risk factors, e.g. gender, 
ethnicity, and family predisposition (11). Strategies applied to prevent distortion of a healthy 
ageing process largely focuses on modifiable risk factors, which will also be the focus of the 
following parts of this introduction. 
2.1 Ageing and Disease 
The shift in ageing patterns has resulted in a change in the leading causes of disease and 
death. Non-communicable diseases, such as CVD, cancer, Alzheimer’s disease and T2DM, 
have largely overtaken infectious and parasitic diseases as the leading health threats. The 
Global Burden of Disease project estimates that among the elderly population, non-
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communicable diseases already account for more than 87% of the disease burden 
worldwide, with CVD resulting in 46% of all deaths globally in elder women (11,12). Women 
specifically, as they live longer than men, represent a growing proportion of all older people. 
Global estimates from the World Health Organization (WHO) report 55% of all adults aged 
60 years or older to be women, a proportion that rises to 58% at the age of 7o and above (13). 
Much of the burden of disease that women face could be prevented by addressing the six 
most critical risk factors for chronic disease: Hypertension, hyperglycaemia, dyslipidaemia, 
overweight/obesity, physical inactivity, and tobacco use. These modifiable risk factors 
account for 63% of all deaths from CVD and T2DM and over 75% of all deaths from 
ischaemic heart disease in women (14,15). WHO has on this note demanded longitudinal 
studies, which incorporate measures specifically focusing on the health of the elderly 
population in order to understand and prevent non-communicable age-related diseases, and 
to focus existing knowledge about prevention and treatment specifically in this fast growing 
segment of the population (5).  
2.2 Obesity 
The increase in life expectancy together with the increased prevalence and severity of 
obesity signifies a double disease burden for the future (16). Obesity, in particular abdominal 
obesity, is a strong risk factor for the development of cardiovascular outcomes such as 
elevated blood pressure, low levels of high-density lipoprotein (HDL)-cholesterol, elevated 
triglycerides and disturbed glucose metabolism (17). This makes abdominal obesity a well-
known and independent risk factor for both T2DM (18) and CVD (19,20). Obesity is therefore 
often referred to as the predecessor of other risk factors known to result in non-
communicable diseases (21).  
2.2.1 Obesity prevalence 
Overweight, defined as a body mass index (BMI) of 25-29.9kg/m2, is by the WHO estimated 
to affect 1.3 billion people and a further 600 million people are classified as obese with a BMI 
≥30kg/m2 (21). The prevalence of overweight and obesity in the adult population is predicted 
to rise from the 33% reported in 2005 to 57.8% in 2030 if the current trends in obesity 
development continue (22).  
Focusing specifically on obesity prevalence in the elderly age group, the reported 
prevalence vary. Data from the Behavioural Risk Factor Surveillance System in the US 
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provided BMI data in 2003 on 52,921 elderly individuals aged 65 years and older. They 
identified 20.3% elderly classified as obese. In the 65-74-year age group, 25% of the elderly 
had a BMI of ≥30 kg/m2, which was significantly higher than the 16.6% in the 75-84-year age 
group. The prevalence of obesity in the ≥85-year age group was 9.9% (23). Another US study, 
the follow-up of the National Health and Nutrition Examination Survey (NHANES II), 
conducted in 2007–2010, indicated that more than one-third of older adults, aged ≥65 years, 
were obese (24,25). The prevalence of obesity was greater in subjects aged 65–74 (40.8 %), 
compared to those aged ≥75 years (27.8 %) in both men and women (24,25). European data 
likewise indicate that the prevalence of obesity in the elderly age group will continue to 
increase, however, varying magnitudes are reported in different European studies. The 
Scottish Health Survey showed that between 1998 and 2008, the overall prevalence of 
obesity showed little increase overall, however, the BMI continued to rise between age 60 
and 70, especially in women (26). In the French Obésité Epidémiologie survey with data 
from 1997 to 2006 an obesity prevalence of 17.9% was reported for the elderly aged ≥65 years. 
In even older ages, the prevalence decreased from 19.5% in the 65-69-year-olds to 13.2% in 
the oldest old aged ≥80 years (27). Further, the European Prospective Investigation on 
Cancer and Nutrition with participants aged 40-65 years in 1996 predicted a prevalence of 
obesity of 30% in 2015 in a linear prediction model and 20% in a levelling off model (28). 
Other longitudinal cohort studies equally demonstrated body weight and BMI values 
decreasing slightly in older adults (29–31). The proposed levelling prediction model has 
recently been confirmed in the pan-European survey of obesity conducted by Gallus et al. 
reporting a European prevalence of 18% obese elderly aged ≥65 years (32).  
In Denmark, 40% of all women are overweight or obese according to the Danish 
National Health profile from 2013. In women aged ³65 years 49.8% are overweight or obese 
(33).  
2.2.2 Obesity and ageing 
Ageing is associated with central changes in metabolism and body composition resulting in 
a decrease in fat-free mass of up to 40%, in return for an increasing fat mass (34–36). The 
body fat distribution also changes with age, with visceral abdominal fat increase and 
subcutaneous abdominal fat decrease (37–39). After the age of 70, both fat-free mass and fat 
mass decrease in parallel with fat increasingly being deposited in skeletal muscle and in the 
liver resulting in an increased insulin resistance. This is more evident in women than in men 
(36).  
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The change in fat distribution resulting in central and visceral obesity have been 
shown to be more pro-inflammatory than global obesity and the inflammatory burden is 
therefore larger in obese elderly compared to normalweight elderly (40). The presence of 
inflammatory markers such as tumour necrosis factor alfa (TNF-α) and interleukin-6 (IL-6) 
are known to have catabolic effects on muscle mass, which are involved in the development 
of sarcopenia and a decrease in fat free mass (34,35,41,42). This has given rise to various 
studies within sarcopenic obesity studying the loss of muscle mass in return for increased 
body fat (42–44). The low-grade inflammatory state described in ageing is, besides the 
association with decreased lean body mass, also reflected in reduced immune function, 
cognitive decline, and insulin resistance (45). 
Obesity and ageing are, besides changes in body composition, also characterized by 
endocrine changes (41). These changes include alterations in gonadal steroids and thyroid 
hormones comprising a decrease in growth hormone and testosterone, following an 
impaired sensitivity to thyroid hormone and leptin, altering satiety (35,36). Further, the 
changes in hormones that occur with normal ageing are amplified in the presence of 
abdominal obesity and insulin resistance (34).  
2.2.3 Obesity pathophysiology 
Obesity pathophysiology and the implications on healthy ageing starts with an 
understanding of adipose tissue biology (Figure 1).  
Adipose tissue modulates the metabolism by releasing free fatty acids (FFA), 
hormones and pro-inflammatory cytokines (46–48) and in obese subjects, the production 
of many of these mediators are increased. The abdominal adipose tissue produces numerous 
inflammatory cytokines such as IL-6 and TNF-α, while the production of adiponectin, the 
anti-inflammatory adipokine, is diminished (49,50). Adiponectin has been found to protect 
from insulin resistance and CVD (51), whereas FFA and pro-inflammatory mediators 
promote the development of insulin resistance (46,52,53).  
2.2.4 Insulin resistance and obesity 
The ability of insulin to regulate circulating FFA and glucose uptake, by mediating disposal 
into skeletal muscle, inhibiting gluconeogenesis in the liver (54), and its ability to suppress 
lipolysis in the adipose tissue, is generally referred to as insulin sensitivity (55). In healthy 
subjects, there is a feedback loop between the insulin sensitive tissues and the insulin 
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producing beta-cells in the pancreas, as they increase insulin supply in response to demand 
by the muscles, liver, and adipose tissue (56). A failure of this feedback loop underlies the 
development of diabetes as it will result in a deviating glucose tolerance (57). The result of 
this beta-cell dysfunction and inadequate insulin secretion is an increase in fasting glucose 
levels owing to incomplete suppression of hepatic glucose production and decreased 
efficacy of liver and muscle glucose uptake. The elevated FFA levels is a second metabolic 
component contributing to the gradual loss of beta-cell function (57). This dual effect is 
referred to a glucolipotoxicity and links obesity with insulin resistance and T2DM. This leads 
to a lower glucose uptake in skeletal muscle, increased levels of FFA, less inhibition of 
hepatic glucose production, and subsequent hyperglycaemia (55). 
 
 
Figure 1 Ageing, obesity and their associations to insulin resistance and metabolic outcomes. 
 
The release of FFA is a critical factor in modulating insulin sensitivity and increased FFA 
levels are observed in both obese and T2DM subjects and are associated with the insulin 
resistance observed in both conditions (58,59). Because insulin regulates both the FFA 
released from adipose tissue triglycerides and the FFA released as a result of lipoproteins 
undergoing lipolysis, the development of insulin resistance leads to an enhancement of both 
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FFA release and impaired lipoprotein clearance (60). This consequently leads to lipid 
deposition and lipotoxicity in ectopic sites, such as liver, skeletal muscle and pancreatic 
islets (61). Alongside this knowledge of the negative effects of excess lipids, the overflow 
hypothesis has been proposed by R.H. Unger in 2003 (62) describing how an excess energy 
intake causes overloading of adipose tissue. The capacity to store FFA in adipocytes is 
exceeded, and lipids accumulate in ectopic sites, which thereby causes insulin resistance.  
Insulin sensitivity fluctuates during the life cycle with an increase in insulin resistance 
observed with ageing (63). An explanation for this increased resistance in ageing is the 
impaired mitochondrial function and reduced cellular energy supply  believed to result from 
defects in mitochondrial oxidative phosphorylation, as this was found to be related to lipid 
accumulation in the muscle of elderly patients (64,65). 
2.3 Metabolic Consequences of Insulin Resistance 
It is now generally accepted, that insulin resistance plays an important role in the clustering 
of risk factors associated with CVD and diabetic outcomes (66). The ageing-associated 
change in body composition further promotes this insulin resistance and in the following 
sections, some of the most common metabolic risk factors related to an increase in fat mass 
are elucidated.  
2.3.1 Hyperglycaemia 
Most obese, insulin resistant subjects will never develop hyperglycaemia as the beta-cells 
increase the release of insulin sufficiently to overcome the decreased efficiency of insulin 
action, which will thereby maintain normal glucose levels (56,67). In order for obesity and 
insulin resistance to be linked with hyperglycaemia and T2DM, the insulin-producing beta-
cells must be unable to compensate for the decreased insulin sensitivity (68). Most often the 
ability of the beta-cells to produce enough insulin subsequently declines over time in insulin 
resistant subjects (69). When beta-cell dysfunction is a reality, impaired glucose tolerance 
(IGT), impaired fasting glucose (IFG), and finally T2DM result (57). The transition from the 
two asymptomatic pre-diabetic stages, IGT and IFG, to full T2DM development may take 
many years (70).  
The 2-hour plasma glucose concentration after an oral glucose tolerance test (OGTT) 
was recommended by WHO in 1980 (71) to determine IGT. The American Diabetes 
Association (ADA) introduced IFG in 1997 and WHO defined the term in 1999 with the 
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purpose of classifying subjects who had fasting glucose levels between normal and diabetic 
levels (72,73). The lower limit for this classification was decreased from 6.1mmol/L to 
5.6mmol/L by ADA in 2004 (74). The two types of hyperglycaemia are proposed to reflect 
different types of insulin resistance (75–78). 
The prevalence of hyperglycaemia is increasing and projected to affect 470 million 
people by 2030 (79). Estimates indicate that up to 70% with pre-diabetic characteristics 
eventually will develop diabetes (80,81). The meta-analysis conducted by Levitan et al. in 
2004 (82) assessed the risk associated with blood glucose levels in the non- and pre-diabetic 
range on CVD outcome. They found an increased risk associated with blood glucose levels 
in the pre-diabetic range, however, they do highlight how the different methods of glucose 
assessment may have contributed to the heterogeneous results in the published studies. 
This uncertainty is equally highlighted by Nathan et al. (70) questioning whether the pre-
diabetic states convey the risk or if it can be attributed to the development of diabetes 
during follow-up. 
It is not known whether elevated blood glucose levels in the elderly are associated 
with the same risk as in middle-aged subjects and whether the different types of 
hyperglycaemia (IGT or IFG) are equally harmful at all ages (83).  
2.3.2 Hypertension 
Hypertension is very common in the older population, affecting up to 50% of all persons 
aged ≥65 years (36). The hemodynamic effects of insulin serve under normal conditions as 
a powerful vasodilator (84). When insulin resistance is present, the vasodilatory effect of 
insulin is lost, which will lead to endothelial dysfunction following an increased risk of 
hypertension (85–87). However, the association has been found to be less strong after 
adjustment for body mass index (88,89) suggesting other factors directly related to adipose 
tissue plays an additional role (90). It is well known that the incidence of CVD is increased 
in hypertensive patients, even when the hypertensive state is treated (91,92).  
2.3.3 Dyslipidaemia 
The increased flux of FFA to the liver in obese individuals increases hepatic production of 
triglyceride-rich very low density lipoprotein (VLDL)-particles (60). Furthermore, decreased 
levels of phospholipids, which are necessary for HDL-particles to form, result in reduced 
breakdown of the VLDL-particles. An elevated level of VLDL-particles in the plasma thereby 
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result in an increased concentration of triglycerides in the HDL-particle and a decreased 
cholesterol concentration (93). The triglyceride-rich HDL-particles are small and dense and 
therefore quickly cleared by the liver, which is manifested in lowered HDL-cholesterol levels 
(94). Hypertriglyceridemia and HDL-cholesterol levels are the main lipid disturbances 
describing the metabolic syndrome (MetS).  
A substantial proportion of older adults are dyslipidaemic, including the oldest old, 
aged 80 years and older (95). In women, the increase in LDL-cholesterol and decrease in 
HDL-cholesterol levels seen during menopause, has been speculated to be the main reason 
for the increase in CVD incidence reported in women after menopause (96). It has been 
established that in older adults, dyslipidemia often coexists with obesity, T2DM, and 
hypertension (95).  
2.4 Metabolic Syndrome and Metabolic Diseases 
In 1988 G.M. Reaven suggested the existence of a syndrome, syndrome X, describing the co-
occurrence of a number of metabolic disorders such as hypertension, hypertriglyceridemia, 
low HDL-cholesterol, and hyperglycaemia (97). Insulin resistance was suggested as the link 
connecting the occurrence of these abnormalities, thus giving rise to the name, the insulin 
resistance syndrome. Further knowledge on the disproportionate flux of FFA from excess 
adipose tissue, and how this was believed to be a central component in the development of 
the syndrome, has later led to the term, the metabolic syndrome. The overall goal of applying 
a definition was to identify individuals at greater risk of developing T2DM and CVD.  
2.4.1 Definitions of the metabolic syndrome 
Several definitions and explanations of the syndrome have emerged based on the outcome 
of interest (T2DM, CVD or both). The MetS definition proposed by the WHO in 1998 was 
developed as a tool to be applied to both diabetic and non-diabetic subjects as it formed 
part of a consultation report on the definition, diagnosis and classification of diabetes 
mellitus and its complications (98). The WHO definition included a pre-requisite for either 
glucose intolerance (defined as either IFG, IGT or diabetes) or insulin resistance (measured 
using the hyperinsulinemic-euglycaemic clamp technique). The WHO definition was the 
first guideline which enabled comparability between studies. The WHO definition 
technically required subjects to undergo an OGTT, clamp studies and measurement of 
microalbuminuria in supplement to at least two of the metabolic risk factors; obesity, 
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hypertension, and dyslipidaemia. In an epidemiological context usually including large scale 
data, the OGTT and insulin resistance measurement was impossible, and not commonly 
performed. Most studies employed the surrogate calculation of insulin sensitivity using the 
homeostatic model assessment (HOMA-IR) instead to quantify assessment of the 
contributions of insulin resistance to the fasting hyperglycaemia (99).  
In 1999 the European Group of the Study of Insulin Resistance (EGIR) followed 
WHO with a definition only to be applied to non-diabetics. The EGIR definition thereby 
acknowledged the lack of rationale associated with identifying those with the MetS who 
already had T2DM, in relation to risk prediction as the main goal (100). In addition, as a 
result of the difficulties in comparing studies using the clamp technique to measure insulin 
resistance, the EGIR version recommended that insulin resistance was defined as the top 
quartile of fasting insulin values in the non-diabetic population of study. A standardized 
cut-off point for insulin measurement was not believed to be possible, due to the different 
standards for assaying insulin. Obesity was defined by waist circumference, new cut-off 
values were proposed for hypertension and dyslipidaemia, and microalbuminuria was 
disregarded (100). 
A more recent definition of the syndrome was presented in the Summary of the Third 
Report of the U.S. National Cholesterol Education Program (NCEP) Adult Treatment Panel 
III (ATP III) (101). The NCEP-ATP III definition of the MetS was designed to be applied in 
clinical practice. A simplified structure of the definition included diagnosis with any three 
of the five metabolic risk factors, and no requirement for an OGTT or insulin resistance 
measurement was included, reflecting the more clinically focused proposal.  
Finally, the latest MetS definition was proposed by the International Diabetes 
Federation (IDF) in April 2005 focusing on large waist circumference as the entrance criteria 
for a further definition of the syndrome (102).  The IDF proposed a worldwide definition, 
with ethnicity-specific cut-points for overweight. The components were identical to those 
used by the NCEP-ATPIII, but with large waist circumference as a prerequisite component. 
The WHO, EGIR, NCEP-ATPIII and IDF definitions are summarized in Table 1. 
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Table 1 Four definitions of the metabolic syndrome in Caucasian women (98,100–102). 
  
WHO criteria 
World Health Organization 
1998 
EGIR criteria 
European Group of the Study of                          
Insulin Resistance 
1999 
 
Impaired regulation of glucose 
identified by either: 
- T2DM 
- IFG (fasting glucose ≥6.1mmol/L) 
- IGT (OGTT) 
- Lowest quartile of glucose uptake using the 
hyperinsulinemic-euglycaemic clamp method 
 
Plus any two of the following risk factors: 
- Blood pressure ≥140/90mmHg or treatment 
- Triglycerides ≥1.7mmol/L or treatment 
- HDL-cholesterol <1.0mmol/L or treatment 
- BMI ³30kg/m2 or waist/hip ratio >0.85 
- Albumin ≥20µg/min or albumin/creatinine 
ratio ≥30mg/g 
 
 
Fasting hyperinsulinemia  
identified by: 
- Highest quartile of the non-diabetic 
population under study 
 
 
 
 
Plus two or more of the following risk factors: 
- Blood pressure ≥140/90mmHg or treatment 
- Triglycerides ≥2.0mmol/L or treatment 
- HDL-cholesterol <1.0mmol/L or treatment 
- Waist circumference ≥80cm  
- IFG (fasting glucose ≥6.1mmol/L) 
NCEP-ATP III 
The National Cholesterol Education Program’s Adult 
Treatment Panel III Report 
2003 
IDF criteria 
International Diabetes Federation 
2005 
 
Any three of the following risk factors: 
- Blood pressure ≥130/85mmHg or treatment 
Triglycerides ≥1.7mmol/L or treatment 
- HDL-cholesterol <1.1mmol/L or treatment 
- Waist circumference ≥88cm  
- IFG (fasting glucose ≥5.6mmol/L) 
 
Central obesity 
- Waist circumference ≥80 cm or BMI≥30kg/m2 
 
Plus two or more risk factors: 
- Blood pressure ≥130/85mmHg or treatment 
- Triglycerides ≥1.7mmol/L or specific treatment 
for this lipid abnormality 
- HDL-cholesterol <1.3mmol/L or specific 
treatment for this lipid abnormality 
- IFG (fasting glucose ≥5.6mmol/L) 
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2.4.2 Prevalence of the metabolic syndrome 
The prevalence of the MetS greatly depends on the definition used. However, the syndrome 
is estimated to increase with age has been increasing in the past decade. From NHANES in 
the US, reports of an age-adjusted prevalence of 24.1 % in 1988-94 was reported using the 
NCEP-ATP III-criteria. The prevalence increased with increasing age from 6.7% to 43.5% in 
the 20-29-year-old subjects compared to those aged 60-69 years, following a small decrease 
in elderly (103). In an investigation of eight European studies, the prevalence of the 
syndrome showed to increase with increasing age and it was more common in men than in 
women. In non-diabetic subjects, the prevalence of the syndrome, as defined by the WHO, 
was 7-36% for men and 5-22% for women in the ages 40-55 years, whereas application of the 
EGIR definition has reported a prevalence of 1-22% for men and 1-14% for women (104). An 
extensive review performed by Ford et al. in 2005 clearly describes how the estimates vary 
with whatever definition is applied; 6–7% for all-cause mortality, 12–17% for CVD, and 30–
52% for T2DM. Ford underlines how further research is needed to establish the use of the 
MetS in predicting risk for death, CVD, and T2DM in various population subgroups (105). 
2.5 Type 2 Diabetes Mellitus  
The number of people with diabetes mellitus has more than doubled over the past three 
decades (106) and the disease is currently diagnosed in 366 million people worldwide (107). 
The fraction of affected people is projected to rise to 439 million by 2030 (108–110) 
representing 7.7% of the worldwide adult population aged 20-79 years, 90% of whom will 
be diagnosed with T2DM (110). In the industrialized world, the increase in T2DM prevalence 
is mainly due to population ageing (111) and increased prevalence of overweight and obese 
individuals (57,112). Further, global estimates of undiagnosed diabetes have been described 
by Beagley et al. to add another 174.8 million diabetics to the global estimate leaving 45.8% 
of all diabetes cases in adults to be undiagnosed (108). The prevalence of diabetes in 
Denmark is comparable to global estimates, with current projections of 380.000 (7%) of all 
Danish citizens having a registered diagnosis of diabetes. Another 200.000 are estimated to 
be undiagnosed and further 750.000 live with pre-diabetes (113).  
The global epidemic of T2DM is closely related to increasing rates of overweight and 
obesity in all age groups (114) and as previously described, overweight is often accompanied 
by other risk factors, referred to as the MetS when occurring in combination (115). T2DM is 
a multifactorial disease with complex interactions between these risk factors. Specifically, 
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in elder people, higher contents of visceral fat have been reported to be the main 
determinant of IGT, following reduced insulin sensitivity ultimately resulting in T2DM. 
Increased pancreatic fat with declining beta-cell function has also been reported to play a 
major role in T2DM development (116). 
The prevalence of T2DM increases progressively with age, peaking at 16.5% in men 
and 12.8% in women at age 75-84 years, and in Framingham Study subjects, diabetes or 
glucose intolerance was present in 30%-40% over the age of 65 (117). A significant increase 
in diabetes incidence has been observed especially within the elderly age group in Denmark. 
From 2000 to 2012, a 140% increase of physician-diagnosed diabetes within the 60-69 year 
age group, a 104% increase in the 70-79-year-olds, and an increase of 87% within the ³80 
years age group has been reported (118). Based on 2012 data from the Danish National 
Diabetes registry, physician-diagnosed diabetes is present in 155,480 Danish women of 
which 66% are aged ≥60 years (119). Danish female diabetics have a 40% relative increased 
mortality risk, based on the 2012 estimates, which is a decrease compared to the 83% 
increased risk reported in 1997. However, decreased risk of mortality does not imply 
decreased risk of morbidity and numbers from 2001 reveal that diabetes, and co-morbidities 
related to diabetes, costs 86 million DKK, daily (120). 
Despite having the highest prevalence of diabetes of any age group, older individuals 
with multiple co-morbidities is not a well-studied population, as they are often excluded 
from randomized controlled trials of treatments. Further, the great heterogeneity of health 
status of older adults challenges the development of health strategies fitting this increasing 
population group (121).  
2.6 Cardiovascular Disease 
The broad description of CVD covers numerous problems, many of which are related to 
atherosclerosis with subsequent plaque formation (122,123). Among CVD, the diseases 
within the heart constitute around two-thirds of the cases, of which ischemic heart disease 
is the most prevalent type of CVD. Other types are apoplexia, heart failure, and arrhythmia 
(124). During the past decades, much knowledge has been achieved concerning the 
pathophysiology related to CVD with hypertension, smoking, hyperlipidaemia and diabetes 
being some of the abnormalities which are generally accepted as risk factors (125). 
It is difficult to get exact numbers for the overall prevalence of CVD in the population. 
A person hospitalized or dying from CVD may have lived with the disease for many years 
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without contact with the healthcare sector. The Danish National Health survey (SUSY) from 
2005 describe how a total of 305,000 Danish people were living with CVD, 17,500 died of 
CVD, and 86,000 were hospitalized with a total of 142,000 admissions (124). Further, a study 
based on consultations in general practice estimated that each year there are approximately 
2.7 million contacts with general practice as a result of CVD in Denmark (126). CVD affects 
women to the same extent as men, but women get the disease at a higher age (124). Almost 
40% of cardiovascular deaths are due to coronary heart disease, and around a quarter is due 
to apoplexia. This applies to both men and women, but women have relatively more deaths 
caused by diseases of the brain vessels and fewer deaths from ischemic heart disease than 
men. The same applies to admissions, where a third of cardiovascular admissions for women 
are due to CVD and two-thirds are caused by heart disease (124). 
2.7 Excessive Tissue Degradation 
There is an inexhaustible list of risk factors associated with the negative impact on healthy 
ageing. In the previous sections, some of the most well-characterized metabolic risk factors 
and following metabolic diseases were elucidated. The following section will focus on tissue 
degradation in relation to ageing.  
The role of low-grade chronic inflammation is often described as a fundamental part 
of the ageing process (127). Also, tissue stiffening, which is a combination of increased 
collagen crosslinking through glycation, often occurring as by-products of lipid oxidation, 
contributes to the ageing process (128,129). The tissue stiffening of aged tissue makes it 
mechanically weaker and more rigid than young tissue (128,130). This changing mechanical 
state, combined with low-grade inflammation, can severely compromise the organisation of 
the extracellular matrix (ECM), which is the essential scaffold of all tissues, thereby 
modifying epithelial organization and function. This can potentially promote age-related 
fibro-proliferative diseases such as cancer, atherosclerosis, osteoarthritis, diabetic 
retinopathy etc. (131,132). 
The common ground in all fibro-proliferative diseases is dysregulated tissue 
remodelling, leading to excessive and abnormal accumulation of extracellular matrix (ECM) 
components in the affected tissues (133–135). It is estimated that fibro-proliferative diseases 
account for 45% of all deaths in the developed world  (133,136). The following sections will 
focus on fibro-proliferative diseases on a cellular level. 
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2.7.1 The extracellular matrix 
The ECM is a three-dimensional protein structure providing support for tissues and 
regulating tissue homeostasis (137). The ECM turnover is tightly controlled during normal 
tissue homeostasis with old and damaged ECM proteins being degraded and replaced by 
new (138). The basic structure and composition of the ECM is similar across different tissues, 
however with variations in the ratio between different ECM proteins, specific protein 
isoform expression and post-translational modifications of the ECM molecules (138). 
The ECM can be divided into the interstitial matrix and the basement membrane. The 
interstitial matrix primarily forms the connective tissue, whereas the basement membrane 
is a specialised layer of ECM dividing epithelial and endothelial cells from the underlying 
stroma (137). In the following sections, focus will solely be on collagen type I, which is the 
main component of the interstitial membrane of the ECM.  
2.7.2 Collagen type I 
Collagens are the most abundant proteins in the human body constituting 30% of the total 
protein mass. Currently, 28 types of collagens have been identified and grouped according 
to structure and function (139,140). Within the many types of collagen, collagen type I is the 
most abundant type expressed in most connective tissues being the major protein in bone, 
skin, tendon, ligaments, sclera, cornea and blood vessels where it assembles the extracellular 
space and provides tensile strength (138,140). Collagen type I is a fibrillar collagen, 
synthesized in the endoplasmatic reticulum as procollagen, most frequently composed of 
two a1 chains and one a2 chain. A key aspect of collagen type I is its posttranslational 
modifications, such as cleavage, cross-linking and degradation. These modifications are 
essential for correct synthesis and structural integrity of the collagen, but also for its tissue-
specific functionality (140). 
2.7.3 Collagen type I biomarkers 
The great content of collagen type I combined with the constant turnover throughout the 
body, has resulted in specified measurements of various fragments of this specific biomarker 
in blood samples (140,141). Biomarkers related to collagen type I are divided into two 
categories; formation and degradation markers.  
The formation markers describe released pro-peptide fragments of collagen type I, 
which are cleaved off during the synthesis of the collagen triple-helix. The amino-(N)-
terminal pro-peptide of procollagen type I is termed PINP, whereas PICP refers to the 
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carboxy-(C)-terminal pro-peptide. Both formation markers are described in studies where 
they are used to reflect the synthesis of bone matrix, and PINP is often used in drug trials 
assessing bone formation and turnover (142,143).  
Collagen type I degradation markers are divided into two types; cathepsin K-
generated collagen type I degradation fragments and matrix-metalloproteinase (MMP)-
mediated collagen type I degradation fragments. The most well-described degradation 
marker is the C-terminal telopeptide of collagen type I (CTX-I). CTX-I reflect bone 
resorption and has been used extensively in clinical studies of anti-resorptive drugs treating 
osteoporosis (142,143).  
2.7.4 C1M – a novel biomarker for collagen type I degradation 
C1M is categorised as an MMP-mediated collagen type I degradation fragment. This 
fragment is not related to bone turnover as it is not released as a function of bone resorption 
(144). Studies have shown that C1M is closely related to chronic inflammation and therefore 
has potential as a biomarker across multiple diseases, including rheumatoid arthritis, 
osteoarthritis, and fibro-proliferative diseases (145–147). These initial findings on 
associations between serum levels of C1M and subsequent disease activity, support the 
assumption, that MMP-mediated destruction of collagen type I is a pathologically relevant 
process associated with fibro-proliferative diseases, rather than bone formation, and that 
monitoring these specific fragments of collagen type I can provide clinical value in relation 
to healthy ageing.  
 
 
Figure 2 Location of collagen type I biomarker target sites, modified with permission from Siebuhr et al (148). 
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2.7.5 Measuring disease burden 
From above description of formation and degradation fragments of collagen type I, it is 
clear, that measurements of the same protein can contain distinct information and reflect 
completely different biological processes depending on which part of the protein is targeted. 
Identifying and assessing different post-translational modifications, such as pro-peptides or 
degradation products, provides a distinct ‘protein fingerprint’ which thereby makes it 
possible to distinguish different pathophysiological processes. Described in other terms; 
whereas the total pool of collagen type I may not change during pathological conditions, the 
various ‘protein fingerprints’ may differ significantly. In these cases, the quantification of a 
protein sub-pool may more accurately describe the pathology of interest, e.g. in elderly 
women, where bone resorption can be extensive in late-life, knowledge on increased CTX-I 
levels are of greater interest than quantifying full-length collagen type I. 
2.7.6 The protein fingerprint technology – measuring C1M in serum 
The fingerprint approach is founded on the previously described principals that specific 
protein fragments are released into the circulation where they can be measured. Proteases 
degrade proteins by cleaving them at a specific amino acid sequence and hereby expose a 
protease-specific epitope (neo-epitope) on the degraded protein fragment that can be 
targeted as a biomarker.  
The protein fingerprint technology is based on competitive enzyme-linked immune-
sorbent assay (ELISA) tests, using monoclonal antibodies to target the specific protease-
generated neo-epitopes. In the case of C1M, this would be the specific MMP-mediated 
fragment generated during tissue turnover. During pathological process, this fragment 
would be assumed to be up-regulated.  
The development of the C1M assay has been performed by colleagues at Nordic 
Bioscience and is fully described in the paper by Leeming et al. (144). In this thesis, further 
emphasis will not be put upon the technical aspects of C1M measurement but solely on its 
use as a descriptive biomarker of increased risk of age-related diseases and consequent death 
in elderly women. 
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2.8 Introductory Overview 
The main focal points of the introduction are summed up in Figure 3, thus giving rise to the 
specific aims formulated in Chapter 3 forming the basis of the presented work.  
  
 
Figure 3 Risk factors of the metabolic syndrome combined with the low-grade inflammation 
related to ageing lead to tissue degradation following adverse metabolic outcomes such as type 2 
diabetes (T2DM) and cardiovascular diseases (CVD) and ultimately death. 
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3 AIM 
There is a need to specifically investigate healthy ageing in elderly women. Ageing is a broad 
term describing the accumulation of various changes over time. In the broadest sense, it can 
refer to everything from cellular ageing of an organism to the ageing of populations 
encompassing both physical, psychological and social changes. The studies in the current 
thesis focus solely on ageing in an epidemiological population-based setting describing risk 
factors directly linked to physical ageing and associated non-communicable diseases.  
The overall aim of this thesis was to study risk factors affecting healthy ageing in women. 
The Prospective Epidemiological Risk Factor Study (PERF), a community-based cohort 
comprising Danish elderly women was the focal point of the conducted research. The cohort 
is described in detail in the form of a cohort profile (study I). The specific aims of the three 
studies that found the basis of the current work all relate to the interplay between risk 
factors and age-related non-communicable diseases. 
The specific aims were to: 
1. Investigate the predictive value of the MetS definition in relation to future risk of T2DM
and CVD by applying the MetS definition set by the IDF. Further, the aim was to
investigate whether the syndrome's predictive power of T2DM and CVD would increase
by further stratifying the reference group. Lastly, the aim was to investigate the risk of
T2DM and CVD based on cumulating numbers of MetS risk factors (study II).
2. Investigate the influence of weight and weight change during a period of 13-years on
the subsequent risk of hyperglycaemia development specifically exploring the risk
within normalweight, overweight and obese women (study III).
3. Investigate whether MMP-mediated tissue degradation of collagen type I could predict
increased risk of premature mortality in elderly women (study IV).
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4 INTRODUCTION TO THE COHORT 
Title 
Cohort Profile: The Prospective Epidemiological Risk Factor (PERF) study 
Aim 
The PERF study is an ambi-directional population-based study of postmenopausal women 
set up with the purpose of obtaining a better understanding of the aetiology and 
pathogenesis of age-related diseases. 
Rationale 
The world’s population is ageing. Knowledge of disease and health in this fast growing 
segment of the population is largely built upon population-based studies of the distribution 
and determinants of disease outcomes. The PERF study was designed with the purpose of 
obtaining a better understanding of the development of age-related diseases in 
postmenopausal women. 
Findings 
The cohort profile outlines the study design, the study population, and an overview of the 
collected data together with a summary of the key findings until now.  
The average lifespan in the cohort was found to be very similar to the average lifespan for 
Danish women. When compared to Danish women aged 45+ the PERF cohort is 
characterized as slightly less physically active and more overweight/obese. The number of 
current smokers is less in the cohort while the group of subject’s not drinking alcohol is 
larger in our cohort compared to Danish women aged 45+. In relation to health, the two 
main causes of death are CVD and cancer in both the cohort and in the background 
population, and the proportion of deaths attributable to these diseases are comparable. For 
other comorbidities, the proportion of subjects with diabetes and depression in the cohort 
are similar to the target population, while the prevalence of hypertension and osteoporosis 
is approximately 2-fold higher in the cohort. 
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Why was the cohort set up?
The world’s population is ageing.1 In Europe alone, the
elderly population over age 65 will double from 88 to 153
million and the fastest growing segment of the population
will be those over 80, tripling in number from 24 to 60 mil-
lion in 2060.2 Low birth rates and increasing longevity are
the key factors in this shifting trend in ageing demograph-
ics.3 Maintaining a healthy life is important, as an ageing
population in good health will limit the pressure on health
care systems.3,4 However, it is likely that risk factors com-
promising healthy ageing, such as smoking, obesity, excess
alcohol consumption, unemployment, and lack of physical
activity, will negatively affect the years people spend in
good non-treatment requiring health.1,5 In 2006, it was
estimated that women in the Western European countries
are expected to live about 80% of their lives in good
health. In other words, this predicts a healthy life expect-
ancy up to 20% shorter than the total life expectancy.4
Focus on a healthy elderly population is therefore of
greater interest than ever.
Age-related diseases are usually expressed as chronic
conditions commonly occurring in combination with each
other, with cardiovascular disease and type 2 diabetes
being two of the most common age-related diseases in the
EU.1,4 The ability to understand the links and underlying
pathogenesis are therefore crucial in order to be able to
shift the treatment regimen from disease treatment to pre-
ventive measures, thereby prolonging the period that eld-
erly people spend in good health.
The Prospective Epidemiological Risk Factor (PERF)
Study, an observational, prospective cohort study of
Danish postmenopausal women, was designed with the
purpose of obtaining a better understanding of the devel-
opment of age-related diseases in postmenopausal women.
In 1999, the source population was identified from a data-
base of subjects who had previously been screened for par-
ticipation in one of 21 clinical randomized controlled trials
(source studies6–24). All living subjects with a unique per-
sonal subject identification number and a valid postal ad-
dress constituted the source population (a total of 8875
women). The source studies were all initiated with the pur-
pose of obtaining further knowledge about the aetiology
and pathogenesis of menopause-related diseases, and
included both intervention and non-intervention studies
(as illustrated in Figure 1). The source population therefore
consists of women who previously participated in a source
study or were screened, without being randomized. The
first source study was initiated in 1977. In 1999, the first
participants were enrolled in the epidemiological cohort of
the PERF study (henceforth termed PERF I), and from
September 2013 to December 2014 the participants com-
pleted the latest follow-up (termed PERF II). The total
number of participants attending the baseline examination
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(PERF I) was 5855, of whom 2103 attended the follow-up
visit (PERF II) approximately 15 years later. Including the
source studies, the study may be considered an ambidirec-
tional cohort study with a total observation period of more
than 35 years. The PERF I and PERF II studies were funded
by the Danish Research Foundation (Den Danske
Forskningsfond).
The current paper outlines the study design, the study
population and an overview of the collected data together
with a summary of the key findings until now.
Who is in the cohort?
Inclusion
In 1999, an invitation to attend the baseline examination
was sent to the entire source population (n ¼ 8875) except
for those who died since their last contact with the clinic
(n ¼ 732). In this subgroup, causes and times of death
were collected from the Danish National Death registry.
No active recruitment initiatives besides the invitation was
taken, leaving a total of 5855 (72%) women to consent
and attend the baseline examination of the epidemiological
PERF I study conducted at the Center for Clinical and
Basic Research (CCBR) in cities of either Aalborg or
Ballerup, Denmark, between 1999 and 2001. There were
no in-/exclusion criteria at the time of enrolment in the co-
hort study.
A subcohort (PERF II), initially being enrolled at the
CCBR clinic in Ballerup, was re-investigated in 2013-14,
when invitations were sent to 2813 women from the ori-
ginal PERF I cohort. Those subjects who did not respond
to the written invitation were contacted by phone. As a re-
sult of this active recruitment, a total of 2103 (75%)
Figure 1. Source studies defining the source population for the Prospective Epidemiological Risk Factor (PERF) study illustrated on a timeline
including number of participants, study duration and type of intervention. Bubble size is proportional and equivalent to the number of partici-
pants. All bubbles are sized relative to the largest study (N¼ 2,789). Color represents type of intervention; white bubbles are nonintervention
studies, light grey bubbles are placebo controlled bisphosphonate studies, medium grey bubbles are placebo controlled hormone replace-
ment therapy studies and dark grey bubbles represent other types of intervention studies. Black lines correspond to the study duration (in
years).
Figure 2. Flowchart of participants and >non-participants in the baseline
and the follow-up study. The repeating occurrence of deceased and
non-responders/declined illustrate the number of deceased and nonres-
ponders/declined between two consecutive time points on the time
scale.
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women attended the follow-up study (PERF II), which
took place either in their own home or at the CCBR clinic
in Ballerup. Figure 2 shows the number of participants and
non-participants from baseline to follow-up. All the sub-
jects were given ample time to consider participation and
gave their written consent before any study-related proced-
ure was carried out. The study was conducted in accord-
ance with Good Clinical Practice and the Helsinki
Declaration II.
Cohort characteristics, a comparison between
baseline participants, follow-up participants and
non-participants
The baseline characteristics of the entire cohort (PERF I)
and the follow-up participants (PERF II) are shown in
Table 1. The mean age in the baseline cohort (PERF I) was
70.8 years (49.7-88.8). Nearly 75% of the cohort had pri-
mary school as their highest level of education and less
than 10% had a university degree. The follow-up
Table 1. Selected baseline characteristics of the Prospective Epidemiological Risk Factor (PERF) study. The full study population
(n ¼ 5855) are shown along with specific subgroups of; subjects who died before follow-up (n ¼ 1649), subjects who attended
the follow-up visit (PERFII) (n¼ 2103) and subjects who did not attend the follow-up visit (n ¼ 2103). Numbers are shown as ab-
solute numbers with percentile in brackets for categorical variables. For numerical variables, the mean 6 standard deviation
(SD) are shown
Parameter N Baseline
Participants
(PERF I)
N ¼ 5855
Dead before
follow-up
N ¼ 1649
Follow-up
participants
(PERF II)
N ¼ 2103
Follow-up
non-participants
N ¼ 2103
P-value*
Follow-up
participants vs
non- participants
Age (mean6 SD, years) 5855 70.8 (6.5) 74.9 (5.9) 68.0 (6.0) 70.3 (5.9) <0.001
Menopause age (mean6 SD, years) 5783 49.0 (4.9) 48.7 (5.0) 49.1 (4.8) 49.1 (4.8) 0.9
Highest level of education 5841 <0.0001
Primary school, n (%) 4178 (72) 1215 (74) 1428 (68) 1535 (73)
High School, n (%) 1250 (21) 320 (20) 482 (23) 448 (21)
University, n (%) 413 (7) 110 (7) 192 (9) 111 (5)
Height (mean6 SD, cm) 5637 161 (5.9) 160 (6.0) 162 (5.8) 161 (5.8) <0.001
Weight (mean6 SD, kg) 5637 67.7 (11.7) 65.5 (11.9) 68.8 (11.4) 68.4 (11.6) 0.2
BMI (mean6 SD, kg/m2) 5637 26.1 (4.3) 25.7 (4.4) 26.2 (4.2) 26.5 (4.2) 0.07
BMI groups 5637 0.1
Underweight (<18.5), n (%) 90 (2) 46 (3) 21 (1) 23 (1)
Normal (" 18.5-25.0), n (%) 2343 (42) 699 (45) 871 (42) 773 (38)
Overweight (> 25.0-30.0), n (%) 2248 (40) 567 (37) 823 (40) 858 (43)
Obese (> 30.0), n (%) 956 (17) 238 (15) 356 (17) 362 (18)
Smoking 5844 0.6
Never, n (%) 2767 (47) 634 (39) 1077 (51) 1056 (50)
Past, n (%) 1762 (30) 525 (32) 610 (29) 627 (30)
Current, n (%) 1315 (23) 487 (30) 416 (20) 412 (20)
Alcohol 5807 <0.0001
Never, n (%) 2531 (44) 757 (46) 843 (40) 931 (45)
<10.5 alcohol units/week, n (%) 1380 (24) 348 (21) 451 (22) 581 (28)
10.5-21 alcohol units/week, n (%) 1497 (26) 423 (26) 615 (29) 459 (22)
>21 alcohol units/week, n (%) 399 (7) 107 (7) 180 (9) 112 (5)
Physical activity 5843 0.05
Never, n (%) 1840 (31) 720 (44) 525 (25) 595 (28)
1 time/week, n (%) 1233 (21) 340 (21) 451 (21) 442 (21)
2 times/week, n (%) 748 (13) 179(11) 308 (15) 261 (13)
3þ times/week, n (%) 2022 (35) 408 (25) 819 (39) 795 (38)
Blood pressure
Systolic (mean6 SD, mmHg) 5677 150 (24.4) 155 (25.4) 147 (23.3) 150 (24.2) <0.001
Diastolic (mean6 SD, mmHg) 5679 81.9 (11.5) 81.7 (12.3) 82.0 (10.7) 81.8 (11.6) 0.6
Hypertension, n (%) 5838 1807 (31) 606 (37) 523 (25) 678 (32) <0.0001
Hyperlipidaemia, n (%) 5845 530 (9) 142 (9) 224 (11) 164 (8) 0.002
Diabetes, n (%) 5842 181 (3) 75 (5) 47 (2) 59 (3) 0.06
*t test for numerical variables and chi-square test for categorical variables.
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participants were characterized as being younger and
slightly higher-educated. With an average BMI of 26.2 kg/
m2, this part of the cohort comprised 57% overweight or
obese women. There were no differences between the
follow-up participants and non-participants with regards
to BMI. In relation to lifestyle variables (smoking, alcohol
and physical activity), follow-up participants and non-
participants for PERF II were found to be similar, although
the follow-up participants comprised a higher proportion
of subjects consuming > 10.5 alcohol units per week. The
systolic blood pressure and the proportion of subjects with
self-reported hypertension were higher in the group of
non-participants than in the participating group, whereas
the proportion of subjects with self-reported hyperlipidae-
mia was lower.
Cohort and target population characteristics
Comparison of study participants with the target popula-
tion was done using data on Danish women aged 45þ,
from the Danish Health Interview Surveys (SUSY) in
200025 and 200526 and the StatBank from Statistics
Denmark27 (Table 2).
The average lifespan in the cohort is very similar to the
average life span for Danish women. When compared with
Danish women aged 45þ generally, the PERF cohort is
characterized as slightly less physically active and more
overweight/obese. The proportion of current smokers is
less in the cohort and subjects not drinking alcohol is larger
in our cohort compared with Danish women aged 45þ. In
relation to health, the two main causes of death are cardio-
vascular disease and cancer in both the cohort and the
background population, and the proportions of deaths at-
tributable to these diseases are comparable. For other
comorbidities, the proportions of subjects with diabetes
and depression in the cohort are similar to the target popu-
lation, but the prevalences of hypertension and osteopor-
osis are approximately 2-fold higher in the cohort.
How often have they been followed up?
Concomitant with the PERF II follow-up study, all subjects
have been followed with registry linkage using population-
based national registries. With approval from the author-
ities, we have collected registry data on all baseline
participants (n ¼ 5855). By use of a personal subject identi-
fication number (CPR-number), the Danish national regis-
tries contain individual-level data on the entire Danish
population. Linkage has been done with the following
registries: the National Danish Patient Registry, the
National Danish Causes of Death Registry, the Danish
National Diabetes Register, the Danish Cancer Registry
and the Danish National Pathology Registry. For more in-
formation on the registries, please refer to Table 3.
The most recent linkage was done in January 2015, and
this linkage is expected to continue until the remaining sub-
jects from the cohort are deceased. The registry information
is available for research within the scope of the study.
Table 2. Comparison of the PERF cohort and the target popu-
lation comprising Danish women aged 45 and older. Data on
the target population are derived from either Statistics
Denmark or the Danish Health Interview Surveys. Values are
shown as percentages if not otherwise indicated
Variable Baseline
cohort
(PERF I)
Danish
Women 45þ
(target
population)
P-valuee
Demography and lifestyle
Age (% of total group)
60-64 18.3 25.3a <0.01
65-69 23.2 22.0a 0.02
70-74 28.7 20.4a <0.01
75-79 20.6 18.9a <0.01
80-84 9.2 13.4a <0.01
Average lifespan (years)b 83.0 82.7a
Smoking (% of total group)
Current 22.5 31.9‡ <0.01
Never 47.3 39.8‡ <0.01
Alcohol (% of total group)
Never 43.6 28.2c <0.01
<10.5 alcohol units/week 23.8 44.1c <0.01
10.5-21 alcohol units/week 25.8 18.2c <0.01
> 21 alcohol units/week 6.9 9.5c <0.01
Physical activity (% of total group)
No 31.5 21.9c <0.01
Yes 68.5 78.1‡ <0.01
BMI (% of total group)
Underweight (<18.5) 1.6 4.1c <0.01
Normal weight (" 18.5 <25) 41.6 54.4c <0.01
Overweight (" 25) 39.8 30.8c <0.01
Obese (" 30) 17.0 10.7c <0.01
Health
Causes of death (% of total group)
Cardiovascular 27.3 25.7a
Cancer 32.2 33.8a
Comorbidities (% of total group)
Hypertension 31.0 16.4c <0.01
Diabetes 3.1 3.9c 0.02
Osteoporosis 10.9 6.1d <0.01
Depression/anxiety 6.6 5.5d 0.02
aRetrieved from Statistics Denmark.
bThe average lifespan was calculated for all deceased subjects by the end of
2014.
cData from the Danish Health Interview Surveys 2000.
dData from the Danish Health Interview Surveys 2005.
eThe z-score test for two population proportions.
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What has been measured?
Baseline and follow-up examination
At the baseline visit (PERF I), participants completed a
health examination involving a physical examination includ-
ing blood pressure measurement, electrocardiogram (ECG),
medical history and a health-related questionnaire (for more
information on the questionnaire see separate section below).
Participants provided blood and urine samples for standard
biochemical analysis and for future analysis by storage in a
biobank. Moreover, dual energy X-ray absorptiometry
(DEXA) scans of the whole-body, spine, hip and arm, X-ray
of the spine and mammography were obtained.
At the follow-up examination (PERF II), medical history
and recording of all current medications were obtained.
Measurements of height, weight, waist and hip circumfer-
ences, blood pressure, heart rate and respiratory frequency
was completed. Muscle strength was determined using a
hydraulic hand-grip dynamometer. An EQ-5D-3L evaluation
was completed by the participant to assess their self-reported
quality of life, and a Category Fluency Test together with a
Short Blessed Test was done to test cognitive performance.
Please refer to Table 4 for information on the data collected
at the baseline and the follow-up examination.
Questionnaire
The baseline and follow-up questionnaire was completed as a
structured interview with an investigator or study nurse and
the participant. Standard demographic information such as
age, menopause age and level of education, along with infor-
mation on physical activity, current and past smoking habits
and current and past drinking behaviour was included in the
questionnaire. Information on diet obtained at baseline was
limited to information on consumption of coffee/tea, dairy
products and vegetarian status. Medical history, including
treatment (medication/surgical) and familial medical history,
was obtained as part of the interview for several disorders
including, but not limited to, neurological or psychological
disorders, cardio-/cerebrovascular disease, lung disorders,
cancers, muscles and joint diseases and metabolic disorders.
Collection, analysis and storage of biological
material
For each participant, urine and fasting blood samples were
collected for routine analysis and biobank storage at base-
line (n ¼ 5668). The biobank also contains DNA samples
for those subjects who gave written consent for this specific
analysis (n ¼ 5553). At the follow-up visit, fasting blood
samples were collected. Samples are stored at -20 $C (urine,
DNA samples) and -80 $C (serum). Routine blood and urine
analysis was carried out at a College of American Pathology
(CAP) certified central laboratory (Nordic Bioscience
Laboratory) at both baseline and follow-up.
Genomics
In collaboration with deCODE genetics, Iceland, and Sct.
Hans Hospital, Denmark, DNA samples from the PERF
study have been genotyped and associations between single
nucleotide polymorphisms (SNPs) and selected outcomes,
including bone mineral density/osteoporotic fractures,34
Table 3. Overview of registry linkage in the Prospective Epidemiological Risk Factor (PERF) study
Registry Type of information received Time period covered Latest linking
National Danish Patient Registry Hospitalization and discharge time 1977 on 31 Dec 2014
Hospital and department 1977 on
Diagnoses (ICD classification) 1977 on
Treatments and operations 1996 on
National Danish Causes of Death Registry Time of death 1970 on 31 Jan 2015
Underlying cause of death 1970 on
Complementary cause of death 1970 on
Danish National Diabetes Register Date of inclusion 1990 on 31 Dec 2014
Inclusion criteria 1990 on
Inclusion cause 1990 on
Danish Cancer Registry Diagnosis and time of diagnosis 1943 on 31 Dec 014
Tumour distribution 1943-2003
Treatment 1943-2003
TNM classification 2004 on
Ann Arbor staging 2004 on
Treatment 1943-2003
Danish National Pathology Registry Data from pathological tests (by SNOMED code) 1997 on (1970 on) 31 Dec 2014
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type 2 diabetes,35 schizophrenia,36 depression37 and cogni-
tive impairment38 have been assessed.
What has it found? Key findings and
publications
The PERF study has generated several important findings cov-
ering the health of elderly women. Selected key findings are
summarized in Table 5. In a cross-sectional nested analysis
from PERF (n¼ 1356), it was shown that peripheral adiposity
exhibits an independent anti-atherogenic effect in elderly
women.39,40 In the entire cohort and in a nested study (n ¼
343), it was shown that endogenous estrogen and hormone re-
placement therapy administered in the early phase of the
menopause may have a protective association with cognitive
impairment later in life.41,42 More recently, it was shown that
matrix metalloproteinase (MMP)-mediated collagen type I
degradation, termed C1M, is an independent risk factor for
all-cause mortality, as subjects with high levels of type I colla-
gen degradation had a 2-fold increased mortality risk com-
pared with subjects with low levels.43 Last, a genome-wide
association study of bone mineral density (BMD) among more
than 30 000 subjects, including samples from PERF I, revealed
a new BMD locus that harbours the PTCH1 gene. The gene is
associated with reduced spine BMD.44
What are the main strengths and
weaknesses?
In this 37-year ambidirectional population-based study,
the participation rate has been higher than 70% through-
out the study. To investigate whether the study population
Table 4. Parameters measured at the baseline (PERF I) and the follow-up visit (PERF II)
Parameter Description PERF I PERF II
General information
Demographics Age ! NA
Body weight ! !
Height ! !
Education level ! NA
Health
Medical history Self-reported questionnaire/interview ! !
Physical examination Full-body examination ! —
Blood pressure ! !
ECG ! —
Cognition Short Blessed Test ! !
Category Fluency Test (Animals) ! !
Body composition Arm, hip and spine DEXA ! —
Whole-body DEXA ! —
X-ray Spine ! —
Mammography ! —
Muscle strength Hand-grip strength test — !
Lifestyle
Physical activity Walking, leisure activity ! !
Smoking Current and past smoking behaviour ! !
Alcohol Current and past drinking behaviour ! !
Diet Consumption of coffee/tea, dairy products ! —
Vegetarians ! —
Psychosocial parameters
Quality of life, well-being EQ-5D-3La — !
Blood
Haematology Haemoglobin, leukocytes and differentiation, etc. ! !
Lipids Total cholesterol, LDL, HDL, triglycerides ! !
Electrolytes Sodium, potassium, calcium ! !
Renal function Creatinine ! !
Liver ALAT, ASAT, albumin, GGT, alkaline phosphatase ! !
Inflammation High sensitive CRP — !
Specialty biomarkers Osteocalcin, CTX-1, VICM, C1M, C4M, TAU-C ! *
NA, not applicable.
aEQ-5D-3L measures health in five dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) and three levels (no problems,
some problems, extreme problems).
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resembled the target population, we compared the baseline
participants with the general female population in
Denmark aged 45 or older. It is well known that study par-
ticipation is often linked to health superior to that of an
otherwise similar, non-participant background population
(healthy participant bias). However, we did not observe a
healthier profile among the baseline study participants.
The cohort is therefore considered representative of
women aged 45þ in the Danish population. In the study
population, we found a higher prevalence of osteoporosis
at baseline. This could either be caused by selection bias,
as a number of the participants had previously participated
in randomized clinical trials focused on osteoporosis.
However it could also reflect underdiagnosis of osteopor-
osis in the general Danish population, since the source
population not only included women randomized for clin-
ical studies but also those who did not meet the inclusion
criteria (e.g. had high bone mineral density) at the time of
recruitment.
Although the follow-up cohort (PERF II) was se-
lected based on geographical limitations due to data
collection in the participants’ own homes, the similarities be-
tween follow-up participants and follow-up non-partici-
pants strengthen the internal validity of the data.
Besides the length of the follow-up period, the linkage
to a range of nationwide registries is a major strength. The
registry data are comprehensive and the registries were es-
tablished relatively early, e.g. cancer and cause-specific
death information since the 1940s and hospitalizations
since the 1970s.51 Registration has been mandatory since
1977. The registry data therefore strongly support the
identification of outcomes and, because of the limited loss
to follow-up, it adds analytical power to the study.
Moreover, this cohort is to our knowledge one of the larg-
est cohorts of postmenopausal women with full-body
DEXA scans, which enables extensive studies of body
composition.
Regarding weaknesses, the cohort only comprised
women and therefore generalization cannot be made to
men of similar ages. Moreover, the duration of time
passed from PERF I (year 1999) to PERF II (year 2014) is
long in a cohort of such advanced age. In order to prevent
selection bias towards the healthier segment of this ageing
cohort, great effort was made in following up on invited
participants not instantly replying to our invitation. Also,
visiting the subjects in their own homes increased the
number of subjects with illnesses still wanting to
participate.
Table 5. Summary of major findings from the Prospective Epidemiological Risk Factor (PERF) study
Endpoint/Exposure Major findings
Cardiovascular disease Localization of fat mass is more important for atherogenesis than obesity per se39,40
Enlarged waist circumference and elevated triglycerides are simple diagnostic tools that could facilitate the
identification of postmenopausal women at increased risk for accelerated atherogenesis and related adverse
outcomes45
Hormone replacement therapy for 2-3 years has relative cardiovascular benefits and reduces the risk of all-
cause mortality46
Bone/osteoporosis Limited hormone replacement therapy given in the early postmenopausal years can provide long-lasting
benefits in terms of preventing bone loss and related fractures47
Bone mass measurement offers effective fracture prediction independent of the site of measurement and age
of the patient48
Association of conditions Aortic calcification seems to independently contribute to the development of osteoporosis in the proximal
femur49
Independent association of peripheral vascular disease with osteoporosis in the proximal femur50
Cognitive function Protective association of body fat mass with cognitive impairment in elderly women, through a more promin-
ent exposure to endogenous estrogens41
Short-term hormone replacement therapy administered in the early phase of the menopause may provide a
long-term protection against cognitive impairment42
Genomics Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes35
Association of dopamine beta-hydroxylase gene variants with cognitive performance and depression in eld-
erly women37,38
Bone mineral density locus identified that harbours the PTCH1 gene. The gene is associated with reduced
spine BMD44
All-cause mortality Increased MMP-mediated tissue degradation, measured by C1M, is an independent risk factor for all-cause
mortality43
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Can I get hold of the data? Where can I find
out more?
All data are stored electronically in anonymous form.
Aliquoted biological material is stored in a biobank at
the Nordic Bioscience Laboratory. Currently, the data
are available only to employees of Nordic Bioscience A/
S, Denmark; however, the PERF study group will
welcome any enquiries regarding collaboration or data
sharing for further investigations. Potential collaborators
are invited to contact the PERF study group at
[perf@nordicbio.com].
Profile in a nutshell
• The Prospective Epidemiological Risk Factor (PERF)
Study is an ambidirectional population-based study
of postmenopausal women set up with the purpose
of obtaining a better understanding of the aetiology
and pathogenesis of age-related diseases.
• Participants were recruited from a source population
of 8875 women residing in Denmark. The baseline
examination (PERF I) comprised 5855 women with
mean age of 70.8 years (49.7-88.8) and took place
between 1999 and 2001.
• All subjects have been followed up with registry link-
age using population-based national registries. Further,
a subcohort was re-invited to attend a follow-up visit
between 2013 and 2014 (PERF II). Registry data are
available for all baseline participants. From the base-
line population, 2103 were enrolled in PERF II.
• The data repository contains a wide range of health-
related and lifestyle measures, biological samples
from the baseline and follow-up studies, genetic in-
formation and linkage to nationwide registries.
• The PERF study group will welcome any enquiries
regarding collaboration or data sharing for further
investigations.
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5 METABOLIC SYNDROME IN ELDERLY WOMEN 
Title 
Metabolic Syndrome and Subsequent Risk of Type 2 Diabetes and Cardiovascular Disease in 
Elderly Women: Challenging the Current Definition. 
Aim 
The aim of the study was to investigate the association of risk factors of the metabolic MetS 
with later risk of T2DM and CVD in elderly Caucasian women. We further investigated if 
stratification of individuals not defined with MetS would add predictive power in defining 
future disease in individuals with MetS. 
Rationale 
The prognostic value of the MetS is believed to vary with age. With an elderly population 
expecting to triple by 2060, it is relevant to evaluate the validity of defining the MetS in this 
age group. 
Findings 
Elderly women with defined MetS presented a 6.3-fold increased risk of T2DM (95% CI: [3.7-
10.5]) and 1.7-fold increased risk of CVD ([1.4-2.1]) compared to women with no MetS risk 
factors. Sub-dividing the control group without defined MetS revealed that both centrally 
obese controls and controls holding other MetS risk factors also had an increased risk of 
T2DM (HR=2.2 [1.3-3.9] and HR=1.8 [1.0-3.0], respectively) and CVD (HR=1.5 [1.3-1.8] and 
HR=1.4 [1.2-1.6], respectively) when compared to controls with no MetS risk factors. The risk 
of both T2DM and CVD increased with cumulative numbers of metabolic risk factors. 
Conclusions 
MetS in elderly Caucasian women increased the risk of future T2DM and CVD. While not 
defined with MetS women holding only some risk factors for MetS were also at increased 
risk of T2DM or CVD compared to women with no MetS risk factors. 
Metabolic syndrome and subsequent risk of type 2
diabetes and cardiovascular disease in elderly women
Challenging the current deﬁnition
Katrine Dragsbæk, MSca,b,
∗
, Jesper S. Neergaard, MSca,b, Janne M. Laursen, MScb, Henrik B. Hansen, MSca,
Claus Christiansen, DMScia, Henning Beck-Nielsen, DMScic, Morten A. Karsdal, PhDa, Susanne Brix, PhDb,
Kim Henriksen, PhDa
Abstract
The prognostic value of the metabolic syndrome (MetS) is believed to vary with age. With an elderly population expecting to triple by
2060, it is important to evaluate the validity of MetS in this age group. We examined the association of MetS risk factors with later risk
of type 2 diabetes (T2DM) and cardiovascular disease (CVD) in elderly Caucasian women. We further investigated if stratiﬁcation of
individuals not deﬁned with MetS would add predictive power in deﬁning future disease prevalence of individuals with MetS.
The Prospective Epidemiological Risk Factor Study, a community-based cohort study, followed 3905 Danish women since 2000
(age: 70.1±6.5) with no previous diagnosis of T2DM or CVD, holding all measurements used for MetS deﬁnition; central obesity,
hypertension, hyperlipidemia, and hyperglycemia combined with register-based follow-up information.
Elderly womenwith deﬁnedMetS presented a 6.3-fold increased risk of T2DM (95% conﬁdence interval: [3.74–10.50]) and 1.7-fold
increased risk of CVD (1.44–2.05) compared to women with no MetS risk factors. Subdividing the control group without deﬁned
MetS revealed that both centrally obese controls and controls holding other MetS risk factors also had increased risk of T2DM
(hazard ratio (HR)=2.21 [1.25–3.93] and HR=1.75 [1.04–2.96]) and CVD (HR=1.51 [1.25–1.83] and HR=1.36 [1.15–1.60]) when
compared to controls with no MetS risk factors.
MetS in elderly Caucasian women increased risk of future T2DM and CVD.While not deﬁned with MetS, women holding only some
risk factors for MetS were also at increased risk of T2DM or CVD compared to women with no MetS risk factors.
Abbreviations: ALAT = alanine-aminotransferase, ASAT = aspartate-aminotransferase, BMI = body mass index, C/P ratio =
central/peripheral fat mass ratio, CCBR = Center for Clinical and Basic Research, CVD = cardiovascular disease, DEXA = dual-
energy X-ray absorption, HDL = high-density lipoprotein, IDF = International Diabetes Federation, LDL = low-density lipoprotein,
MetS =metabolic syndrome, PCA = principal component analysis, PERF = Prospective Epidemiological Risk Factor Study, T2DM =
type 2 diabetes mellitus, WBC = white blood cell count.
Keywords: cardiovascular disease, central obesity, elderly, metabolic syndrome, principal component analysis, type 2 diabetes
1. Introduction
The risk of developing type 2 diabetes mellitus (T2DM) and
cardiovascular disease (CVD) increases with age,[1–3] and with a
generally aging population,[4] deﬁnite measures of disease risk in
elderly individuals are necessary. Such strategy would facilitate
timely preventive approaches to reduce the disease burden, as
well as medical costs in an aging population.[5,6] Metabolic
syndrome (MetS) is widely used as a measure to predict the future
risk of T2DM[7,8] and CVD,[9,10] and is founded on ﬁve
metabolic risk markers: central obesity, elevated blood pressure
(BP), dyslipidemia (involving both elevated serum triglycerides
and lowered high-density lipoprotein (HDL) cholesterol), and
elevated fasting glucose.[11,12] Insulin resistance, commonly
believed to be originating from central obesity,[13] is considered
the cornerstone in risk proﬁles describing both T2DM and
CVD,[14] and central obesity has, therefore, with the 2005
International Diabetes Federation (IDF) deﬁnition, been set as the
“entrance criteria” in deﬁning MetS.[15,16] Many studies have
described the association between MetS-based risk factors and
subsequent disease risk; however, most studies are conducted on
middle-aged populations.[10,17–19] There is, a need for studies on
how the current MetS deﬁnition associates to disease risk
speciﬁcally in elderly individuals. This study aimed to investigate
the predictive value of MetS in relation to future risk of T2DM
andCVD in a cohort of elderly Caucasianwomen by applying the
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MetS deﬁnition set by the IDF. This investigation would allow for
an assessment of whether the MetS-based assessment criterion
remains valid in the estimation of future increased risk of T2DM
and CVD development also in an older population.
All present studies within the ﬁeld of MetS report the risk
estimate based on the use of a deﬁnedMetS-group compared to a
reference group not deﬁned with the syndrome. When applying
this dichotomized deﬁnition, it is likely that the reference group
will be heterogeneous and contain individuals who display
variable metabolic proﬁles. Such reference group heterogeneity
would be based on the inclusion of individuals who, while not
meeting the central obesity entrance criterion, might still hold
many otherMetS risk factors, such as hypertension, dyslipidemia
(elevated serum triglycerides and lowered HDL cholesterol), and
hyperglycemia. We here hypothesized that a heterogeneous
metabolic state of the reference group could potentially inﬂuence
the syndrome’s predictive power of disease. To test the inﬂuence
of the reference group, we separated our study control group
into three reference subgroups: centrally obese controls not
deﬁned with MetS, controls with no central obesity but other
MetS risk factors, and controls with no MetS risk factors, and
used principal component analysis (PCA) to visualize the
differences between the MetS group and these reference
subgroups. We further investigated whether the syndrome’s
predictive power of T2DM and CVD would increase when
stratifying the reference group into the three subgroups of
varying risk character. Finally, we also explored the disease risk
proﬁle of T2DM and CVD based solely on cumulating numbers
of MetS risk factors.
2. Methods
2.1. Study population
The Prospective Epidemiological Risk Factor (PERF) study is an
observational, prospective study of elderly Danish women (n=
5855) conducted in 1999 to 2001. The cohort consists of
postmenopausal women who either had previously participated
in clinical randomized placebo-controlled studies or were
screened without being randomized for previous studies at the
Center for Clinical and Basic Research (CCBR) in Copenhagen or
Aalborg, Denmark. Prior studies run at CCBR, which ultimately
lead to the study population in PERF, mainly focused on age-
related diseases such as osteoporosis and osteoarthritis, and both
screen failures and enrolled participants from these studies (n=
8875) were invited and included on equal terms in the PERF
study. The study was carried out in accordance with ICH-GCP
with study protocol approval from the local ethics committees;
The Research Ethics Committee of Copenhagen County and the
Research Ethics Committee of Viborg and North Jutland
Counties, Denmark (approval reference: KA 99070gm). Written
informed consent was obtained from all participants.
Baseline examination comprised a physical examination
including a full-body dual-energy X-ray absorptiometry (DEXA)
scan, blood sampling, and a self-reported questionnaire compil-
ing information on smoking habits, alcohol intake, medical
history, menopause age, physical activity level, and educational
level.
2.2. Deﬁnition of the metabolic syndrome
MetS was deﬁned using a modiﬁed version of the deﬁnition set by
IDF.[15] Waist circumference was not directly measured in PERF,
and therefore the deﬁnition of central obesity was based on a
calculated central/peripheral fat mass ratio (C/P ratio) deter-
mined by DEXA scan. Central fat mass was deﬁned as fat located
at the torso and peripheral fat mass deﬁned as fat located on
arms, legs, and head as determined by DEXA scan. The cohort
was divided into quartiles based on the C/P ratio, and only
subjects in the fourth quartile were deﬁned as centrally obese in
the analysis. All subjects in this quartile had a C/P ratio >1.
The MetS inclusion criteria were deﬁned as a C/P ratio >1 or a
body mass index (BMI) >30kg/m2, and 2 or more of the
following risk factors: increased triglycerides (>1.7mmol/L),
decreased HDL cholesterol (<1.29mmol/L), increased fasting
plasma glucose (>5.6mmol/L), and increased BP (systolic >130
mm Hg or diastolic >85mm Hg or treatment of previously
diagnosed hypertension).
The IDF criteria state that treatment for lipid abnormalities
speciﬁcally targeting HDL cholesterol or triglycerides can be used
as deﬁning the risk factor, rather than the actual serum value
itself. However, as speciﬁed hyperlipidemia treatment was not
part of the questionnaire, we were not able to determine the
speciﬁc lipid-lowering treatments; therefore, only the serum
measurements for these 2 variables were part of the MetS-
deﬁning criteria of dyslipidemia in this study.
2.3. Study endpoints
The study endpoints were a T2DM diagnosis or a CVD event
occurring after participation in PERF. Follow-up information on
T2DM and CVD diagnosis was retrieved from The National
Danish Diabetes Registry and The National Danish Patient
Registry, respectively, using a unique personal identiﬁcation
number for each subject. Classiﬁcation of CVD diagnoses was
completed according to The International Classiﬁcation of
Diseases, 10th revision (version 2016). All diagnoses from
Chapter IX (Diseases of the circulatory system) were included in
the analysis as CVD events.
The dataset used for analysis was deﬁned as subjects with no
missing data for all MetS-deﬁning variables and no T2DM or
CVD diagnosis before PERF (n=3905) as illustrated in Fig. 1.
The maximum follow-up period was 15.1 years (mean follow-
up: 12.7±3.0 years) starting on the day of study enrollment and
ending at either occurrence of an event (register-based diagnosis)
or on December 31, 2014 (registry data retrieval date), whichever
came ﬁrst. Of the entire study population, a total of 762 diabetics
were identiﬁed, whereof 229 subjects were excluded from the
analysis due to diagnosis before study enrollment. CVD diagnosis
was identiﬁed in 3744 subjects, whereof 1313 subjects were
excluded for having a CVD event before study enrollment. Of
these 1313 subjects, 69 were also diagnosed with diabetes before
enrollment, leaving 1217 unique subjects excluded based solely
on CVD event history.
One or several data points for deﬁning MetS were missing for
446 subjects. Sixty-three subjects were underweight (BMI18.5
kg/m2), and thus, the DEXA scan may not be suitable for the
deﬁnition of a relevant C/P ratio in this subgroup. In total, 509
subjects had either missing or inconclusive data points to permit
deﬁnition of MetS. Altogether, 3905 subjects were included for
further analysis.
In addition to the stratiﬁcation based on identiﬁed MetS, data
were analyzed based on a cumulative number ofMetS risk factors
(0–5) in order to investigate the cumulative effect of risk factors.
In this regard, risk factors were dichotomized based on the cutoff
for the MetS criteria.
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2.4. Statistical analysis
Statistical analysis was conducted using MedCalc Statistical
Software v. 14.8.1 (MedCalc Software, Ostend, Belgium),
GraphPad Prism v.6 (GraphPad Software, La Jolla, CA), and
SAS software, Version 9.4 (SAS Institute Inc., Cary, NC). PCA
was performed in R v. 2.15.3 (R Development Core Team,
Vienna, Austria) using the ggbiplot package.
Baseline characteristics of subjects with deﬁned MetS com-
pared to subjects with no risk factors for MetS (Table 1) were
analyzed using Mann–Whitney U test (numerical variables) or
chi-square test (categorical variables).
Multivariate Cox proportional hazards regression model with
age as time scale was used to assess three aspects of theMetS: risk
of developing T2DM and CVD in women deﬁned with MetS
compared to women not deﬁned with the syndrome; risk
associated with the individual MetS risk factors and subsequent
T2DM or CVD (Fig. 2); risk of developing T2DM and CVD in
womenwith deﬁnedMetS, in womenwith central obesity, and up
to one additional MetS risk factor, but not deﬁned with MetS,
and in women with other risk factors for MetS than central
obesity.Women holding no risk factors forMetS were used as the
reference group (Fig. 4A). Categorical variables included in
all multivariate Cox proportional hazard regression models
were current smoking (yes/no), current alcohol consumption (<7
vs≥7 drinks/wk), and physical activity other than walking (<2 vs
≥2 sessions/wk). The Cox proportional hazard regression model
was further used to assess the risk of T2DM and CVD based on
the cumulative number of metabolic risk factors (1–5), where
subjects with no MetS risk factors were used as reference group
(Fig. 4B). Incidence rates were calculated for all groups (Table 2)
as incidence per 1000 person-years.
PCA (Fig. 3A) was computed from C/P ratio, BMI,
triglycerides, HDL cholesterol, fasting glucose, systolic BP,
diastolic BP, smoking status, alcohol consumption, physical
activity, low-density lipoprotein (LDL) cholesterol, total choles-
terol, white blood cell count (WBC), alanine-aminotransferase
Figure 1. Deﬁnition of the study population. CVD = cardiovascular disease, MetS = metabolic syndrome, IDF = International Diabetes Federation, PERF =
Prospective Epidemiological Risk Factor study.
Table 1
Cohort characteristics of elderly women
with and without deﬁned MetS.
MetS by
IDF deﬁnition
(n=818)
Controls not
deﬁned with MetS
(n=3087)
Demographics
Age, y 70.5 (69.8–71.0) 70.3 (69.9–70.6)
Menopause age, y 50.0 (49.0–50.0) 50.0 (50.0–50.0)
Family history of diabetes (%) 8.5 (62) 8.1 (216)
Education
Primary school (%) 71.0 (579) 69.9 (2158)
High school (%) 21.2 (173) 23.0 (709)
University (%) 7.8 (64) 7.1 (220)
Occupation (working, %) 76.0 (621) 74.7 (2303)
Lifestyle
Current smoking (%) 20.8 (170) 22.6 (697)
Alcohol (>7gl/wk, %) 31.2 (255) 34.5 (1059)
Physical activity (≥2 sessions/wk, %) 63.7 (521)
∗
73.5 (2269)
Vitals
Height, cm 160.5 (160.2–161.0) 161.1 (160.8–161.3)
Weight, kg 76.4 (75.4–77.4)
∗
64.6 (64.2–65.1)
BMI, kg/m2 30.0 (29.5–30.3)
∗
24.9 (24.8–25.1)
Systolic blood pressure, mm Hg 155.0 (153.0–156.0)
∗
145.0 (144.0–147.0)
Diastolic blood pressure, mm Hg 85.0 (84.0–86.0)
∗
80.0 (80.0–81.0)
Serum chemistry
Glucose, mmol/L 5.8 (5.8–5.9)
∗
5.2 (5.2–5.2)
Cholesterol, mmol/L 6.4 (6.4–6.5)
∗
6.3 (6.3–6.3)
LDL, mmol/L 4.1 (4.0–4.2)† 3.9 (3.9–3.9)
HDL, mmol/L 1.5 (1.4–1.5)
∗
1.8 (1.8–1.8)
Triglycerides, mmol/L 1.8 (1.7–1.8)
∗
1.1 (1.1–1.2)
White blood cells, 109 cells/L 5.9 (5.8–6.1)
∗
5.4 (5.4–5.5)
ALAT, mmol/L 27.0 (26.0–27.0)
∗
23.0 (23.0–23.0)
ASAT, mmol/L 24.0 (24.0–25.0)
∗
23.0 (23.0–23.0)
Data shown as median value (95% conﬁdence interval) or as percentage (absolute number of cases).
ALAT = alanine-aminotransferase, ASAT = aspartate-aminotransferase, BMI = body mass index,
HDL = high-density lipoprotein, IDF = International Diabetes Federation, LDL = low-density
lipoprotein, MetS = metabolic syndrome.
∗
Signiﬁcantly different from controls (P<0.001).
† Signiﬁcantly different from controls (P=0.007).
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(ALAT), and aspartate-aminotransferase (ASAT). All variables
were assessed for normality, and C/P ratio, BMI, and triglyceride
levels were log-transformed to ensure normality in the data
distribution. Subjects with a WBC serum levels >109 cells/L, or
ALAT or ASAT levels>50mmol/L, were excluded from the PCA
(n=161) to secure a representative presentation of the metabolic
risk factor distribution in the cohort, so that subjects with
extreme WBC, ALAT, and ASAT values would not distort the
analysis. After centering and scaling the data, we obtained the
principal components (PCs) describing the systematic variation in
data across the 15 variables, hence revealing the metabolic
proﬁles in the dataset. The differences between the PC1
components of the four groups were compared using one-way
analysis of variance with 95% conﬁdence limits. Tukey’s test was
applied as post hoc analysis to determine pairwise differences
between groups (Fig. 3B). The relationship between subjects
deﬁned with MetS compared to the 3 non-MetS subgroups was
also analyzed using a Kruskal–Wallis test (Supplemental Digital
Content 1, http://links.lww.com/MD/B253). For P values less
than 0.05, a post hoc test for pairwise comparison of subgroups,
according to Conover,[20] was performed.
3. Results
3.1. Metabolic syndrome in elderly women
Among the elderly women in the PERF cohort, we found that
20.9% were deﬁned having MetS (n=818) (Table 1). The
demographic characteristics, education level, and lifestyle did not
vary among subjects with MetS and controls except for physical
activity level, which was greater in the control group (P<0.001).
Serum LDL and total cholesterol, which are lipid parameters
not used in the MetS deﬁnition, varied signiﬁcantly between the
two groups (P<0.001 and P=0.007, respectively). This was also
the case for WBC and the liver function markers ALAT and
ASAT (P<0.001 for all three variables).
We found a 3.6-fold increased risk of developing T2DM
(hazard ratio (HR)=3.63, 95% conﬁdence interval: [2.93–4.48])
Figure 2. Risk associated with the 5 metabolic risk factors used to deﬁne the metabolic syndrome showed central obesity to be the only risk factor contributing to
increased risk of both T2DM and CVD outcome. Multivariate Cox regression analysis for the risk of developing T2DM and CVD based on individual metabolic risk
factors; central obesity, high blood pressure, elevated fasting glucose, decreased HDL cholesterol, and increased triglyceride levels. Values were adjusted for age,
smoking, alcohol consumption, and physical activity. CVD = cardiovascular disease, T2DM = type 2 diabetes mellitus. Data represent hazard ratio with 95%
conﬁdence interval.
Table 2
Incidence rates of T2DM and CVD within elderly women in the PERF cohort
stratiﬁed based on metabolic deﬁnitions or based on number of risk factors.
Type 2 diabetes CVD
Groups
Person-years
at risk
T2DM
cases
Incidence per
1000 person-years
Lower
95% CI
Upper
95% CI
Person-years
at risk
CVD
cases
Incidence per
1000 person-years
Lower
95% CI
Upper
95% CI
MetS by IDF deﬁnition 8993.4 164 18.2 15.7 21.3 7292.5 487 66.8 61.1 73.0
Central obesity
but no MetS
6923.7 44 6.4 4.7 8.5 5361.6 316 58.9 52.8 65.8
Risk factors for MetS
but no central obesity
25,504.5 127 5.0 4.2 5.9 19,875.5 1093 55.0 51.8 58.4
Controls
not deﬁned with MetS
5636.6 16 2.8 1.7 4.6 4632.2 168 36.3 31.2 42.2
Type 2 diabetes CVD
Number of
risk factors
Person-years
at risk
T2DM
cases
Incidence per
1000 person-years
Lower
95% CI
Upper
95% CI
Person-years
at risk
CVD
cases
Incidence per
1000 person-years
Lower
95% CI
Upper
95% CI
5 662.3 24 36.2 24.3 54.1 520.4 50 96.1 72.8 126.8
4 2963.8 62 20.9 16.3 26.8 2387.5 163 68.3 58.6 79.6
3 7332.5 99 13.5 11.1 16.4 6011.3 364 60.6 54.6 67.1
2 13,001.0 90 6.9 5.6 8.5 10,040.7 601 59.9 55.3 64.8
1 17,461.9 60 3.4 2.7 4.4 13,569.6 718 52.9 49.2 56.9
0 5636.6 16 2.8 1.7 4.6 4632.2 168 36.3 31.2 42.2
CI = conﬁdence interval, CVD = cardiovascular disease, IDF = International Diabetes Federation, MetS = metabolic syndrome, T2DM = type 2 diabetes mellitus.
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and a 1.3-fold increased risk of a CVD event (HR=1.29
[1.16–1.43]) after 12.7±3.0 years of follow-up for subjects with
MetS compared to controls without deﬁned MetS. Given the
strong effects of MetS on disease risk, we further investigated the
relationship between the individual MetS risk factors and
subsequent T2DM or CVD events (Fig. 2).
Central obesity was the only MetS risk factor contributing to
increased risk of both outcomes with a 2-fold increased risk of
T2DM (HR=1.98 [1.57–2.48]) and a 1.5-fold increased risk of a
CVD event (HR=1.48 [1.30–1.68]) (Fig. 2). Elevated fasting
glucose was only related to the development of T2DM (HR=
3.38 [2.71–4.22]) and did not contribute to an increased risk of
Figure 3. A heterogeneous metabolic risk proﬁle within the control group. (A) Principal component analysis score plot colored by group: reference group subjects
with nometabolic risk factors (green), subjects with risk factors for MetS but no central obesity (gray), subjects with central obesity and up to 1 other MetS risk factor
(purple), and subjects with deﬁned MetS (orange). The ellipses cover 68% of the subjects belonging to a given subgroup. Loadings for the included parameters are
shown with arrows. ALAT = alanine-aminotransferase, ASAT = aspartate-aminotransferase, C/P ratio = central/peripheral fat mass ratio, cholesterol = total
cholesterol, glucose = fasting glucose, WBC = white blood cell count. Exercise: physical activity. (B) Distribution of the principal component 1 scores for the 4
subgroups. Boxes represent the upper quartile, the mean, and the lower quartile of the data. Whiskers designate the Tukey interval with outliers shown as staggered
dots.
∗∗∗
P<0.001. MetS = metabolic syndrome, non-CO = non-central obese.
Figure 4. Stratiﬁcation of the heterogeneous control group in identiﬁed intermediate subgroups with increased risk for later T2DM and CVD. (A) Multivariate Cox
regression analysis for the risk of developing T2DM and CVD based on control group stratiﬁcation. Subgroups represent reference group with no risk factors for
MetS, subjects with risk factors for MetS but no central obesity, subjects with central obesity and up to one additional MetS risk factor, and subjects with deﬁned
MetS. Values are adjusted for age, smoking, alcohol consumption, and physical activity. CVD = cardiovascular disease, MetS = metabolic syndrome, non-CO =
non-central obesity, T2DM = type 2 diabetes mellitus. (B) Risk of developing T2DM and CVD for subjects with 1 to 5 risk factors for MetS as compared to the
reference group with no MetS risk factors. 0: n=432; 1: n=1404; 2: n=1083; 3: n=647; 4: n=271; and 5: n=68. Values are adjusted for age, smoking, alcohol,
and physical activity. Data represent hazard ratio with 95% conﬁdence interval.
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CVD. Conversely, high blood pressure was a contributor to the
development of CVD events (HR=1.19 [1.09–1.30]) but did not
contribute to an increased risk of T2DM. Neither HDL
cholesterol nor triglyceride levels contributed to an increased
risk of T2DM and CVD in this cohort of elderly Caucasian
women.
3.2. Subgrouping the control group consisting of subjects
with heterogeneous MetS risk factor proﬁles
Since central obesity alone contributed to increased risk of both
T2DM and CVD, we speculated if the subjects with central
obesity in the control group would take part in reducing the
prediction of future disease prevalence within deﬁned MetS
subjects. To examine this question, we divided the heterogeneous
control group into 3 subgroups: subjects with central obesity, and
up to 1 additional MetS risk factor, but not deﬁned with MetS;
subjects without central obesity, but with other risk factors for
the MetS; and subjects with no MetS risk factors.
To capture the multivariate features of the dataset, we used
PCA to visualize the differences between the MetS group and
the three control subgroups (Fig. 3A). We observed a distinct
separation between subjects with deﬁned MetS (orange) and the
control group comprising subjects with no risk factors for MetS
(green), while the non-MetS subjects with central obesity (purple)
and subjects with other MetS risk factors (gray) cut in between
the non-MetS risk factor controls and MetS subjects in the PCA
score plot. Based on the group distributions, the multivariate
analysis indicated that subjects with central obesity and up to 1
MetS risk factor are metabolically more similar to MetS subjects,
while subjects with other MetS risk factors than central obesity
are more similar to the reference group with noMetS risk factors.
The 4 subgroups were found to statistically separate in PC1
(Fig. 3B), meaning that all subgroups differed in the parameters
pulling in the PC1 direction within the loading plot. The
parameters driving this separation are mainly MetS classiﬁcation
parameters such as C/P ratio, BMI, fasting glucose, HDL
cholesterol, triglycerides, and blood pressure. Smoking, LDL
cholesterol, and ASAT had no inﬂuence on the separation of the
subjects in PC1.
Since the PCA indicated that the three subgroups from the
former control group showed differentiated metabolic proﬁles,
we used Cox regression analysis to investigate whether these
subjects also showed different risk proﬁles for T2DM and CVD.
We found that controls with central obesity without MetS had a
2.2-fold increased risk of T2DM (HR=2.21 [1.25–3.93]) and
a 1.5-fold increased risk of CVD (HR=1.51 [1.25–1.83])
compared to the reference group with no risk factors for
MetS (Fig. 4A). Likewise, controls with other MetS risk factors
than central obesity had a 1.8-fold increased risk of T2DM
(HR=1.75 [1.04–2.96]) and a 1.4-fold increased risk of CVD
(HR=1.36 [1.15–1.60]). Moreover, the stratiﬁcation of the
former control group also affected the disease risk in MetS
subjects, as subjects with deﬁned MetS showed a 6.3-fold
increased risk of developing T2DM (HR=6.29 [3.74–10.50])
and a 1.7-fold increased risk of a CVD event (HR=1.72
[1.44–2.05]), when speciﬁcally compared to the reference group
without MetS risk factors.
Further, we explored the effect of the risk factor distribution
further by analyzing the relationship between the cumulated sum
of risk factors and subsequent disease events. The average
number of MetS risk factors for all subjects in the analytical
sample was 1.8±1.2. T2DM risk was increased for subjects with
≥2 MetS risk factors compared to subjects with no risk factors;
1 risk factor: HR=1.20 (0.69–2.09), 2 risk factors: HR=2.44
(1.43–4.17), 3 risk factors: HR=4.70 (2.77–7.98), 4 risk factors:
HR=7.27 (4.19–12.61), and 5 risk factors: HR=11.57
(6.12–21.88), respectively (Fig. 4B). An increased risk of a
CVD event was found with ≥1 risk factor for MetS: HR=1.33
(1.12–1.58), HR=1.47 (1.24–1.75), HR=1.55 (1.29–1.86),
HR=1.75 (1.41–2.18), and HR=2.52 (1.83–3.46), respectively,
as illustrated in Fig. 4B. The incidence rates shown in Table 2
further manifested the differentiated risk within the metabolic
subgroups when stratiﬁed either based on metabolic deﬁnitions
or based on number of risk factors. The lowest incidence was
found in the control group holding no risk factors for MetS, with
an incidence of 2.8 (1.7–4.6) per 1000 person-years for T2DM
and an incidence of 36.3 (31.2–42.2) per 1000 person-years for
CVD. The highest incidence was found in the group holding
5 risk factors for MetS, with an incidence of 36.2 (24.3–54.1) per
1000 person-years for T2DM and an incidence of 96.1
(72.8–126.8) per 1000 person-years for CVD.
4. Discussion
Elderly women with MetS proved to have an increased risk of
developing T2DM and CVD when compared to women not
deﬁned with the syndrome. The increased risk of 3.6-fold for
T2DM and 1.3-fold for CVD found in this study correlated well
with ﬁndings reported in previous studies using a heterogeneous
control group, although these results mostly originate from
cohorts of middle-aged men and women.[10,17–19] We further
reﬁned these results by highlighting how a control group with
heterogeneousMetS risk proﬁles in women without deﬁnedMetS
can lead to a distortion of the hazard estimations associated with
the MetS. We showed how speciﬁcally comparing subjects with
deﬁned MetS to subjects with no risk factors for MetS increased
the risk estimate of future T2DM from 3.6 to 6.3-fold and the risk
of a future CVD event from 1.3 to 1.7-fold. This clearly suggests
that the risk of developing T2DM and CVD in women with
deﬁned MetS is much greater than previously proposed and
further, that the risk of T2DM and CVD also was greater in
women not deﬁned with the syndrome but still holding some risk
factors for MetS. To our knowledge, this type of risk assessment
of the MetS has not previously been reported. In addition, the
analysis of cumulating MetS risk factors showed increasing
risk of later disease with increasing number of risk factors; with
5 MetS risk factors resulting in 11.6-fold increased the risk of
T2DM development and 2.5-fold risk of CVD. This underlines
the value of identifying subjects with MetS risk factors in the
elderly population as well.
Central obesity was the only MetS risk factor that indepen-
dently contributed to the risk of both future T2DM and CVD
(2- and 1.5-fold, respectively). As central obesity is consistently
highlighted as a key contributor to risk in any deﬁnition of the
MetS,[16] our ﬁnding is congruent with this prominent role of
central obesity in the MetS deﬁnition. By partitioning the control
group of non-MetS subjects into 3 subgroups, we repeated our
ﬁnding of a 2-fold increased risk of T2DM and 1.5-fold for
CVD outcomes in subjects with central obesity without MetS.
Furthermore, the PCA revealed that subjects with central obesity
displayed a higher degree of similarity toMetS subjects than the 2
other subgroups without this risk factor, emphasizing the role of
central obesity as a key driver of both T2DMandCVD.While we
clearly demonstrated the predictive value of the MetS in relation
to later risk of T2DM and CVD in elderly Caucasian women,
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we also showed that women not fulﬁlling the full MetS criteria
likewise have a higher risk of developing T2DMandCVD later in
life, if they have one or more of the MetS risk factors at baseline.
This was further illustrated in the differentiated incidence rates
found within the subdivided reference group. Further, the
calculated incidence rates also underlined how the incidence of
both T2DM and CVD increased with increasing numbers of risk
factors.
The prognostic importance of the MetS compared to the
prognostic capability of the sum of the individual MetS risk
factors has previously been challenged by others.[21–23] With the
PCA and risk estimates presented in this study, we add to this
debate by assessing the risk of the individual components,
highlighting the heterogeneity in the metabolic proﬁles of subjects
not deﬁned with MetS, and determining the predictive ability of
the cumulating sum of risk factors constituting the MetS. Other
studies have compared the predictive ability for CVD using both
theMetS deﬁnition and the FraminghamRisk Score[24–26] ﬁnding
similar results for the two scoring systems, and further found the
Diabetes Prediction Model to be superior to the MetS deﬁnition
in predicting the risk of diabetes development.[25] Similarly, the
ﬁndings in our study indicated that deﬁning the MetS does not
supersede the risk estimated when summing the risk of the
individual risk factors. Consequently, our ﬁndings add to the
questioning of applying a MetS deﬁnition to commonly
cooccurring risk factors will provide auxiliary value in the
general practice. Thus, it might be more practical to focus on
developing a classiﬁcation scheme that reﬂects both the degree
and sum of risk factor abnormalities instead of using the current
MetS deﬁnition. This suggestion is founded on the assumption
that cooccurring factors indeed enhance the risk of adverse
outcomes, as was also the result of our current cumulating risk
factor analysis.
Regardless of focusing on MetS as a joined deﬁnition or on the
sum of risk factors, it is known that the prevalence of the risk
factors forMetS increases with age, reaching a prevalence of 40%
in people aged >60 years.[2] The initial indicator of a high-risk
metabolic proﬁle is central obesity, and our present study
coherently points to the high priority of this risk factor in the
elderly segment of the population, when focusing on preventing
T2DM and CVD and in advancing efforts to regulate the obesity
epidemic.
The strengths of this study include its longitudinal design,
detailed assessment of metabolic risk factors, and exclusion of
subjects with T2DM and CVD at baseline. The study’s follow-up
information was derived from Danish registry data, which is of
high quality based on the use of a unique personal identiﬁer and
nationwide electronic patient records, and thus results in limited
loss of data from baseline to follow-up. The cohort consists of a
large group of women in Denmark, where the homogenous
population with equal access to primary care (tax-paid, not
individually paid) may limit extrapolations to other populations.
However, the hazard ratios found in this study are comparable to
associations found in similar cohorts, though with different age
distributions, which indicates that such generalizations are
indeed plausible. By applying PCA as a multivariate tool to
assess risk proﬁles, we introduce a possible confounder, as we
subdivide the study population before PCA based on central
obesity. With this common denominator being present in both
the MetS group and the non-MetS group with central obesity, we
potentially skew these 2 subgroups toward each other compared
to the non-MetS group holding other risk factors forMetS, as this
subgroup may be regarded as being more heterogeneous (by not
having obesity as a common denominator). However, based on
the MetS deﬁnition, it is not possible to circumvent this type of
limitation. In this study, central obesity was determined byDEXA
scan rather than waist circumference originally proposed by IDF.
However, IDF does highlight that DEXA scan can be used as an
additional factor in research of theMetS, which can allow further
modiﬁcation of the deﬁnition if necessary.
Elderly Caucasian women fulﬁlling the MetS criteria set by the
IDF showed increased risk of future T2DM or CVD diagnosis;
however, subjects who did not fulﬁll the criteria for MetS but
presented one or more of the components of MetS were also at
increased risk. A further subdivision of the reference group
proved to increase the risk of T2DM to 6.3-fold (from 3.6-fold)
and 1.7-fold for CVD (from 1.3-fold) for MetS subjects when
compared to a reference group only including subjects with no
MetS risk factors. In clinical practice, employment of the MetS in
elderly women should be focused as a tool for identifying subjects
with metabolic high-risk proﬁles. However, the sum of risk
factors are proposed to be equally considered, as subjects not
ﬁtting the MetS-criterion, but still holding one or more risk
factors for MetS, were here identiﬁed also to be at increased risk
of T2DM and CVD.
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Additional Results (not published) 
Figure – additional: Accumulated sum (%) of the five risk factors defining the MetS for subjects 
with 1, 2, 3, 4 or 5 risk factors for MetS. 0: n=432, 1: n=1404, 2: n=1083; 3: n=647, 4: n=271; 5: n=68. 
Entrance criteria: 1: 4.8%, 2: 23.0%, 3: 25.9%, 4: 22.8%, 5: 20.0%. Triglycerides: 1: 2.6%, 2: 8.5%, 3: 15.3%, 
4: 21.9%, 5: 20.0%). Fasting glucose: 1: 4.8%, 2: 17.8%, 3: 20.0%, 4: 18.6%, 5: 20.0%. HDL cholesterol: 1: 
1.4%, 2:4.3%, 3: 7,1%, 4: 13.3%, 5: 20.0%. Blood pressure: 1: 85.8%, 2: 46.4%, 3: 31,6%, 4: 23.4%, 5: 20.0%). 
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6 WEIGHT CHANGE AND HYPERGLYCAEMIC RISK 
Title 
Weight Change and Risk of Hyperglycaemia in Elderly Women 
Aim 
The aim of the study was to investigate the interplay between weight change and risk of 
hyperglycaemia in elderly women.  
Rationale 
Hyperglycaemia increases the risk of T2DM, heart disease, and stroke and is influenced by 
weight. It has been proposed that the association between BMI and the development of 
hyperglycaemia and T2DM is more complex than just a dose-response relationship and the 
impact of preceding weight change on blood glycemia levels in late-life is not well 
understood.  
Findings 
Overweight and obese elderly women with stable weight at follow-up presented an 
increased risk of hyperglycaemia, OR=2.2 [95% CI: 1.3-3.8] and OR=2.0 [1.0-4.2], compared 
to weight-stable women with normal weight at baseline. Overweight and obese women who 
lost weight during the follow-up period decreased their risk of hyperglycaemia to a level 
comparable with weight-stable normalweight women, whereas weight gain resulted in a 2.7-
fold increased risk in overweight gainers and a 3.2-fold increased risk in obese weight 
gainers. 
Conclusions 
Losing weight in late life had a positive effect on the risk of hyperglycaemia in overweight 
and obese women, while further weight gain increased the risk of hyperglycaemia. The study 
highlights that strategies to reduce weight in obese and overweight elderly women could 
have a positive influence on hyperglycaemia and following disease burden in late-life. 
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ABSTRACT (250 words) 
Background Hyperglycaemia increases the risk of type 2 diabetes, heart disease, and stroke and is 
influenced by weight. However, the impact of preceding weight change on blood glycemia levels in 
late-life is less well understood. 
Aim We studied the interplay between weight change and risk of hyperglycaemia in a prospective cohort 
of elderly women. 
Methods Elderly Caucasian women (age: 67.1 years at baseline, n=1,173) enrolled in the Prospective 
Epidemiological Risk Factor (PERF) study with baseline and 13-year follow-up measurements of BMI 
and fasting glucose levels (FPG) and no previous history of diabetes or impaired fasting glucose. 
Multivariate logistic regression was used to determine risk of hyperglycaemia (FPG≥5.6mmol/L or 
HbA1c≥42mmol/mol) in normalweight (BMI≤25kg/m2), overweight (BMI=25-29.9kg/m2) and obese 
(BMI≥30kg/m2) women who either lost weight, were weight-stable or had gained weight at follow-up. 
Results Overweight and obese elderly women who had gained weight at follow-up presented an 
increased risk of hyperglycaemia, OR=2.7 [1.6-4.6] and OR=3.2 [1.5-6.8], compared to weight-stable 
normalweight women. Overweight and obese women who lost weight decreased their risk of 
hyperglycaemia to a level comparable to weight-stable normalweight women. Overweight and obese 
women with stable weight presented a 2-fold increased risk of hyperglycaemia compared to 
normalweight weight-stable women. 
Conclusions Losing weight in late life had a positive effect on the risk of hyperglycaemia in overweight 
and obese women, while further, weight gain increased the risk of hyperglycaemia. The study highlights 
that strategies to reduce weight in obese and overweight elderly women could have a positive influence 
on disease burden in late-life. 
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MAIN TEXT 
Hyperglycaemia is a risk factor for type 2 diabetes, heart disease, and stroke at all ages (1,2). With the 
increasing number of elderly people, of which many are chronically ill, the change in aging 
demographics is now considered a global burden (3). Obesity-induced hyperglycaemia in late life is a 
risk factor that greatly contributes to chronic illnesses, which justifies the eligibility of a cohort study of 
weight change and hyperglycaemia in the old age group (80+ years). 
Hyperglycaemia is the first clinical symptom of type 2 diabetes resulting from defects in insulin 
production, insulin action, or both (4). Impaired glucose tolerance and impaired fasting glucose levels 
are important risk factors for the development of future diabetes and compared to subjects with normal 
glucose tolerance, the risk of type 2 diabetes increase 10-20 fold when hyperglycaemia is present (5). 
This increased risk does not seem to vary with age (6), highlighting the importance of continuous 
glucose monitoring even in late life. 
The major driver of prediabetes and diabetes, besides age, is obesity and the obesity prevalence is 
concurrently increasing until 60 years of age. The Scottish Health Survey has in 2014 presented that 
while the overall prevalence of obesity showed little increase in the population aged 16-64, the body 
mass index (BMI) continued to rise specifically in women between age 55 and 74 with 78% being 
overweight or obese. This was 72% for the oldest age group (+75) (7). While diabetes risk studies are 
mainly focused on mid-life populations, elderly with diabetes have increased disease burden due to 
greater risk of acute and chronic microvascular and cardiovascular complications (8) which are linked 
to increased mortality, reduced functionality, and increased risk of institutionalization (9). Centers for 
Disease Control and Prevention propose that even if diabetes incidence will stagnate in the coming years, 
the prevalence of diabetes will double in the next 20 years, in part due to the aging of the population 
(10). The elder age group (>65 years of age) already presents the highest prevalence of diabetes globally 
(10), and therefore, effective strategies to reduce diabetes development, also in elderly, are highly 
warranted. 
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Here we aimed to investigate the influence of baseline weight and weight change during a period of 13-
years on the subsequent risk of hyperglycaemia development in elder women. Subjects were 67(standard 
deviation 0.3) years of age at baseline and took part in the Prospective Epidemiological Risk Factor 
Study, which is a community-based cohort in Denmark. 
RESEARCH DESIGN AND METHODS 
The Prospective Epidemiological Risk Factor (PERF) study was an observational, prospective study of 
elderly Danish women conducted in 1999-2001 (PERF I) (n=5,855) with a follow-up visit (PERF II) in 
2014-2015 (n=2,103). A full description of the cohort has been published elsewhere (11). The cohort 
consists of postmenopausal women who had either previously participated in clinical randomized 
placebo-controlled studies or were screened without being randomized for previous studies at the Center 
for Clinical and Basic Research (CCBR) in Copenhagen or Aalborg, Denmark. Prior studies run at 
CCBR, which ultimately lead to the study population in PERF, mainly focused on age-related diseases. 
Both screen failures and enrolled participants from these studies (n=8,875) were invited and included 
on equal terms in the PERF study. The participation rate was 72% in PERF I and 75% in PERF II. The 
baseline and follow-up visits comprised a physical examination, including height and weight 
measurement, and blood sampling performed by trained staff. Further, a self-reported questionnaire 
compiling information on medication, smoking status, alcohol intake, educational level, and physical 
activity. Both baseline and follow-up visits were carried out in accordance with Good Clinical Practice 
following the Helsinki declaration (ICH-GCP) with study protocol approval from The Research Ethics 
Committee of Copenhagen County (approval reference for PERF I: KA 99070gm and for PERF II: H-
2-2012-074). 
Study population 
Elderly Caucasian women with baseline and follow-up data on BMI and fasting plasma glucose levels 
were included in this study. The dataset used for analysis (n=1,173) excluded women with missing BMI 
data (n=169), a pre-existing diabetes diagnosis prior to the follow-up visit (n=222), self-reported use of 
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antidiabetic medication in women who did not have a diagnosis elsewhere (n=5), fasting plasma glucose 
levels ≥5.6mmol/L at baseline (n=528) or missing data on plasma glucose levels (n=6). Information on 
pre-existing diabetes diagnosis was retrieved from The Danish National Diabetes Register (NDR) using 
a unique personal identification number for each subject. NDR is based on information from Danish 
health registries, including the Danish National Patient Registry, the Danish National Prescription 
Registry, and the Danish National Health Service Registry. The study endpoint was pre-diabetic 
hyperglycaemia determined as a fasting plasma glucose level ≥5.6mmol/L (≥100 mg/dL), or a pre-
diabetic HbA1c-level ≥5.7% (≥42mmol/L) as defined by ADA (12), measured at the follow-up visit. At 
follow-up 447 women had hyperglycaemia of which 29 women had diabetic glucose levels with a fasting 
plasma glucose level >7.0mmol/L (>126 mg/dL) or an HbA1c-level >6.5% (>48mmol/L) (Figure 1). 
Fasting plasma glucose was measured directly after collection in both PERF I and II, using a Vitros 250 
slide cartridge with no reagent system from Ortho Clinical, in PERF I, and an enzymatic measurement 
method using the Avida 1800, from Siemens, in PERF II. 
BMI characteristics 
Height and weight were recorded at baseline and follow-up with BMI calculated at both visits (weight 
(kg)/height squared (m2)). Height was measured using a Charder transportable stadiometer and weight 
was measured using a Seca 899 class III standardized scale with yearly calibration. Trained staff 
performed the measurements. The BMI classification at baseline was done according to WHO definition 
(13) with BMI criteria for underweight: BMI≤18.5 kg/m2 (n=19), normal weight: BMI>18.5-24.9 kg/m2 
(n=589), overweight: BMI=25.0-29.9 kg/m2 (n=427) and obesity: BMI≥30 kg/m2 (n=138). The 
underweight and normal weight women were combined in one group for logistic regression analysis and 
denoted normalweight. Each baseline BMI group was stratified in tertiles based on delta-BMI from 
baseline to follow-up to reflect BMI change. Women in the lower tertile group were denoted weight-
losers, women in the middle tertile weight-stable and women in the upper tertile weight-gainers.  
Spearman’s correlation test was used to correlate BMI at follow-up with waist circumference, hip 
circumference, waist-hip ratio and muscle strength at follow-up. Tape measuring was used for 
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determining waist and hip circumference. The measuring band was applied midway between the inferior 
margin of the last rib and the crest of the ileum, in a horizontal plane. The hip was measured at the 
widest point in a horizontal plane. Muscle strength was measured by Jamar handgrip dynamometer using 
an average of three continuous measurements on the dominant hand. Trained health professionals 
carried out the measurements. 
Statistical analysis 
Statistical analysis was conducted using MedCalc Statistical Software version 16.4.3 (MedCalc 
Software bvba, Ostend, Belgium). 
Women who developed hyperglycaemia were compared to women who did not develop hyperglycaemia 
at baseline and follow-up using an independent two-way t-test for numerical variables following Welch 
test in case of unequal variance and a Chi-square test for categorical variables at baseline and follow-
up. 
Further, logistic regression analysis was applied to assess the association between BMI change and risk 
of a hyperglyacemic outcome. Subjects defined as normalweight at baseline with a stable weight at 
follow-up was used as reference group. Covariates known from the literature to influence the risk of 
hyperglycaemia was included in the multivariate regressions. In the partly adjusted model, adjustments 
were made for age at baseline and the categorical variables; educational level (primary school (ref), high 
school, university), smoking (never (ref), past, present), current alcohol consumption (<10.5 units/week 
vs. ≥10.5 units/week, with 10.5 units equal to 7 drinks) and, physical activity other than walking (<2 
times/week vs. ≥2 times/week) at baseline. In the fully adjusted model, additional variables were added; 
systolic and diastolic blood pressure (per 10 mmHg increase), fasting glucose level at baseline, LDL- 
and HDL-cholesterol, triglycerides, self-reported treatment of hypertension (yes/no) and dyslipidaemia 
(yes/no), and self-reported family history of diabetes (yes/no). The Hosmer-Lemeshow test was applied 
to test for goodness of fit for the logistic regression model. The test indicated a good model fit based on 
the resulting low Chi-squared value. 
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RESULTS 
Physiological changes from baseline to 13-years follow-up 
The elderly women in the PERF study who developed hyperglycaemia in late life already showed 
significantly increased fasting glucose levels at baseline compared to women staying normoglycaemia 
at follow-up, yet still within the normoglycemic range (5.1 mmol/L vs. 5.0 mmol/L, P<0.0001). A larger 
fraction of the normoglycemic women was normalweight at baseline compared to women with future 
hyperglycaemia (5.4% vs. 41.8%, P<0.0001). At follow-up, the overall BMI were found to be slightly 
decreasing for normoglycemic women (from 25.1 kg/m2 to 24.9 kg/m2 from baseline to follow-up, 
P=0.07) whereas hyperglycemic women showed an overall increase in BMI during the follow-up period 
(from 25.9 kg/m2 to 26.6 kg/m2, P<0.001). In addition, 61.3% of the hyperglycemic women were either 
overweight or obese compared to 43.0% in the normoglycemic group at follow-up (P<0.001 for both 
BMI groups) (Table 1). 
Other markers used to define metabolic dysfunction such as systolic blood pressure, HDL-cholesterol 
and triglycerides were significantly different in future hyperglycemic women as compared to 
normoglycemic women already at baseline (P<0.001 for all). HDL-cholesterol was still significantly 
lower and triglycerides significantly higher in hyperglycemic women at follow-up (P>0.0001 for both) 
(Table 1). 
Alcohol consumption and physical activity level were not significantly different between the two groups 
at either baseline or follow-up. However, the fraction of current smokers was significantly higher in the 
hyperglycaemic group at follow-up (P<0.05). The physical activity level declined in both from baseline 
to follow-up and the decline was largest in the hyperglycaemic women, with 79% being physically 
active at baseline and 66% being active at follow-up. The decline was only 5.5% in the normoglycaemic 
group (Table 1). 
Spearman’s correlation test of BMI and waist circumference, hip circumference and waist-hip ratio at 
follow-up revealed a significant correlation between the BMI and the other markers of weight (waist: 
rho=0.84 P<0.0001, hip: rho=0.87 P<0.0001, waist-hip ratio: rho=0.44 P<0.0001) (Figure  2A-C), 
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illustrating that BMI is an acceptable surrogate marker for central obesity in this study population. We 
found no correlation between BMI and muscle strength (rho=0.08, P=0.009) and no trend in muscle 
strength profile changes within any of the BMI groups (Figure 2D), indicating that subjects with low 
BMI did not experience reduced muscle strength resulting from low BMI and possible sarcopenic 
conditions. 
BMI change and hyperglycaemia 
BMI change after the 13-year follow-up was determined for each baseline BMI group (Table 2). 
Weight-gainers in all BMI groups increased their BMI with two BMI units or more from baseline to 
follow-up with normalweight women gaining less than the heavier subgroups; 2.5 kg/m2 [2.3-2.7] gain 
for normalweight women, 3.1 kg/m2 [2.8-3.3] for overweight weight-gainers and 4.7 kg/m2 [2.6-4.1] for 
obese gainers. Both normalweight and overweight weight-gainers showed to increase BMI to a level 
now exceeding the BMI of weight-losers from the heavier baseline BMI groups. This exemplified in 
overweight weight-gainers having a BMI of 30.3 kg/m2 [30.0-30.6] at follow-up whereas obese weight-
losers ended up at a BMI of 28.1 kg/m2 [27.1-29.0] at follow-up, resulting in a BMI category change for 
both BMI groups. The same tendency was seen in normal weight-gainers with a follow-up BMI of 25.1 
kg/m2 [24.8-25.4] compared to overweight weight-losers dropping to a follow-up BMI in the normal 
weight range of 24.4 kg/m2 [24.1-24.7].    
Logistic regression was used to determine the risk of hyperglycaemia in weight-losers, weight-stable, 
and weight-gainers stratified based on baseline BMI group (Table 3). In elderly women who had gained 
weight at follow-up, regardless of their baseline BMI, we found, in univariate analysis, an increased risk 
of developing hyperglycaemia in late-life when compared to normalweight women being weight-stable 
at follow-up. This risk pattern was conserved in both the partly and fully adjusted analysis. 
We did observe a differentiated risk as weight-gaining women who were normalweight or overweight 
at baseline did not increase their risk of hyperglycaemia to a level of that seen in obese weight-gainers 
(OR=2.5 [1.5-4.0], OR=2.7 [1.6-4.6] and OR=3.2 [1.5-6.6], respectively, in the multivariate analysis). 
The risk of hyperglycaemia in women with a stable overweight or obese BMI from baseline to follow-
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up was 2-fold higher (OR=2.2 [1.3-3.8] and OR=2.0 [1.0-4.21]) than for normalweight women staying 
normalweight during the follow-up period. The increased risk was not found to be statistically 
significant in the obese subgroup in the multivariate adjusted analysis, assumedly based on the low 
number of women in this group (n=46 in the obese group and n=143 in the overweight group) (Table 
3). 
Overweight and obese weight-losers decreased their risk of hyperglycaemia compared to women who 
were overweight and obese weight-stable after 13 years (Table 3).Women who were overweight at 
baseline and became normalweight during the follow-up period (BMI=24.4 kg/m2 [24.1-24.7]) showed 
no clear increased risk of hyperglycaemia, OR=1.1 [0.6-1.9], compared to women who were 
normalweight at baseline and stayed normalweight at follow-up. The same tendency was also observed 
for obese weight-losers, OR=1.3 [0.6-2.9], however, as previously highlighted, a lack of power (n=46) 
could explain the overlapping confidence interval in this subgroup. 
Baseline glucose levels, despite being in the normoglycaemic range, were found to have a significant 
impact on future risk of hyperglycaemia. This was reflected in the multivariate adjusted risk estimates 
when adjusting for this variable. Further, metabolic risk factors such as triglyceride and systolic blood 
pressure levels, and current smoking status were found to have an impact on the risk of future 
hyperglycaemia in elderly women (Table 3). 
CONCLUSIONS 
In this prospective study of weight change and hyperglycaemic risk in elderly women, we found positive 
effects of weight reduction during a 13-year period, while weight gain increased the risk of 
hyperglycaemia. Specifically, weight reduction in elderly obese and overweight women showed to 
decrease their risk of hyperglycaemia in late life, whereas weight gain in both normalweight, overweight, 
and obese women increased the risk of hyperglycaemia by up to 3-fold when compared to normalweight 
weight-stable women. 
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Previous studies focusing on weight change specifically in the elder population have focused mainly on 
mortality, highlighting how overweight BMI in elderly is associated with a lower relative mortality in 
this age-group (14–16). Such interpretation can have a drawback by implying that obesity is not as 
harmful in elderly as compared to middle-aged persons (17). Hyperglycaemic risk, and the development 
specifically related to obesity is therefore important to monitor in the elderly. This in order to prevent 
possible development of type 2 diabetes, which can ultimately lead to serious complications, with elderly 
diabetics having the highest rates of major lower limb amputation (18), myocardial infarction (19), 
visual impairment (20), and end-stage renal disease (21) of any age-group (8,22). 
Our findings suggest that elderly women who gain weight, regardless of baseline BMI level, are at 
increased risk of hyperglycaemia. This finding is in agreement with previous studies on type 2 diabetes 
risk emphasizing that weight gain in adulthood is associated with increased risk of developing diabetes 
(23–26). Further, we showed how weight-loss reduced the risk of hyperglycaemia which is in 
accordance with reports on decreased incidence of type 2 diabetes among adults aged 60 years or older 
as a result of weight-loss (27,28). Applying hyperglycaemia as an endpoint, as done in this study, is not 
directly relatable to a type 2 diabetes diagnosis. However, since hyperglycaemia is the first clinical sign 
of a higher risk of type 2 diabetes and cardiovascular disease, and since more than half of all older adults 
suffer from pre-diabetes (9,29,30), the use of hyperglycaemia, as determined by fasting glucose samples, 
is deemed valid as an initial marker for increased pre-diabetes risk. However, impaired fasting glucose 
does not reveal the full risk of pre-diabetes. Impaired glucose tolerance, another measure of insulin 
resistance and risk of pre-diabetes, has not been measured in the PERF study. However, a study 
performed by Larsson et al. showed in post-menopausal women how the two measures identified 
different women at risk of pre-diabetes (31). 
Several aspects of weight loss need consideration in relation to interpretations of the associated risk of 
hyperglycaemia in elderly women. In this regard, the use of BMI, as an estimate for weight change, can 
introduce errors, as fat-free mass (muscle) decreases in elderly while the relative adiposity, and 
specifically the intra-abdominal fat, continues to increase (32,33), thus changing the proportion of 
muscle to fat mass in a less healthy direction. Moreover, since height is also reduced with age in women, 
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BMI calculations can be misleading if continuous measures are lacking. In this cohort, we found no 
overall change in BMI from baseline to follow-up and this absent change in BMI over a period of 13 
years could be masking a loss in muscle mass as height equally decreased. To analyze for a possible 
bias associated with the use of BMI, we applied correlation analysis between follow-up BMI and waist 
circumference, hip circumference and waist-hip ratio which correlates highly with both total and intra-
abdominal fat (17,34) of which especially the latter plays a vital negative role in metabolic disorders 
including hyperglycaemia (17). We found a high correlation (r=0.84, r=0.87 and r=0.44, respectively) 
between follow-up BMI and the additional measurements of abdominal fat, and, contrarily, no pattern 
of decreased muscle strength as a function of BMI (r=0.08), which supports that BMI can be used as a 
reliable marker of weight change in this cohort. 
We showed how elderly women developing hyperglycaemia in late life (80+ years) had significantly 
higher fasting glucose levels (still in the normoglycemic range) 13 years prior to revealing a 
hyperglycemic outcome. This observation of a slightly unhealthier phenotype was further signified as 
significantly higher weight, systolic blood pressure, triglyceride levels and decreased HDL-cholesterol 
were present already at baseline. Further, a larger fraction of the women who developed hyperglycaemia 
at follow-up was smoking. These risk factors have all previously been reported to distort the metabolic 
state resulting in hypertension, diabetes, and the metabolic syndrome (35). Associating obesity 
specifically to hyperglycaemia therefore only illustrates part of the dysmetabolic phenotype. 
Limitations 
Hyperglycaemic women in this study smoke and drink more and exercise less at follow-up. Even though 
smoking is the only statistically significant observation, it reflects a group of hyperglycaemic women 
with an assumedly unhealthier lifestyle. We can therefore only speculate whether there are other causal 
reasons for hyperglycaemia, thus associated with these risk factors, which are confounding the effects 
of weight gain. This is to some extend tried adjusted for in the multivariate logistic analysis, however, 
it could be argued that weight change is always a consequence of preceding mediators, thus being a 
surrogate for a preceding unhealthier phenotype. 
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In very late life (the 80+ year age group) the prevalence of obesity is approximately half of that in the 
50–59-year group (36,37). This overall trend of weight reduction in late life is likely to arise from 
confounding factors such as survival bias, competing mortalities, smoking, and unintentional weight 
loss in the sick elderly (17), together with the loss of muscle mass as previously described. Specifically 
smoking, which is known to induce weight loss in elderly, could distort our results, as the women in our 
study who develop hyperglycaemia, has a significantly larger fraction of smokers than the women 
staying normoglycaemic, so losing weight would perhaps reflect smoking status and thereby be 
associated with being hyperglycaemic. 
In this cohort of elderly Caucasian women, we saw an increase in the number of obese women at follow-
up. This could indicate that the fraction of elderly women participating in a clinical study in very late 
life could be somewhat subjective to ‘healthy participant’s bias’, as only the overweight and obese 
women healthy enough to survive into late-life are included, as opposed to the perhaps weaker obese 
non-survivors. As a strategy to prevent an even further overrepresentation of a metabolically healthier 
subgroup in the PERF study, we decided to collect data in the women’s own home at follow-up, hence 
allowing for a broader group of women to be enrolled in the follow-up study. 
By means of study design, we sought to eliminate a possible confounding factor by excluding pre-
diabetics, women with register-based diabetes diagnosis or reported use of antidiabetic medication from 
the study group, since this group might curb with the study outcome due to focused weight loss as 
requested by the general practitioner, thereby introducing reverse causality. However, reverse causation 
owing to other, either pre-existing or prediabetes related chronic diseases occurring in the follow-up 
period, may also lead to intentional weight loss, in order to treat the conditions. Possible approaches to 
addressing these potential biases could be to disregard women with diagnosed cardiovascular and 
rheumatic diseases, but also cancer, which is known to decrease body weight in elderly, occurring in the 
follow-up period thereby restricting the analysis to elderly women without any known weight related 
diseases. However, an introduction of these exclusion criteria would leave in only the most biologically 
advantaged obese women. Therefore, we decided that this was not the correct approach for this study. 
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The PERF cohort is a Danish community-based cohort of Caucasian women with tax-paid (not 
individually paid) health care, and the results obtained in this study would need replication in other 
ethnic groups and other health care systems to confirm if data are representative for all women. Further, 
the cohort consists only of women wherefore a similar study in men would be required in order to 
conclude if weight and weight change would imply the same risk of hyperglycaemia in elderly men. 
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Figure 1. Definition of the study population. Abbreviations: PERF: Prospective Epidemiological Risk 
Factor study (baseline visit); BMI: Body Mass Index.  
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Figure 2. A: Correlation between waist circumference and BMI at follow-up (n=1172). B: Correlation 
between hip circumference and BMI at follow-up (n=1172). C: Correlation between waist-hip ratio and 
BMI at follow-up (n=1172). D: Correlation between muscle strength and BMI at follow-up stratified 
based on BMI group; lightest grey: Underweight at follow-up (n=36), light gray: Normalweight at 
follow-up (n=551), dark gray: Overweight at follow-up (n=408); black: Obese at follow-up (n=178)
64
Table 1: Baseline and follow-up information on hyperglycemic and normoglycemic women enrolled in the PERF study (n=1,173). Data 
are shown as mean value (95% confidence interval) or as percentage (absolute number of cases). 
BASELINE FOLLOW-UP 
N Normoglycemic N Future hyperglycaemic P-value N Normoglycemic N Hyperglycaemic p-value 
Age (years)  726 67.5 (67.0 – 67.9) 447 67.2 (66.7 – 67.8) 0.6 726 80.8 (80.4 – 81.2) 447 80.6 (80.0 – 81.1) 0.5 
Family history of diabetes (%) 634 9.6 (61) 387 9.3 (36) 0.9 
Smoking  
     Never (%) 726 54.3 (394) 447 49.7 (222) 0.1 723 51.2 (370) 447 44.3 (198) 0.02 
     Previous (%) 726 26.4 (192) 447 26.4 (118) 0.99 723 11.6 (84) 447 12.3 (55) 0.7 
     Current (%) 726 19.3 (140) 447 23.9 (107) 0.06 723 37.2 (269) 447 43.4 (194) 0.04 
Alcohol, current (>10.5 units/week, %) 723 40.5 (293) 442 35.1 (155) 0.06 717 0.4 (3) 435 1.1 (5) 0.1 
Physical activity (≥2 sessions/week, %) 726 75.5 (548) 447 79.2 (354) 0.1 723 70.0 (506) 444 66.0 (293) 0.2 
Height (cm)  726 162.3 (161.9 – 162.7) 447 162.3 (161.8 – 162.9) 0.9 726 160.1 (159.7 – 160.6) 447 160.3 (159.7 – 160.9) 0.7 
Weight (kg) 726 66.0 (65.3 – 66.8) 447 68.3 (67.3 – 69.3) 0.0004 726 63.9 (63.1 – 64.8) 447 68.4 (67.2 – 69.6) <0.0001 
BMI (kg/m2)  726 25.1 (24.8 – 25.3) 447 25.9 (25.6 – 26.3) 0.0002 726 24.9 (24.6 – 25.2) 447 26.6 (26.2 – 27.0) <0.0001 
     Underweight (%) 726 1.8 (13) 447 1.3 (6) 0.6 726 3.9 (28) 447 1.8 (8) 0.05 
     Normal weight (%) 726 55.4 (402) 447 41.8 (187) <0.0001 726 53.2 (386) 447 36.9 (165) <0.0001 
     Overweight (%) 726 32.5 (236) 447 42.7 (191) 0.0004 726 30.7 (223) 447 41.4 (185) 0.0002 
     Obese (%) 726 10.3 (75) 447 14.1 (63) 0.05 726 12.3 (89) 447 19.9 (89) 0.0004 
Systolic blood pressure (mmHg) 726 143.4 (141.8 – 145.1) 447 147.0 (144.9 – 149.1) 0.009 724 139.5 (138.0 – 141.0) 447 141.6 (139.6 – 143.6) 0.09 
Diastolic blood pressure (mmHg) 726 81.4 (80.6 – 82.1) 447 81.9 (81.0 – 82.9) 0.4 724 80.2 (79.3 – 81.4) 447 81.6 (80.5 – 82.6) 0.04 
Glucose (mmol/L) 726 5.0 (5.0 – 5.0) 447 5.1 (5.1 – 5.2) <0.0001 726 5.1 (5.0 – 5.1) 447 5.8 (5.8 – 5.9) <0.0001 
Low density lipoprotein (mmol/L)  720 3.8 (3.8 – 3.9) 441 3.9 (3.8 – 4.0) 0.09 726 3.4 (3.3 – 3.4) 447 3.4 (3.2 – 3.5) 0.9 
High density lipoprotein (mmol/L) 720 1.8 (1.8 – 1.8) 441 1.7 (1.7 – 1.7) 0.0003 726 2.1 (2.1 – 2.1) 447 1.9 (1.9 – 1.9) <0.0001 
Triglycerides (mmol/L) 726 1.2 (1.2 – 1.2) 446 1.3 (1.3 – 1.4) <0.0001 726 1.1 (1.1 – 1.2) 447 1.4 (1.3 – 1.4) <0.0001 
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Table 2: Baseline body mass index (BMI), BMI change and BMI at follow-up for elderly women in 
the PERF cohort (n=1,173). Data are shown as mean with 95% confidence interval. 
BMI GROUP 
AT BASELINE 
N 
BMI 
AT BASELINE 
(kg/m2) 
BMI 
CHANGE 
N 
BMI 
AT FOLLOW-UP 
(kg/m2) 
∆BMI 
(kg/m2) 
NORMALWEIGHT 608 22.6 [22.4-22.7] 
LOSS 203 20.8  [20.5-21.1] -1.8 [-2.0-(-)1.7] 
STABLE 202 22.7  [22.4-22.9] 0.2 [0.1-0.3] 
GAIN 203 25.1  [24.8-25.4] 2.5 [2.3-2.7] 
OVERWEIGHT 427 27.0 [26.9-27.2] 
LOSS 142 24.4  [24.1-24.7] -2.6 [-2.9-(-)2.3] 
STABLE 143 27.2  [27.0-27.5] 0.4 [0.3-0.5] 
GAIN 142 30.3  [30.0-30.6] 3.1 [2.8-3.3] 
OBESE 138 32.6 [32.2-33.0] 
LOSS 46 28.1  [27.1-29.0] -4.7 [-5.3-(-)4.1] 
STABLE 46 32.0  [31.3-32.8] -0.5 [-0.8-(-)0.2] 
GAIN 46 35.9  [34.8-36.9] 3.7 [2.6-4.1] 
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Table 3: Univariate and multivariate-adjusted odds ratios (ORs) for risk of hyperglycaemia in 
normalweight, overweight and obese elderly women with either weight loss, stable weight, or 
weight gain after 13 years of follow-up (n=1,173). CI: confidence interval.  
Univariate Partly Multivariate 
Variable OR (95% CI) OR (95% CI) OR (95% CI) 
Baseline BMI BMI Change 
Normal 
Loss 1.16 (0.74-1.80)   1.14 (0.73-1.79)  1.06 (0.63-1.77) 
Stable 1 (reference)   1 (reference)  1 (reference) 
Gain 2.28 (1.49-3.48)   2.31 (1.51-3.55)  2.47 (1.52-4.02) 
Overweight 
Loss 1.41 (0.88-2.27)   1.39 (0.86-2.26)  1.06 (0.61-1.85) 
Stable 2.91 (1.84-4.60)   2.86 (1.80-4.55)  2.22 (1.31-3.75) 
Gain 3.50 (2.21-5.54)   3.52 (2.22-5.60)  2.67 (1.56-4.55) 
Obese 
Loss 1.47 (0.73-2.95)   1.44 (0.72-2.91)  1.34 (0.61-2.92) 
Stable 2.79 (1.44-5.40)   2.97 (1.52-5.79)  2.01 (0.96-4.21) 
Gain 3.95 (2.03-7.68)   4.12 (2.10-8.08)  3.20 (1.50-6.80) 
Other Baseline characteristics 
Age (per years of ageing) 1.0 (0.98-1.02)   1.00 (0.98-1.03)  0.98 (0.95-1.00) 
Education 
    Primary school 1 (reference)   1 (reference) 1 (reference) 
    High School 0.79 (0.59-1.04)   0.80 (0.60-1.08)  0.81 (0.58-1.14) 
    University 0.67 (0.43-1.04)   0.71 (0.45-1.12)  0.78 (0.45-1.33) 
Smoking history 
    Never 1 (reference)  1 (reference)  1 (reference) 
    Past       1.09 (0.82-1.45)  1.14 (0.85-1.52)  1.20 (0.86-1.67) 
    Current 1.36 (1.00-1.53)  1.43 (1.04-1.97)  1.49 (1.04-2.14) 
Alcohol Consumption (>10.5 units/week) 0.80 (0.63-1.02)   0.85 (0.66-1.10)  0.86 (0.65-1.15) 
Physical activity (≥2 time/week) 1.23 (0.93-1.64)   1.43 (1.06-1.93)  1.35 (0.97-1.87) 
Systolic blood pressure (per 10 mmHg increase) 1.07 (1.02-1.13) 1.11 (1.03-1.21) 
Diastolic blood pressure (per 10 mmHg increase) 1.05 (0.94-1.18) 0.84 (0.71-0.99) 
Glucose (mmol/L) 4.35 (2.94-6.44) 4.47 (2.85-7.03) 
Low density lipoprotein (mmol/L)  1.12 (0.98-1.27) 1.04 (0.89-1.21) 
High density lipoprotein (mmol/L) 0.58 (0.43-0.78) 0.94 (0.64-1.39) 
Triglycerides (mmol/L) 1.64 (1.30-2.07) 1.51 (1.11-2.06) 
Treated hypertension (yes/no) 1.26 (0.92-1.71) 0.97 (0.67-1.42) 
Treated dyslipidaemia (yes/no) 1.42 (0.76-2.65) 1.08 (0.52-2.23) 
Family history of diabetes 0.96 (0-63-1.49) 1.19 (0.74-1.91) 
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Additional Results (not published) 
Baseline and follow-up characteristics of elderly Caucasian women enrolled in the PERF 
study (n=1,173) Data shown as mean value (± 95% CI) or as percentage (absolute number of cases). 
N Baseline Follow-up P-value 
Age (years)  1173 67.1 (66.8-67.5) 80.5 (80.2-80.8) - 
Family history of diabetes (%) 1021 29.3 (299)  - - 
Smoking, never (%) 1170 52.5 (614) 48.5 (568) <0.0001 
Alcohol, current (≥7gl/week, %) 1144 39.0 (446) 0.7 (8) <0.0001 
Physical activity (≥2 sessions/week, %) 1167 76.9 (897) 68.5 (799) <0.0001 
Height (cm)  1173 162.2 (161.9-162.6) 160.1 (159.7-160.5) <0.0001 
Weight (kg) 1173 66.1 (65.5-66.7) 64.6 (63.9-65.2) <0.0001 
BMI (kg/m2) 1173 25.1 (24.9-25.3) 25.2 (24.9-25.4) 0.3 
     Underweight (%) 1173 1.6 (19) 3.1 (36) 0.003 
     Normal weight (%) 1173 50.2 (589) 47.0 (551) 0.02 
     Overweight (%) 1173 36.4 (427) 34.8 (408) 0.3 
     Obese (%) 1173 11.8 (138) 15.2 (178) 0.0005 
Systolic blood pressure (mmHg) 1171 142.9 (141.7-144.2) 138.8 (137.6-140.0) <0.0001 
Diastolic blood pressure (mmHg) 1171 80.9 (80.3-81.5) 79.8 (79.1-80.5) 0.008 
Glucose (mmol/L) 1173 5.0 (5.0-5.0) 5.3 (5.3-5.4) <0.0001 
Cholesterol (mmol/L)  1173 6.1 (6.0-6.2) 5.6 (5.5-5.6) <0.0001 
Low density lipoprotein (mmol/L)  1161 3.7 (3.7-3.8) 3.2 (3.1-3.3) <0.0001 
High density lipoprotein (mmol/L) 1161 1.7 (1.7-1.7) 2.0 (1.9-2.0) <0.0001 
Triglycerides (mmol/L) 1172 1.2 (1.1-1.2) 1.1 (1.1-1.2) 0.02 
White blood cells (109cells/L)  1169 5.3 (5.2-5.4) 5.9 (5.8-6.0) <0.0001 
Alanine-aminotransferase (mmol/L) 1173 24.4 (23.9-24.8) 18.7 (18.3-19.1) <0.0001 
Aspartate-aminotransferase (mmol/L)  1173 23.8 (23.5-24.1) 22.8 (22.4-23.1) <0.0001 
Gamma-glutamyltransferase (mmol/L) 1173 30.0 (29.2-30.8) 23.5 (22.6-24.5) <0.0001 
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7 COLLAGEN DEGRADATION AND MORTALITY 
Title 
Matrix Metalloproteinase Mediated Type I Collagen Degradation – An Independent Risk 
Factor for Mortality in Women.  
Aim 
The aim of the study was to investigate whether MMP mediated type I collagen degradation 
(C1M) was predictive of mortality in elderly Danish women.  
Rationale 
Chronic fibro-proliferative diseases are associated with nearly 45% of all deaths in the 
developed world. Matrix metalloproteinase (MMP) mediated remodelling of the 
extracellular matrix (ECM) plays an important role in disease development. Degradation of 
type I collagen is considered having a major role in this matter. 
Findings 
Subjects with high serum C1M levels showed significantly increased mortality. The adjusted 
three-year HR was 2.0 [95% CI: 1.5-2.8] for all-cause mortality, 2.3 [1.5-3.6] for cancer and 1.8 
[1.0-3.2] for CVD. The adjusted nine-year HR was 1.50 [1.3-1.8] for all-cause mortality, 1.5 [1.2-
1.9] for cancer and 1.7 [1.3-2.2] for CVD. 
Conclusions 
Increased MMP-mediated tissue degradation, as an independent risk factor, was associated 
with a 2-fold increase in all-cause mortality within three years of follow-up and a 1.5-fold 
increase in all-cause mortality up to nine years prior to death.  
MMP-mediated tissue degradation may be an important predisposition for the cause of 
disease and subsequent mortality.  
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Chronic ﬁbro-proliferative diseases are associated with nearly 45% of all deaths in the developed world. Matrix
metalloproteinase (MMP)mediated remodeling of the extracellular matrix (ECM) plays an important role in dis-
ease development. Degradation of type I collagen is considered having a major role in this matter. C1M is a bio-
markermeasuring type I collagen degradation fragments in blood. The aimof the current studywas to investigate
whether MMPmediated type I collagen degradation (C1M)was predictive of mortality in a large prospective co-
hort of Danish women aged 48–89 (n = 5855).
Subjects with high serumC1M showed signiﬁcant increasedmortality. The adjusted three year HRwas 2.02 [95%
CI: 1.48–2.76] for all-cause mortality, 2.32 [95% CI: 1.51–3.56] for cancer and 1.77 [95% CI: 0.98–3.17] for cardio-
vascular diseases. The adjusted nine year HR was 1.50 [95% CI: 1.28–1.75] for all-cause mortality, 1.49 [95% CI:
1.16–1.90] for cancer and 1.69 [95% CI: 1.27–2.24] for cardiovascular diseases.
High MMP-mediated type I collagen degradation was associated with increased mortality. Subjects with high
C1Mhad a 2-fold increase inmortality compared to subjectswith low levels of this collagen degradation product.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
It is estimated that women in the European (EU15) countries are
expected to live approximately 80% of their lives in good health —
resulting in a healthy life expectancy up to 20% shorter than their total
life expectancy (Health and Consumer Protection Directorate-General,
2006). A major contributor to the decrease in healthy life expectancy
is chronic ﬁbroproliferative diseases such as ﬁbrosis and cancer, and
nearly 45% of all deaths in the developed world are associated with
some form of tissue remodeling disease (Wynn, 2007; Pinzani, 2008). Tis-
sue remodeling in relation to diagnosis and prognosis is therefore a hot
topic, consequent to the prevalence of diseases associatedwith this remod-
eling, following decreased healthy life expectancy and premature death.
The common denominator of ﬁbroproliferative diseases is dysregu-
lated tissue remodeling causing an accumulation of extracellularmatrix
(ECM) components in tissues of different organs (Wynn, 2007, 2008;
Wynn and Barron, 2010; Schuppan et al., 2001). The ECM consists
mainly of collagens, proteoglycans and glycoproteins. Collagens consti-
tute approximately 30% of all proteins in the body, with type I collagen
as the most ubiquitous collagen (Muiznieks and Keeley, 2013). Under
pathological conditions the normal remodeling balance is disturbed re-
placing original proteins of the ECMwith different matrix components, in
turn leading to an altered composition and quality of the matrix (Karsdal
et al., 2013a). Emerging evidence suggests that altered components and
post-translational modiﬁcations (PTMs) of proteins in the ECMmay both
initiate and drive disease progression (Leeming et al., 2011a).
Matrix metalloproteinases (MMPs) constitute a principal family of
enzymes involved in degradation of ECM proteins. The pathological
over-expression of MMPs results in small protein fragments holding
PTMs, which are released into the blood. These PTM fragments can
be referred to as neoepitopes or so-called ‘protein ﬁngerprints’. A
neoepitope is a protease-generated PTM, which has potential as a bio-
chemical marker of ECM remodeling (Karsdal et al., 2013b). Despite
the notion that MMP-mediated ECM remodeling is a central event in
initiation and progression of connective tissue diseases (Wynn, 2007;
Pinzani, 2008), technologies for measurement are limited in the diag-
nostic armamentarium.
Type I collagen may be measured by 4 different epitopes (CTX-I,
C1M, ICTP and PINP). Measurement of the pro-peptide of type I collagen
(PINP) is a standard marker for bone formation, while a cathepsin K de-
graded product (CTX-I) is the standard measure of bone resorption
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(Rosenquist et al., 1998). Bone formation and bone resorption are
completely different and opposite directed processes, emphasizing the
need in clinical chemistry to measure the right protein in the right
way. The marker of the cross-linked carboxyterminal telopeptide of
type I collagen (ICTP), is an MMP derived intermediate conformational
epitope which has been evaluated for ECM-related diseases (Elomaa
et al., 1992). Recently we developed an ELISA assay detecting MMP-
mediated type I collagen degradation fragments in serum (termed
C1M). The competitive ELISAmeasures the end product of tissue degra-
dation, i.e. a pool of peptides/proteins all having this speciﬁc MMP-
mediated binding site as the denominator. The monoclonal antibody
recognizes a 6 amino acid sequence at position 764 in the C-terminus
of type 1 collagen (Leeming et al., 2011b). The collagen degradation
fragment is generated byMMPs 2, 9 and 13 and is destroyed by cathep-
sin K,making this a soft tissue speciﬁcmarker not originating from bone
turnover.
In the period from1999–2001 a total of 5855Danish postmenopaus-
al women participated in the large Prospective Epidemiological Risk
Factor (PERF I) study aimed at identifying risk factors associated with
age-related diseases. Serum samples originally collected in the PERF I
cohort were in the current study analyzed in relation to levels of C1M
and combined with register data from Danish national registries de-
scribing cause and time of death of the deceased part of the cohort.
We hypothesized that MMP-mediated tissue degradation of type I
collagen was predictive for mortality.
2. Methods
2.1. Study Design
The Prospective Epidemiologic Risk Factor (PERF I) studywas an ob-
servational, prospective follow-up study of Danish postmenopausal
women who had previously either participated in clinical randomized
placebo-controlled studies or were screenedwithout being randomized
for previous studies at the Center for Clinical and Basic Research (CCBR)
in either Copenhagen or Aalborg. Invitations for participationwere done
by including all subjects in the CCBR subject database regardless of their
previous medical history, ensuring no overrepresentation of subjects
with history of speciﬁc diseases. A total of 5855 Danish postmenopausal
Caucasian women aged 48-89 were enrolled in the PERF I Study from
1999–2001. The study was carried out in accordance with ICH-GCP
with study protocol approval from the local ethics committee.
2.2. Baseline Examinations
Vital signs and fasting serum samples were collected at time of en-
rollment and serum samples were stored at−80 °C for later use. Sub-
jects reported on demographic characteristics; smoking status, alcohol
consumption, physical activity and level of education as well as hyper-
tension, hyperlipidemia, cancer history and diabetes in a self-reported
questionnaire.
2.3. Outcome Variables
The primary end-points were all-cause mortality and cause speciﬁc
mortality. Date of death of the deceased sub-group of the PERF I cohort
(n=1505)was obtained from theDanish Civil Registration System and
cause of death was obtained from the National Danish Causes of Death
Registry. Registry data was obtained up to 31st December 2012 leading
to an average follow-up period of 12.1 years (11.4–13.1) for censored
subjects. Causes of death were classiﬁed according to the International
Classiﬁcation of Diseases, tenth revision (ICD10). The primary cause of
death was used for further evaluation of serum C1M levels in speciﬁc
disease groups; cardiovascular diseases (ICD10 codes I00–I99), cancer
(C00–C97), lung diseases (J00–J99), and other deaths (remaining
ICD10 codes). Subjects who were dead due to external causes (ICD10
codes V01–X59) were excluded from survival analysis (n = 39). The
time of survival was deﬁned as the time from date of enrollment to
date of death or to 31st December 2012.
2.4. Type I Collagen Degradation
MMP-degraded type I collagen was measured in serum by enzyme-
linked immunosorbent assay (ELISA) as described by Leeming et al.
(2011b)(n=5629). The analytewas tested for stability andwas consid-
ered to be stable after 12 years of storage (−80 °C). In order to conﬁrm
analyte stability, 10 consecutive freeze-thaw cycles were done with no
signiﬁcant change in C1M level. Three year stability studies were per-
formed to validate detection of analyte (C1M), by measuring the same
sample in one year intervals. Moreover, the mean level of C1M found
in the present study was compared to mean levels of C1M in studies
with similar study population conducted at later time points with sam-
ple storage of shorter duration.
The cohort was divided into quartiles based on serum C1M level. Q1
(n= 1411): 26.2 ng/mL [21.2–31.3 ng/mL], Q2 (n= 1400): 35.2 ng/mL
[31.4–39.5 ng/mL], Q3 (n = 1391): 46.2 ng/mL [39.6–56.0 ng/mL], Q4
(n = 1400): 87.1 ng/mL [56.1–458.8 ng/mL].
Serum CTX-I (n = 5611) was measured by Serum CrossLaps one
step ELISA as described by Rosenquist et al. (1998).
2.5. Statistical Analysis
Statistical analysis was conducted using Medcalc® (v 12.3.0) and
SAS® (v 9.4). Data are shown as mean ± standard error mean (SEM)
if not otherwise indicated. Baseline characteristics of survivors and
dead were compared using one-way analysis of variance (ANOVA) for
numerical variables while a Chi-square test was used to compare cate-
gorical variables (Table 1).
Multivariate Cox proportional-hazard analysis was used to deter-
mine proportional hazard ratios for selected risk factors (age, BMI,
smoking, exercise, alcohol consumption, education level, hypertension,
hyperlipidemia, cancer history and diabetes) (Table 2).
Serum C1M values were normalized using log-transformation.
Univariate and multivariate Cox proportional-hazard analysis was
used to assess the relation between mortality and serum levels of C1M
(log-transformed) in the full follow up period. The adequacy of the
Cox proportional-hazard analysis was tested by checking the functional
form and the assumption of proportional hazards as described by Lin,
Wei, and Ying (Lin et al., 1993). The Kolmogorov-type supremum test
revealed no misspeciﬁcation of the functional forms for the continuous
covariates. The proportional hazard assumption was violated with log-
transformed C1M in the 12 year follow-up period. Therefore, the multi-
variate Cox proportional-hazard analysis was split in three year inter-
vals (0–3 years, 3–6 years, 6–9 years, 9–12 years) where the relation
between serum levels of C1M (log-transformed) and all-causemortality
was assessed assuming conformity with the proportional hazard as-
sumption in each three year time interval (Fig. 1). Risk factors from
Table 2 were included in themultivariate analysis. Likewise the relation
between serum levels of CTX-I (log-transformed) and all-cause mortal-
ity was assessed in each time interval (data not shown).
Hazard ratios for each quartile of serum C1M was determined by
multiplying the parameter estimate of the log-transformed C1M value
derived from the multivariate Cox proportional-hazard analysis, with
the range between the log-transformed means of serum C1M levels in
each quartile, followed by a back-transformation to the original scale
using the exponential function. The lower quartile (Q1) was used as
reference.
A Kaplan–Meier survival curve was applied to illustrate mortality
over time in the four quartiles in the full follow-up period (Fig. 2A)
and in three year time intervals (Fig. 2B–E). A log-rank test was used
to determine differences between the survival curves.
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Multivariate Cox proportional-hazard analysis was further used to
assess levels of serum C1M (log-transformed) in the time interval
from 0–9 years (Fig. 3). Risk factors from Table 2 were included in the
multivariate analysis.
Hazard ratios were determined for deaths caused by cancer, cardio-
vascular diseases, lung diseases and other types of death for subjects
with serum C1M level in the upper quartile (Q4) versus subjects in
the lower quartile (Q1) in time intervals 0–3 years and 0–9 years
(Fig. 4). Hazard ratios for cause-speciﬁc diseases were calculated solely
on the contribution of deaths with the speciﬁc diagnose. The remaining
part of the deceased population was excluded from the analysis.
3. Results
3.1. PERF I Cohort Characteristics
Table 1 summarizes baseline characteristics of the PERF I cohort
stratiﬁed in alive and dead subjects, 12 years after initiation of the
study. The mean age for the total population was 70.8 years (49.7–
88.8). From study entry until 31st December 2012 a total of 1505 sub-
jects died. The age in the deceased subgroup was signiﬁcantly higher
compared to the group of subjects still alive. The entire cohort was
characterized by being slightly overweight (BMI 26.2 ± 0.1) with the
deceased subgroup having a signiﬁcantly lower BMI compared to the
subjects still alive (25.7 ± 0.1 versus 26.3 ± 0.1) (p b 0.001). The living
group was characterized by less smokers (19.8% versus 30.2%), subjects
with slightly higher education level (22.2% versus 19.1% high school ed-
ucated), and a larger proportion of physically active subjects (72.8% ver-
sus 55.7%). In the cohort 33% consumed more than 7 drinks/week and
the proportion of alcohol-consumers drinking ≥7 drinks/week was
equal in the living and the deceased group. The deceased group was
characterized by having a signiﬁcantly higher proportion of hyperten-
sive and diabetic subjects, whereas the proportion of subjects with hy-
perlipidemia did not differ between the two groups. The proportion of
subjects with a history of cancer was signiﬁcantly larger in the deceased
part of the cohort (8.2% versus 4.1%).
The serum C1M level was signiﬁcantly higher (p= 0.001) in the de-
ceased part of the cohort compared to those still alive, while no signiﬁ-
cant difference was seen in serum levels of CTX-I (p = 0.7).
3.2. Risk Factors for All-cause Mortality
A multivariate Cox proportional-hazard model was used to assess
the independent contribution of risk factors (age, smoking, BMI, physi-
cal inactivity, alcohol consumption, education level, hypertension, hy-
perlipidemia, cancer history and diabetes) to mortality in the cohort
(Table 2).
All risk factors, except for education level, alcohol consumption (≥ 7
drinks/week), and hyperlipidemia, were associated with mortality.
3.3. Survival
A multivariate Cox proportional-hazard analysis was used to assess
hazard ratios for C1M, after adjusting for risk factors listed in Table 2,
in different time intervals from blood sampling until time of death.
This was done to determine the predictive nature of C1M (Fig. 1).
An increase in mortality with increasing C1M was observed in the
0–3 year interval. This will introduce a “survivor effect” when applying
the three year stratiﬁcation approach in the remaining time intervals, as
it will drive the high risk group towards the low risk group over time.
Table 1
PERF I cohort characteristics. Actual numbers are shown next to percentages.
Variable Total Alive Dead P-value
(n = 5855) (n = 4350) (n = 1505) Alive vs. Dead
Age (years) 70.8 ± 0.1 69.4 ± 0.1 74.9 ± 0.2 b0.001
BMI (kg/m2) 26.2 ± 0.1 26.3 ± 0.1 25.7 ± 0.1 b0.001
Underweight (b18.5) (%) 1.6 (90/5637) 1.1 (46/4226) 3.1 (44/1411)
Normal (≥18.5–25.0) (%) 41.6 (2343/5637) 40.5 (1713/4226) 44.6 (630/1411)
Overweight (N25.0–30.0) (%) 39.9 (2248/5637) 40.9 (1729/4226) 36.7 (518/1411)
Obese (N30.0) (%) 17.0 (956/5637) 17.5 (738/4226) 15.5 (219/1411)
Current smoking (%) 22.5 (1315/5844) 19.8 (861/4342) 30.2 (454/1502) b0.0001
Exercise (≥1 time/week, %) 68.5 (4003/5843) 72.9 (3165/4340) 55.8 (838/1503) b0.0001
Alcohol (≥7 drinks/week, %) 32.6 (1896/5812) 32.7 (1411/4317) 32.4 (485/4795) 0.9
Education (%) 0.03
Primary school 71.5 (4178/5841) 70.6 (3064/4339) 74.2 (1114/1502)
High school 21.4 (1250/5841) 22.2 (963/4339) 19.1 (287/1502)
University 7.1 (413/5841) 7.2 (312/4339) 6.7 (101/1502)
Hypertension (%) 31.0 (1807/5838) 28.9 (1252/4337) 37.0 (555/1501) b0.0001
Hyperlipidemia (%) 9.1 (530/5845) 9.4 (407/4342) 8.2 (123/1503) 0.2
Cancer history (%) 5.2 (301/5808) 4.1 (178/4313) 8.2 (123/1495) b0.0001
Diabetes (%) b0.0001
Type 1 0.7 (39/5845) 0.6 (26/4342) 0.9 (13/1503)
Type 2 2.4 (144/5845) 1.9 (83/4342) 3.9 (59/1503)
Serum C1M (ng/mL) 50.7 ± 0.5 49.8 ± 0.6 53.4 ± 1.0 0.001
Serum CTX-I (ng/mL) 0.44 ± 0.003 0.44 ± 0.004 0.44 ± 0.007 0.7
Table 2
Hazard ratios for risk factors associated with mortality.
All hazard ratios are mutually adjusted.
Variable Multivariate analysis
Hazard
ratio
95% conﬁdence
interval
P-value
Age (years) 1.13 1.12 to 1.14 b0.0001
BMI (kg/m2)
Underweight (b18.5) 1.59 1.16 to 2.18 0.004
Normal (≥18.5–25.0) Reference
Overweight (N25.0–30.0) 0.90 0.80 to 1.02 0.1
Obese (N30.0) 0.86 0.73 to 1.01 0.08
Current smoking (yes/no) 1.90 1.69 to 2.14 b0.0001
Physical inactivity (vs. ≥1 time/week) 1.52 1.36 to 1.70 b0.0001
Alcohol (≥7 drinks/week) 1.07 0.95 to 1.20 0.3
Education
Primary school Reference
High school 0.91 0.79 to 1.04 0.2
University 0.90 0.73 to 1.11 0.3
Hypertension (yes/no) 1.18 1.05 to 1.32 0.004
Hyperlipedemia (yes/no) 1.07 0.88 to 1.30 0.5
Cancer history (yes/no) 1.86 1.53 to 2.26 b0.0001
Diabetes (no/Type 1/Type 2)
Type 1 1.52 0.88 to 2.62 0.1
Type 2 1.88 1.41 to 2.51 b0.0001
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Despite confounding from “healthy” survivors in the 3–6, 6–9 and
9–12 year intervals, a trend towards an increase in hazard ratio from
the lowest quartile (Q1) to the upper quartile (Q4) was observed in all
time intervals from 0–9 years. A 2-fold increase in risk of mortality
was observed in the interval from 0–3 years (Fig. 1A, HR 2.02 [95% CI:
1.48–2.76]) for subjects with serum C1M levels in the upper quartile
(Q4) compared to the lowest quartile (Q1). The same tendency, howev-
er non-signiﬁcant, was seen in the interval from 3–6 years (Fig. 1B, HR
1.32 [95% CI: 1.00–1.74]) and from 6–9 years (Fig. 1C, HR 1.41 [95% CI:
1.12–1.78]). In the interval from 9–12 years no signiﬁcant change in
hazard ratio could be observed between the four quartiles (Fig. 1D).
Contrary, the other type I collagen degradation product (CTX-I) was
not found to be a predictor of all cause mortality in neither of the three
year intervals from the multivariate Cox proportional-hazard model
(data not shown).
A Kaplan–Meier survival curve was applied to illustrate survival
over time (Fig. 2A). Part of the cohort with serum C1M levels in the
upper quartile (Q4) had a decreased survival probability compared
to the three other quartiles in the entire 12 year follow-up period
(p = 0.0001). No signiﬁcant difference was seen comparing the lowest
quartile (Q1) and the two middle quartiles (Q2 and Q3) in the full
follow-up period. Pooled data from Q1–Q3 was used for determining
thedifference inmortality compared to theupper quartile (Q4). A signif-
icant difference in mortality was seen in time intervals from 0–9 years;
0–3 years (p = 0.0001), 3–6 years (p = 0.01), and 6–9 years (p =
0.002) (Fig. 2B–D). No difference in mortality was found in the time in-
terval from 9–12 years (p = 0.38, Fig. 2E).
ACoxproportional-hazard analysiswasused to assess themortality risk
in part of the follow-up period where an increase in hazard ratio was
observed (0–9 year) (Fig. 3). In the univariate Cox proportional-hazard
analysis a 59% increased risk of mortality (HR 1.59 [95% CI: 1.38–1.85])
was found, when comparing Q4 to Q1 (Fig. 3A). The increase in mortality
risk was 50% (HR 1.50 [95% CI: 1.28–1.75]) within the nine year follow-
up period when a multivariate Cox proportional-hazard analysis was ap-
plied accounting for risk factors known to impact mortality (Fig. 3B).
3.4. Cause Speciﬁc Mortality
Cause speciﬁc mortality was assessed in part of the cohort with
serum C1M levels in the upper quartile (Q4) versus subjects with
serum C1M levels in the lowest quartile (Q1). A multivariate Cox
proportional-hazard analysis was used to assess the cause speciﬁc mor-
tality risk in the time intervals 0–3 years and 0–9 years (Fig. 4).
In themultivariate Cox regression-analysis, the hazard ratiowas 2.32
[95% CI: 1.51–3.56] for cancer, 1.77 [95% CI: 0.98–3.17] for cardiovascu-
lar diseases, 1.67 [95% CI: 0.48–5.84] for lung diseases, and 1.77 [95% CI:
0.71–4.42] for other deaths within the 0–3 year interval (Fig. 4A).
In the 0–9 year follow-up interval, the hazard ratio was 1.49 [95% CI:
1.16–1.90] for cancer, 1.69 [95% CI: 1.27–2.24] for cardiovascular dis-
eases, 1.09 [95% CI: 0.63–1.88] for lung diseases, and 1.63 [95% CI:
1.19–2.24] for other deaths (Fig. 4B).
4. Discussion
We have identiﬁed MMP-mediated type I collagen degradation
(C1M) as an independent risk factor for all-cause mortality. Contrary,
we found no association between cathepsin K degraded type I collagen
(CTX-I) and all-cause mortality. This suggests that speciﬁcally MMP-
mediated tissue degradation of type I collagen is associated with
mortality.
We found a 2-fold increase inmortality risk in the ﬁrst three years of
follow-up and a 1.5-fold increase was observed with nine year follow-
up time in individuals having high MMP-mediated type I collagen deg-
radation compared to individuals with a low serum level of this type I
collagen degradation marker.
During pathological remodeling of the ECM excessive levels of
tissue- and pathology-speciﬁc turnover products are released into the
circulation consequently becoming biomarkers. In the present study
degradation of type I collagen was measured as a marker for tissue
degradation as it is assumed to be a key player in ECM remodeling.
Our results emphasize that the enzymatic processing is important
since only the MMP-mediated type I collagen degradation was predic-
tive of mortality, not cathepsin K degraded type I collagen. Increased
serum C1M levels have previously been shown to be associated with
diseases in which chronic inﬂammation is a key driver, such as ankylos-
ing spondylitis (Bay-Jensen et al., 2012), osteoarthritis (Siebuhr et al.,
2014), rheumatoid arthritis (Bay-Jensen et al., 2014), and different
types ofﬁbrosis (Leeming et al., 2012, 2013)- diseaseswhich are all con-
tributing to a decreased healthy life expectancy and ultimately death.
The prognostic nature of C1M was assessed by dividing the follow-
up period into three year intervals. A 2-fold increase in risk of mortality
was determinedwithin the ﬁrst three years of the follow up period. The
increase in mortality with increasing C1M observed in the 0–3 year in-
terval introduce a “survivor effect” when applying the three year strat-
iﬁcation approach. This may explain why the HRs decrease over time,
driving the associations towards the null hypothesis in the remaining
time intervals (3–12 years). The observed potential association in the
intermediate time spans (3–6 and 6–9 years) is therefore very likely,
but presumably underestimated since the “survivor effect” will drive
the high risk group towards the low risk group over time. Despite this,
we believe that C1M may predict an increased risk of mortality up to
nine years prior to death for subjects with C1M levels in the upper
quartile. A 1.5-fold hazard ratio was determined for the combined
0–9 year interval (Fig. 3). The higher risk in the 0–3 year interval under-
lines the understanding that an event, in this case death, is easier to
N HR (95% CI)
Q1 1205 124 1 [Reference]
Q2 1193 134 0.96 (0.91-1.02)
Q3 1153 131 0.93 (0.84-1.04)
Q4 1100 110 0.86 (0.68-1.08)
N HR (95% CI)
Q1 1350 68 1 [Reference]
Q2 1337 59 1.07 (1.00-1.15)
Q3 1327 63 1.14 (1.00-1.30)
Q4 1302 83 1.32 (1.00-1.74)
HR (95% CI) for quartiles of C1M
1 2 30.6
HR (95% CI) for quartiles of C1M
1 2 30.6
HR (95% CI) for quartiles of C1M
1 2 30.6
HR (95% CI) for quartiles of C1M
1 2 30.6
N HR (95% CI)
Q1 1383 33 1 [Reference]
Q2 1371 34 1.19 (1.10-1.28)
Q3 1364 37 1.39 (1.20-1.62)
Q4 1369 67 2.02 (1.48-2.76)
N HR (95% CI)
Q1 1282 77 1 [Reference]
Q2 1278 85 1.09 (1.03-1.15)
Q3 1264 111 1.18 (1.06-1.31)
Q4 1219 119 1.41 (1.12-1.78)
0 - 3 years
3 - 6 years
6 - 9 years
9 - 12 years
A
B
C
D
Fig. 1. Hazard ratios with 95% CI for all-cause mortality in quartiles (Q1–Q4) of C1M. A:
0–3, B: 3–6, C: 6–9 and D: 9–12 years. Values are adjusted for age, BMI, smoking, alcohol
consumption, physical inactivity, education level, hypertension, hyperlipidemia, cancer
history and diabetes.
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predict closer to time of occurrence. Subjects with high MMP-mediated
type I collagen degradation may therefore be predisposed to a de-
creased life expectancy based solely on their degree of type I collagen
degradation.
The PERF I cohort comprised slightly overweight elderly women at
risk of developing commonwestern-lifestyle diseases such as type II di-
abetes, hypertension and hyperlipidemia. These lifestyle diseases affect
many tissues and organs resulting in chronic low grade inﬂammation
possibly following ﬁbroproliferative changes to the ECM and thereby
collagen degradation. The most prevalent primary causes of death in
the PERF cohort were cancer and cardiovascular diseases accounting
for 34% and 27% of all deaths, respectively. Similarly, the two largest
causes of death for women aged 70–74 in the EU, as reported in the
European Health Report, are cancer and cardiovascular diseases ac-
counting for 37% and 42% respectively (WHO, 2013). High MMP-
mediated type I collagen degradation was associated with both cancer
and cardiovascular mortality. At ﬁrst glance, two markedly different
diseases, however with increased tissue turnover being a common de-
nominator of both diseases. The risk of dying from cancerwas increased
2.3-fold in theﬁrst three years of follow-up and an approximate 1.5-fold
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Fig. 2. Kaplan–Meier survival curves for A: 0–12 years with C1M levels divided into quartiles (Q1 (lowest), Q2, Q3 and Q4). Black: Q1, dark gray: Q2, gray: Q3, light gray: Q4; B: 0–3 years,
C: 3–6 years, D: 6–9 years and E: 9–12 yearswith C1M levels divided into Q1–Q3 (pooled) andQ4 (upper quartile). Black: Q1–Q3, light gray: Q4. *p b 0.05, **p b 0.01, ***p b 0.001, ns=not
signiﬁcant.
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increasewas observedwithin the nine year follow-up period in individ-
uals having high MMP-mediated type I collagen degradation. These
ﬁndings correspondwell with the association between ECM remodeling
and tumorgenesis (Bonnans et al., 2014; Lu et al., 2012) as ECM remod-
eling in cancer leads to a dysregulation in tumor growth, inﬂammation,
tissue invasion, and metastasis (Kessenbrock et al., 2010).
In addition, risk of dying from cardiovascular diseases was increased
1.8-fold in theﬁrst three years of follow-up and an approximate 1.7-fold
increase was observed with nine year follow-up period in individuals
having high MMP-mediated type I collagen degradation. Atherosclero-
sis is a typical hallmark of cardiovascular diseases leading to a distur-
bance of the ECM homeostasis in the artery wall combined with low-
grade inﬂammation. This results in a disrupted structure of the ECM of
the artery wall, ultimately leading to cardiovascular disease and fatal
events (Hobeika et al., 2007; Raines, 2000; Galis and Khatri, 2002).
Other tissue turnover markers have been associated with mortality; al-
beit not type I collagen degradation byMMPs. P3NP, a formationmarker
of type III collagen, was associated with all-cause mortality in the
Framingham study (Velagaleti et al., 2010). Endostatin, a degradation
fragment of type XVIII collagen, was associated with all-cause, cancer
and cardiovascular mortality in two independent cohorts from Sweden
(Ärnlöv et al., 2013).
Degradation and formation are interlinked in the tissue turn-
over balance, making both processes equally important. Determining
the better biomarker is therefore not easy. Formation markers, like
P3NP, are generated in all tissues comprising type III collagen.
However, when measuring a MMP-mediated degradation product,
like C1M, it is a prerequisite that the protease is co-expressed in the af-
fected tissue, making this a speciﬁc marker for pathologic tissue turn-
over. When assessing mortality, MMP-mediated type I collagen
degradationmay possibly either reﬂect a consequence or a cause of dis-
ease leading to mortality (Karsdal et al., 2010). In order to further an-
swer this question, it would be beneﬁcial to have sequential
measurements of C1Mwhich couldmore closely relate diagnosis of dis-
ease rather than early prognosis. In the current study it can only be spec-
ulated that some individuals may be predisposed for an increased
degradation, potentially making them prone to certain diseases and
eventually premature death.
Increased serum levels of C1M have shown to be associated with
pain and progression of disease in rheumatoid arthritis, and conversely,
a decrease by anti-inﬂammatory modulation (anti-interleukin-6) of
more than 35%was associatedwith protection fromdisease progression
(Siebuhr et al., 2013). This may suggest that attenuation of high remod-
eling by intervention could be associated with increased life-span. The
relation between inﬂammation and tissue turnover is of particular in-
terest. In autoimmune diseases like rheumatoid arthritis CRP and C1M
have been proven to be highly correlated (Siebuhr et al., 2013). In dis-
eases like ﬁbrosis, inﬂammation may initiate disease, however once
present ﬁbrosis can progress without inﬂammation (Trautwein et al.,
2015). The nature and extent of inﬂammation and ECM remodeling
are therefore likely to be very different in different diseases and stages
within the same disease. Although this current study identiﬁed the
HR (95% CI), adjusted
0.6 0.8
HR (95% CI), unadjusted
1 21 2 30.6
N HR (95% CI)
Q1 1411 188 1 [Reference]
Q2 1400 185 1.12 (1.08-1.16)
Q3 1391 217 1.25 (1.16-1.34)
Q4 1400 280 1.59 (1.38-1.85)
N HR (95% CI)
1383 178 1 [Reference]
1371 178 1.10 (1.06-1.15)
1364 211 1.21 (1.13-1.30)
1369 269 1.50 (1.28-1.75)
BA
Fig. 3. Hazard ratios with 95% CI for all-cause mortality in quartiles (Q1–Q4) of C1M with nine year follow-up. A: unadjusted, B: adjusted. Adjusted values are corrected for age, BMI,
smoking, alcohol consumption, physical inactivity, education level, hypertension, hyperlipidemia, cancer history and diabetes.
HR (95% CI), adjusted
0.8 546.0
HR (95% CI), adjusted
1 2 3
1 2 3 56.0 40.8
N HR (95% CI)
All 1369 269 1.50 (1.28-1.75)
Cancer 1209 109 1.49 (1.16-1.90)
CVD 1183 83 1.69 (1.27-2.24)
Lung 1116 16 1.09 (0.63-1.88)
Other 1161 61 1.63 (1.19-2.24)
N HR (95% CI)
All 1369 67 2.02 (1.48-2.76)
Cancer 1337 35 2.32 (1.51-3.56)
CVD 1324 22 1.77 (0.98-3.17)
Lung 1305 3 1.67 (0.48-5.84)
Other 1309 7 1.77 (0.71-4.42)
A
B
Fig. 4.Hazard ratios with 95% CI for all-cause mortality and cause speciﬁc mortality (cancer, cardiovascular diseases, lung diseases and other diseases) for the upper quartile of the cohort
(Q4) in time intervals 0–3 years (A) and 0–9 years (A). Hazard ratios are adjusted for age, BMI, smoking, alcohol consumption, physical inactivity, education level, hypertension, hyper-
lipidemia, cancer history and diabetes.
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prognostic importance of C1M assessment in serum, it remains to be
shown whether lowering this marker can result in a reduction of the
mortality risk.
Interpreting biochemical markers found in serum is associated with
many limitations, as several different tissues at different rates may pro-
duce and thus contribute to the total pool of molecular marker. Type I
collagen is highly abundant in many tissues throughout the body, and
an increase in the serological levels of C1M is a hallmark of several
ﬁbroproliferative diseases. Further studies on disease-speciﬁc contribu-
tions to the total pool of ECM remodeling are therefore needed. Impor-
tantly however,measuring increased levelsmay assist in identifying the
sub-groups predisposed for increased ECMremodeling. This could aid in
early diagnosis of subjects with high tissue turnover, leading to connec-
tive tissue diseases, which may beneﬁt from increased medical atten-
tion thereby potentially increasing their lifespan.
This cohort is solely comprised of Danish postmenopausal women
and further generalization to other demographics needs to be investi-
gated. However, the risk factors identiﬁed in the Cox proportional-
hazard analysis (smoking, alcohol consumption, physical inactivity,
education level, hypertension, hyperlipidemia and diabetes) had similar
associations to risk factors found in the Nurses' Health Study, a cohort of
middle-aged women (Baer et al., 2011).
Moreover, as in other epidemiological studies, ﬁndings in the
present study may be affected by selection bias caused by possible
over-representation of relatively healthy subjects in the cohort. One
could however argue that this would tend to draw the results in a direc-
tion towards the null hypothesis and therefore cannot explain our pos-
itive results.
5. Conclusion
We found that increased MMP-mediated tissue degradation, as an
independent risk factor, was associated with a 2-fold increase in all-
cause mortality within three years of follow-up and a 1.5-fold increase
in all-cause mortality up to nine years prior to death.
MMP-mediated tissue degradationmay be an important predisposi-
tion for cause of disease and subsequent mortality.
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8 GENERAL DISCUSSION 
Longitudinal studies can aid in identifying the predictors of disease, which can then be 
assessed and ultimately manipulated for their determinant roles in reducing the functional 
decline in ageing persons (149). The work presented in this thesis manifests the importance 
of studying ageing and age-related diseases in a longitudinal set-up. We clearly describe how 
some elderly women are of greater risk of disease and death than others, as a result of 
specific risk factors contributing to distortion of the healthy ageing process. The description 
of these risk factors has contributed specifically to broadening the knowledge of non-
communicable diseases and death in elderly Danish women. 
The PERF study is one of the largest longitudinal ageing studies focusing specifically 
on women’s health. Other longitudinal studies with specific focus on female health are the 
Women’s Health and Aging Study (WHAS I and II) (185), the Study of Women’s Health 
Across the Nation (SWAN) (150), and the Nurses’ Health Study (NHS) (186), all from the 
United States, together with The Australian Longitudinal Study on Women's Health (151). 
The PERF study is thus believed to contribute to this list of female ageing studies by 
specifically providing knowledge about Danish female health in ageing.  
8.1 Ageing and Tissue Degradation 
The WHO describes the complexity of the ageing process in simple terms (11): 
‘The changes that constitute and influence ageing are complex. At a biological level, ageing is 
associated with the gradual accumulation of a wide variety of molecular and cellular damage. 
Over time, this damage leads to a gradual decrease in physiological reserves, an increased risk 
of many diseases, and a general decline in the capacity of the individual. Ultimately, it will 
result in death.’  
We add further evidence to this statement with the study of collagen type I degradation and 
how an increased degradation leads to premature death. This finding underlines how some 
women age better than others and that the risk of mortality is related to MMP-mediated 
tissue degradation of collagen type I.  
Collagen turnover is highly affected by age wherefore the study of degraded collagen 
can describe different outcomes in different populations (152). The PERF study thus provides 
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a solid cohort for the study of collagen type I degradation specifically in relation to ageing 
as described in study IV. Previous studies in the same cohort have added significantly to the 
knowledge about collagen degradation consequent to the loss of sex hormones, resulting in 
a corresponding loss in bone mineral density followed by bone resorption (187, 188). 
However, with the application of C1M, a marker specifically related to tissue degradation 
not associated with bone loss (144,153), it adds to the understanding of underlying cellular 
damage of connective tissue, the extracellular matrix as a scaffold, and how this is associated 
with the ageing process.  
We found that women with the highest levels of the degradation marker C1M 
presented an independent risk of premature mortality compared to women with lower levels 
of this tissue degradation marker. This is assumed to reflect that the extracellular matrix 
composition and quality may very well be an important predisposition for disease and 
ultimately death. However, the argument of what triggers excessive tissue degradation is 
still debatable; or put differently: what comes first? Either, the influence of a risk factor, e.g. 
excess adipose tissue, which thereby triggers the altering of the tissue homeostasis leading 
to excessive tissue degradation. Or, the other way around, an underlying genetic 
predisposition of a high level of tissue degradation leads to an increased adverse impact of 
other risk factors? The multivariate statistical analysis performed in the study reflects an 
independent contribution of the marker to the increased risk of mortality. However, it does 
not reveal if there is an underlying impact, or triggering effect, from other risk factors, as in 
the scenario described previously.  
Siebuhr et al. investigated whether serum levels of C1M could aid in the identification 
of rheumatoid arthritis patients with fast progression of disease and whether C1M levels 
were altered following treatment of the disease (154). They found how high levels of C1M at 
baseline was a significant predictor of disease progression and that treatment dose-
dependently lowered the serum level of C1M. This study does not give us the answer to what 
triggers the inflammatory development of rheumatoid arthritis, but it does however reveal 
that the extent of MMP-mediated collagen type 1 degradation is modifiable by medical 
treatment of the inflammatory processes. Applying this association in the setting of the 
ageing population, a population described by higher levels of low-grade chronic 
inflammation, it can be speculated if what is presented in study IV as MMP-mediated tissue 
degradation is a somewhat surrogate or perhaps the result of the low-inflammatory state. It 
is evident, that especially monocytes and macrophages, are the most important mediators 
of chronic inflammation with functions described to have a direct effect on toxicity of the 
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extracellular matrix and collagen deposition (155). Future studies, in the PERF cohort, 
correlating levels of pro-inflammatory markers, triggered by the mononuclear phagocyte 
system, with levels of C1M, would be interesting and aid in the understanding of the low-
grade inflammatory state associated with ageing and following tissue degradation.  
8.2 Metabolic Risk Factors Distorting Healthy Ageing 
From a clinical point of view, the presented statement from the WHO can be translated into 
the conclusion that most major health problems surface during the late years of life resulting 
in an increased risk of age-related diseases.  
The associations between risk factors and following disease are described in study II, 
highlighting how women with metabolic risk factors presented a greater risk of developing 
T2DM and CVD. 
Insulin resistance forms an underlying ‘common ground’, as presented in figure 1 of 
the introduction, for the development of both hyperglycaemia, hypertension and 
dyslipidaemia, ultimately leading to T2DM and CVD. Insulin resistance is often, though not 
always, originating from excess adiposity and abdominal obesity. It is therefore generally 
accepted that insulin resistance and abdominal obesity both are key features in the 
pathophysiology of these outcomes (57). This is well reflected in study II where we find 
obesity to be the only risk factor, of the MetS, associated with increased risk of both T2DM 
and CVD. 
8.3 Relevance of the Metabolic Syndrome 
The obvious need for a research instrument in the presentation of the combination of risk 
factors commonly associating with T2DM and CVD has resulted in the development of 
several different clinical definitions of the MetS, as highlighted in table 1. The concept of the 
MetS has been, and still is, a topic of great debate, especially concerning its pathogenesis 
and clinical usefulness (156–158).  
The term MetS is not new and extensive research has been undertaken to define its 
epidemiology. However, studies conducted solely in the ageing population are still sparse. 
Especially when taking into account the many definitions which are somewhat difficult to 
compare.  
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The main differences in the agreement of the usefulness of applying a syndrome-
definition are caused by different visions (from the WHO definition to NCEP-ATPIII), of 
whether or not to specifically demonstrate insulin resistance or instead apply the surrogate 
measure of obesity (159). Nevertheless, and regardless of the chosen definition, the concept 
of focusing on multiple risk factors concurrently improves the understanding of the 
underlying pathophysiology and the mechanisms by which metabolic risk factors like 
hypertension, dyslipidaemia and hyperglycaemia are interlinked as a result of insulin 
resistance. It further provides insights into the mechanisms by which obesity influence both 
insulin target tissues and vasculature, thereby improving the overall understanding of the 
link between obesity, T2DM, and CVD.  
With the definition introduced by the IDF, which is applied in the current work, the 
thresholds for increased waist circumference and glucose levels were lowered compared to 
previous definitions. In concept, this new definition, as a thought construct, has advantages 
because it elegantly puts forward the central role of abdominal obesity in the MetS. 
However, we showed, that applying this construct, at least in an ageing cohort, leaves out a 
subgroup not meeting the threshold. The subgroup thus still provided significantly 
increased risk of disease by holding other risk factors also known to manifest in T2DM and 
CVD. We therefore argue, that the application of the MetS, thus cannot be used to describe 
a synergistic effect associated with the clustering of risk factors, when demands for a set pre-
requisite, assuming central obesity to always manifest, in order for the risk factors to be 
interlinked. This is further backed up by studies showing that the incidence of T2DM is 
higher among adults with normal weight but with insulin resistance or MetS, defined by the 
NCEP-ATPIII, where central obesity is not a pre-requisite than in overweight subjects who 
do not have insulin resistance or the MetS (160,161). This gives rise to the discussion of why 
the MetS is defined, and what it is used for. Is it applied based on evidence of a synergistic 
risk occurring when requirements for the MetS are fulfilled (those requirements being 
continuously changed during the last decade) or is it merely a clinical construct used for 
clinicians to comprehend the common clustering of metabolic risk factors associated with 
the increasing diagnosis of non-communicable diseases? Regardless of the rationale, the 
application of the definition aids in the focus of treating multiple risk factors 
simultaneously. However, we do argue to apply a construct that values the amount of 
presented risk factors higher than the impact of a specified pre-requisite.  
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8.3.1 Risk prediction in elderly 
The risk prediction in the PERF cohort is stronger in regards to T2DM outcome than CVD 
risk. Ford et al. confirm this observation in their quantitative review from 2008 of 
prospective studies examining the association between the MetS and incident diabetes. 
They conclude that the MetS predicts diabetes more strongly than it predicts coronary heart 
disease events. Although considerable heterogeneity existed among the studies in the 
review, as a result of the many MetS definitions, the average estimated relative risk of 3.5–
5.2 for incident diabetes with any MetS criteria is greater than the association of MetS with 
CVD events, with relative risks from 1.5 to 2.0 (105,162). These data confirm the MetS to be 
more strongly associated with risk for incident diabetes, concluding how this most like 
relates to particular fasting glucose and waist circumference as they are more strongly 
associated with diabetes risk than with CVD (163). This is confirmed in the PERF cohort set-
up, where we similarly see a strong association specifically between elevated FPG, central 
obesity and risk of T2DM. This association was not present in the analysis of risk factor 
contributions for a CVD outcome, where hypertension and central obesity were the main 
components driving the outcome (figure 2, study II). If the underlying risk factors, although 
commonly believed to associate from a ‘common ground’ of insulin resistance, is not to a 
greater extent overlapping than what is observed in the PERF study, it could be argued that 
risk scores specifically focusing on one or the other outcome would aid in a more specific 
risk prediction of the specific outcome.  
A variety of both diabetes and CVD risk prediction models have already been proposed 
and will not be further elaborated upon in this thesis. However, one is worth mentioning; 
The Diabetes Risk Score, as this score has been compared to the MetS in three different 
studies (157,164,165). The Diabetes Risk Score includes age, sex, ethnicity, fasting glucose, 
systolic blood pressure, HDL cholesterol, BMI and family history of diabetes (166). These 
components are highly comparable to the MetS criteria, however with the great difference, 
that they are assessed in a continuous manner. Contrary to this risk estimation approach, 
the application of the MetS, as well as its component risk factors, is entirely dependent on 
the choice of cut-points to dichotomize the population into those with and without the 
condition. Dichotomizing continuous variables results in a loss of predictive power, which 
is confirmed in the three studies, where the risk of diabetes was significantly larger using 
The Diabetes Risk Score, than what was predicted using the MetS defined cut-points. 
Assessment of the MetS, using continuous variables, have been performed by Wijndaele et 
al. in 2006 with CVD as outcome variable. First, they describe, how PCA was applied to the 
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normalized risk factors in order to extract PCs representing large fractions of MetS variance, 
revealing two PCs with eigenvalue ³1. Second, a continuous MetS score was calculated by 
summing both PC scores, each weighted for the relative contribution of PC1 and PC2 in the 
described variance. Using this approach, they start by confirming that the continuous MetS 
score is found to be significantly higher in part of the cohort originally diagnosed with MetS 
using the IDF definition and that the continuous MetS risk increased progressively with 
increasing numbers of risk factors. They conclude, that the continuous score is a more 
suitable and valid alternative for epidemiological analyses, although the binary definition 
remains useful for clinical practice (167). It would be interesting, to apply this approach to 
the PERF dataset using the PCA setup. This would aid in the understanding of the different 
sub-groups not defined with the syndrome and how the risk would increase with increasing 
numbers of risk factors in all of the defined groups.  
8.3.2 Metabolic risk in elderly 
The currently available definitions of the MetS do not specifically consider the effect of 
ageing on the five diagnostic variables. In a study performed on the Italian Longitudinal 
Study of Aging, the diagnosis of MetS according to the IDF criteria showed no relationship 
to the risk of myocardial infarction or stroke in elderly without a previous CVD diagnosis 
(168). In study II we do find an increased risk of a CVD diagnosis, in women with no previous 
CVD diagnosis. Applying a clinical construct, as the MetS, in a cohort like the PERF cohort, 
will exclude a large fraction of the women based on the exclusion related to CVD outcomes 
prior to the initial visit (PERF I). However, as it has been shown that patients with clinical 
manifestations of atherosclerosis are generally considered to have more than 20% absolute 
risk of developing a new CVD events in the next 10 years (169), this would indicate an even 
higher risk in this particular group, most likely associated with the MetS defining risk 
factors. It would consequently be interesting to conduct the same analysis as described in 
study II, but on the previously diagnosed CVD subjects, excluded from the analysis, in order 
to determine whether risk predictions would vary in the two groups. This would aid in 
understanding if the syndrome is able to discriminate future risk of an outcome based on 
preceding disease.  
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8.3.3 The age-dependent metabolic syndrome  
Another aspect of the syndrome not being age focused is the missing application of 
age as part of the criteria. The waist circumference criterion is modified in the IDF definition 
based on ethnicity and sex, however, cut-off values are not modified according to age. None 
of the classifications described in Table 1 in the introduction have considered the age-
dependent effects, even though a significant age-dependent increase of several parameters 
has been shown (189-192).  
The worldwide increase in the ageing population, combined with the increased 
prevalence of obesity, are likely to result in the increasing prevalence of MetS reported in 
recent years. The question is whether the increased metabolic parameters seen in the elderly 
should be considered as consequent risk factors for disease or natural age-dependent 
phenomena. Figure 2 in study II reflect, how none of the lipid parameters of the syndrome 
contributed to the increased risk of neither T2DM nor CVD, questioning if they should be 
taken into consideration particularly in the diagnosis of MetS in elderly. Put simply, it 
should be decided whether to apply the same criteria in the diagnosis of MetS for the elderly, 
as done in the middle-aged population. Limited research has been conducted on this topic, 
however, Motta et al. have in 2008 studied the relevance of an age-specific definition, 
employing age-specific cut-points, and how this compared to the IDF criteria in predicting 
vascular complications. They conclude that the IDF-criterion is not useful for diagnosing 
MetS in the elderly patients and further highlighting the need of further epidemiological 
studies of long duration, and wide coverage, involving numerous correlated parameters, in 
relation with the MetS, age, and ethnicity of the patients. An interesting observation done 
by the group was further to calculate the prevalence of acute myocardium infarct and stroke 
in elderly with and without a waist circumference above what is proposed as the entrance 
criteria for the IDF definition. They found no difference in the subjects with and without 
central obesity, arguing how this explains the diversity of many proposals, which are often 
contradictory, on the risk of CVD. These data do indicate that the cut-points of the five set 
IDF risk factors are not valid for the diagnosis of MetS in the elderly, and it would be 
interesting to verify this use of age-specific cut-points in the PERF cohort in order to 
determine if the model proposed by Motta et al. is equally predicting the age-related risk in 
a cohort in which the age-specific definition was not developed.  
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8.4 Weight and Weight Change in Late-life 
Although obesity is a risk factor for morbidity and mortality in the younger part of the 
population, the effect of obesity in elderly is much more complex (170). We confirm in study 
III how weight gain increases the risk of hyperglycaemia in overweight and obese elderly 
women compared to those classified as normalweight at baseline. We thereby underline 
that a significant risk of hyperglycaemia is linked to obesity in elderly women.  
Elderly women with high levels of body fat who do not appear overweight as a result 
of loss of lean tissue, manifested as sarcopenic obesity, are believed to be somewhat limited 
within the PERF cohort, as we see no tendencies in decreasing muscle mass within any of 
the BMI groups (figure 3, study III). Further, as correlations between BMI and waist-hip-
circumference were found to show acceptable correlation, it is argued that BMI is a valid 
tool for the assessment of weight in the PERF cohort. However, the age-related height 
modification, which can obstruct BMI measurement, was clearly present in the PERF cohort 
(see additional table in study III). This phenomenon has previously been reported to induce 
a false BMI increase of 2.5 units in women suggesting an overweight BMI in elderly to instead 
be defined as a BMI ³27.0 (171). This approach of an age-dependent BMI threshold runs well 
in line with the above discussion related to an age-dependent MetS criteria in elderly. 
However, in the presented study III in which BMI is used, the weight definition merely 
functions as a tool for division of the women in the cohort. The cut-points can be looked 
upon as being somewhat arbitrary, as long as they divide the women in baseline BMI groups, 
which reflect their weight in a clear manner. However, it would be interesting to run the 
statistical analysis with this age-dependent cut-point for BMI in order to see if risk estimates 
in the overweight and obese group would change. 
In relation to weight change, evidence from previous studies underlines how body 
weight associated with maximal survival increases with increasing age (170). This is by 
Chapman referred to as the ‘obesity paradox’, as increased weight leads to increased CVD 
morbidity but a decrease in CVD-related mortality (170). Chapman therefore argues, that 
there are few if any indications for recommending weight loss to older people based on their 
weight alone (170). However, intentional weight loss by obese elderly is likely to be beneficial 
if they have obesity-related morbidities and Harrington et al. confirms in a fairly recent 
meta-analysis how intentional weight loss is not related to increased mortality (172). In study 
III the reason for weight loss is not known, as we merely work with non-interventional 
assessment of the cohort, wherefore we cannot argue if it is intentional or not. However, a 
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clear association is observed between lowered weight and decreased risk of hyperglycaemia. 
Other studies regarding weight loss specifically in elderly are greatly focused upon the 
evidence that weight loss by overweight older people is associated with improved quality of 
life. In the Nurses’ Health Study, weight loss in initially overweight women was associated 
with improved physical function and vitality as well as decreased pain (173). Overall, weight 
change and its relation to risk factor development in longitudinal setups are sparse. The 
current literature either focus on weight as the main component of the conducted research 
or the associated risk factor, e.g. hyperglycaemia, as the component of greatest importance 
for the health outcomes. The combination of the two associations is therefore somewhat 
limited, which clearly justifies the need for the research presented in study III. 
8.4.1 Hyperglycaemia in elderly 
Assessing the outcome variable of study III, hyperglycaemia, in the context of weight 
change, literature is limited. It has however been shown that subjects who are older, 
overweight, and have other diabetes risk factors are more likely to progress from 
hyperglycaemia to diabetes (174). This is well in hand with the findings from Alexander et 
al. showing that fasting glucose, diabetes risk, and systolic blood pressure values show a 
linear relationship with ageing and the BMI (175).  
Focusing specifically on hyperglycaemia, however not in the context of weight change 
as such, but merely in relation to weight, the concept of being metabolically obese, despite 
a normal weight, has been proposed to explain the high risk of hyperglycaemia and T2DM 
in some normalweight subjects (176). This is confirmed by Meigs et al. in 2006 concluding 
how the incidence of T2DM is higher among individuals with normal weight but with insulin 
resistance or the metabolic syndrome than in overweight individuals who do not have 
insulin resistance or the metabolic syndrome (160,161). Thus the relevance of assessing risk 
in all weight groups are of importance.  
In study III we only assess hyperglycaemic risk in the presence of IFG and HbA1c. 
However, in a meta-analysis of prospective studies published between 1979 and 2004, 
annualised incidence rates of progression to diabetes in patients with isolated IGT (4-6%) 
or isolated IFG (6-9%) were lower than those with both IFG and IGT (15-19%) (79). indicating 
that although both IFG and IGT are insulin-resistant states, they differ in their site of insulin 
resistance (76,177). These observations are confirmed in a Swedish longitudinal study on 
post-menopausal women concluding that IGT and IFG are two diagnostic entities which 
overlap only partly. They find a larger fraction of women with IGT than IFG and conclude 
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that choosing to measure only FPG would result in missing a pre-diabetic state (81). It could 
therefore be argued, that we in study III only partly cover the fraction of elder women at 
pre-diabetic risk by only assessing FPG.  
8.5 Limitations in Longitudinal Research  
Each manuscript has its respective limitations, which are discussed in the individual papers. 
This section is thought as a description of the overall pitfalls associated with the use of 
epidemiological data.  
The PERF cohort is a homogeneous group of elderly Danish women; same age-group, 
gender, same rights to health care services (government funded health care) with all contact 
to the health care system linked to a unique social security number. The work presented in 
this thesis is built largely upon the use of register-based information of outcomes which are 
obtained from Danish national registries applying this unique construct. The national 
registries can be used to obtain figures for the most serious part of morbidity leading to 
hospitalization or death, but an overall assessment of disease incidence can only be achieved 
by examination of representative samples of the population as done in the PERF cohort. A 
clear advantage of applying register based data is the very limited loss to follow-up and also 
the low information bias, as it is not a self-reported diagnosis but a medically confirmed 
diagnosis applied in as the end-point in the statistical analysis. However, one limitation 
needs to be considered, when applying data specifically from the National Diabetes Registry. 
As reported on a global level, diabetes is greatly underdiagnosed. This is also the case in 
Denmark. Findings from the Inter99 study indicated that more than half of the persons with 
diabetes according to the diagnostic criteria are undiagnosed (178). So, the register is not 
complete in the clinical sense that all diabetics are actually diagnosed. The misclassification 
of this discrete variable will lead to misclassification, which will alter the calculated risk 
estimates. Green et al. validated the register in 2014 and found that approximately 20% of 
the registrations in the registry may be false positive inclusions of persons with frequent 
measurements of blood glucose without having diabetes. They, therefore, recommended 
changes for improving validity, by reducing the impact of current sources of bias and 
misclassifications (179). The diabetes register has later been terminated and will re-open in 
another format.  
One last note to be touched upon in relation to metabolic risk factors; confounding. 
Rothman describes confounding in its most simple term as a confusion of effects (4). In 
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relation to the presented studies, a confusion of effect, or ‘what is the actual exposure’ are 
relevant to touch upon as obesity and insulin resistance are so interlinked. In study IV of 
this thesis, the reason for weight loss is not known and the associations between obesity and 
hyperglycaemia are constructed in a way, where obesity is assumed to precede 
hyperglycaemia. However, a possible risk of misinterpreting weight relations as a result of 
hyperglycaemia risk (or the other way around) is possible, as the follow-up period is 13 years. 
An obese woman with normoglycaemic levels at baseline developing hyperglycaemia over 
time (prior to follow-up), might be advised to lose weight as a result of the hyperglycaemic 
levels, thereby initiating a weight-loss based on the outcome parameter of the study. She 
will most likely end up in ‘obese weight losing’ category thereby increasing the risk estimate 
in the weight losing category, as she has actively lost weight as a result of the outcome 
parameter. This is considered to greatly confound the risk estimate attained in this type of 
study setup. 
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9 CONCLUDING REMARKS 
This thesis contributes to enhance the information currently available from longitudinal 
research studies in elder women.  
The PERF cohort profile demonstrates that the PERF cohort is representable for the 
elderly Danish female population and that the characteristics of the PERF II follow-up 
participants did not vary significantly from women from the PERF I cohort, who were not 
followed up.  
The studies presented in the thesis specifically showed that: 
• Elderly women defined with MetS showed an increased the risk of future T2DM and 
CVD. This risk increased when the reference group only comprised women holding 
no risk factors for MetS. 
• Women not defined with MetS, however still holding metabolic risk factors, which 
are used to define the syndrome, were also at increased risk of T2DM or CVD 
compared to women with no MetS risk factors. 
• Overweight and obese elderly women had a significantly increased risk of 
hyperglycaemia compared to normalweight elderly women. 
• Losing weight in late life had a positive effect on the risk of hyperglycaemia in 
overweight and obese women, while further weight gain increased the risk of 
hyperglycaemia.  
• Increased MMP-mediated tissue degradation was identified as an independent risk 
factor of increased all-cause mortality measurable up to nine years prior to death.  
• MMP-mediated tissue degradation may be an important predisposition for the cause 
of disease and subsequent mortality.  
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10 FUTURE PERSPECTIVES 
The work presented in this dissertation only touches upon a fraction of the pressing research 
questions related to upholding a healthy ageing process. One major risk indicator when 
discussing MetS, T2DM and CVD is clearly missing from the presented analysis, namely 
insulin. Insulin, was not measured as part of the biomarker panel available from the PERF 
dataset, however, new funding has made it possible to measure insulin within the full cohort 
both at baseline (PERF I) and follow-up (PERF II). This will give us valuable insights into 
associations between insulin and weight in elderly women. It will further help in the 
investigation of how insulin levels, and insulin resistance collate with weight, waist 
circumference and BMI, but also hand-grip strength; all parameters which have been 
touched upon in this thesis. Their associations with insulin would contribute to a more 
thorough evaluation of sarcopenic obesity and also help us to determine if obesity or insulin 
resistance, per se, is the actual driver of the metabolic disorders associated with the MetS 
preceding T2DM and CVD in elder women. 
In relation to the further exploration of collagens, as a scaffold for disease, and their 
association with metabolic disorders, collagen type VI should be further explored. The C-
terminal pro-peptide of collagen type VI has been shown to function as the hormone 
endotrophin, which is associated with the MetS. Endotrophin is a co-stimulator of 
pathological paths within the adipose tissue ultimately triggering fibrosis and inflammation 
leading to enhanced insulin resistance and metabolic dysfunction (180). It would be 
interesting to explore this association further, by analysing if increased endotrophin levels 
are a predecessor for T2DM by correlating delta-HOMA-IR values and endotrophin levels 
applying samples from PERF I and PERF II.  
Moreover, an interesting parameter could be to address biomarkers reflecting protein 
formation, as the ratio between formation and degradation of the same protein may also 
add additional knowledge to what is currently known regarding ECM remodelling in ageing. 
The neo-epitope biomarker could also be combined with other existing or novel biomarkers 
of inflammation and insulin resistance for improving accuracy.  
As a final remark on the future employment of the PERF cohort, the potential that 
this cohort has to explore the use of personalized healthcare are promising. The term 
personalized healthcare is increasingly used and has been extensively elaborated upon as 
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the worldwide population is ageing. Personalized healthcare is thought to limit costs of 
treatment by only treating the group of individuals actually responding to the medication 
available. With this approach in mind, prediction of response to treatment and further 
demonstration of efficacy of a drug candidate are among the most difficult challenges in 
drug development. Based on the current data, C1M seems to have the prognostic potential 
for prediction of mortality, and may therefore possibly help identifying patients with 
increased tissue degradation, which could possibly benefit from treatment. 
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11 EPILOGUE 
In industrialised countries, health care systems are criticised, latest by the WHO, for being 
better designed to treat and cure acute conditions rather than to manage and minimize the 
consequences of the chronic states of disease, which are most commonly prevalent in older 
people (11,181–183). This paradox is one of the main reasons why the health of older people 
is not keeping up with the increasing longevity (184). Reducing severe disability from disease 
is a key feature of controlling the economic burden associated with the demographic 
changes. Health systems need better data to understand the health risks faced by older 
people and to target appropriate prevention and intervention strategies. Knowledge of risk 
factors is pivotal in this strategy (11). 
The vision for following up the PERF cohort was to specifically aid in these strategies 
by combining longitudinal data analysis, register-based information, and panels of well-
described biomarkers. But also to apply novel neo-epitope biomarkers, such as C1M, which 
help us to provide a broader definition of what underlines a chronic state of excessive tissue 
remodelling. Combined, all of this information will aid in gaining valuable information 
needed in order to obtain a further compression of morbidity of the ageing population, and 
thereby increase the quality of life at older age.  
 
_____  
91 
12 REFERENCES 
 
1.  Prince MJ, Wu F, Guo Y, Gutierrez Robledo LM, O’Donnell M, Sullivan R, et al. The 
burden of disease in older people and implications for health policy and practice. 
Lancet. 2014 Nov 7;385(9967):549–62.  
2.  The Lancet (Editorial). Ageing well: a global priority. Lancet. 2012 Apr 
7;379(9823):1274.  
3.  Merrill RM, Timmreck TC. Introduction to Epidemiology. Sudbury, Massachusetts: 
Jones and Bartlett Publishers; 2006.  
4.  Rothman KJ, Greenland S, Lash TL. Modern Epidemiology. Philadelphia: Lippincott 
Willams & Wilkins; 2008.  
5.  National institute on Aging, National Institutes of Health, U.S. Department of Health 
and Human Services, World Health Organization. Global Health and Aging.  
6.  He W, Goodkind D, Kowal P. An Aging World: 2015. Washington, DC: National 
Institute on Aging, U.S. Department of Commerce; 2016.  
7.  National Institute on Aging, National Institutes of Health, U.S. Department of Health 
and Human Services, U.S. Department of State. Why Population Aging Matters - A 
Global Perspective. 2007.  
8.  United Nations. World Population Prospects: The 2015 Revision. New York; 2015.  
9.  United Nations. World Population Prospects: The 2010 Revision. New York; 2010.  
10.  Nusselder WJ. Compression of Morbidity. In: Robine J-M, Jagger C, Mathers CD, 
Crimmins EM, Suzman RM, editors. Determining Health Expectancies. Chichester, 
UK: John Wiley & Sons, Ltd; 2003. p. 35–58.  
11.  World Health Organization. World Report on Ageing and Health. Geneva; 2015.  
12.  World Health Organization. WHO Fact sheet | Ageing and Health. Geneva; 2016.  
13.  United Nations. Department of Economic and Social Affairs. Population Division. 
World Population Prospects. The 2015 Revision. Key Findings & Advance Tables. New 
York; 2015.  
92 
14.  World Health Organization. Women and Health: Today’s Evidence - Tomorrow’s 
Agenda. Geneva; 2009.  
15.  World Health Organization. Global Health Risks: Mortality and burden of disease 
attributable to selected major risks. Geneva; 2009.  
16.  Arterburn DE, Crane PK, Sullivan SD. The coming epidemic of obesity in elderly 
Americans. J Am Geriatr Soc. 2004;52(11):1907–12.  
17.  Redinger RN. The pathophysiology of obesity and its clinical manifestations. 
Gastroenterol Hepatol (NY). 2007 Nov;3(11):856–63.  
18.  Chan JM, Rimm EB, Colditz GA, Stampfer MJ, Willett WC. Obesity, Fat Distribution, 
and Weight Gain as Risk Factors for Clinical Diabetes in Men. Diabetes Care. 1994 
Sep;17(9):961–9.  
19.  Lakka H-M, Lakka TA, Tuomilehto J, Salonen JT. Abdominal obesity is associated 
with increased risk of acute coronary events in men. Eur Heart J. 2002 May;23(9):706–
13.  
20.  Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P, et al. Obesity 
and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-
control study. Lancet. 2005 Nov 5;366(9497):1640–9.  
21.  World Health Organization. WHO Fact sheet | Obesity and overweight. Geneva; 
2016.  
22.  Kelly T, Yang W, Chen C-S, Reynolds K, He J. Global burden of obesity in 2005 and 
projections to 2030. Int J Obes. 2008 Sep 8;32(9):1431–7.  
23.  Li F, Fisher KJ, Harmer P. Prevalence of overweight and obesity in older U.S. adults: 
Estimates from the 2003 behavioral risk factor surveillance system survey. J Am 
Geriatr Soc. 2005 Apr;53(4):737–9.  
24.  Fakhouri THI, Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of obesity among 
older adults in the United States, 2007-2010. NCHS Data Brief. 2012 Sep;(106):1–8.  
25.  National Heart Lung and Blood Institute and National Institutes of Health (NIH) 
Clinical guidelines on the identification, evaluation, and treatment of overweight and 
obesity in adults. The Evidence Report, NIH Publication No. 98-4083. Vol. 158, 1998.  
26.  The Scottish Government. The Scottish Health Survey, 2014 edition. Edinburgh; 2014.  
27.  Diouf I, Charles MA, Ducimetière P, Basdevant A, Eschwege E, Heude B. Evolution of 
93 
obesity prevalence in France: an age-period-cohort analysis. Epidemiology. 
2010;21(3):360–5.  
28.  von Ruesten A, Steffen A, Floegel A, van der A DL, Masala G, Tjønneland A, et al. 
Trend in obesity prevalence in European adult cohort populations during follow-up 
since 1996 and their predictions to 2015. PLoS One. 2011;6(11):e27455.  
29.  Grinker JA, Tucker K, Vokonas PS, Rush D. Body habitus changes among adult males 
from the normative aging study: relations to aging, smoking history and alcohol 
intake. Obes Res. 1995 Sep;3(5):435–46.  
30.  Kannel WB, Gordon T, Castelli WP. Obesity, lipids, and glucose intolerance. The 
Framingham Study. Am J Clin Nutr. 1979 Jun;32(6):1238–45.  
31.  Fogelholm M, Kujala U, Kaprio J, Sarna S. Predictors of Weight Change in Middle-
aged and Old Men. Obes Res. 2000 Aug;8(5):367–73.  
32.  Gallus S, Lugo A, Murisic B, Bosetti C, Boffetta P, La Vecchia C. Overweight and 
obesity in 16 European countries. Eur J Nutr. 2015 Aug 5;54(5):679–89.  
33.  Sundhedsstyrelsen, Statens Institut for Folkesundhed. Den Nationale 
Sundhedsprofil. 2013.  
34.  Kennedy RL, Chokkalingham K, Srinivasan R. Obesity in the elderly: who should we 
be treating, and why, and how? Curr Opin Clin Nutr Metab Care. 2004;7(1):3–9.  
35.  Zamboni M, Mazzali G, Zoico E, Harris TB, Meigs JB, Di Francesco V, et al. Health 
consequences of obesity in the elderly: a review of four unresolved questions. Int J 
Obes (Lond). 2005 Sep;29(9):1011–29.  
36.  Villareal DT, Apovian CM, Kushner RF, Klein S. Obesity in Older Adults: Technical 
Review and Position Statement of the American Society for Nutrition and NAASO, 
The Obesity Society. Obes Res. 2005 Nov;13(11):1849–63.  
37.  Enzi G, Gasparo M, Biondetti PR, Fiore D, Semisa M, Zurlo F. Subcutaneous and 
visceral fat distribution according to sex, age, and overweight, evaluated by computed 
tomography. Am J Clin Nutr. 1986 Dec;44(6):739–46.  
38.  Zamboni M, Armellini F, Milani MP, De Marchi M, Todesco T, Robbi R, et al. Body 
fat distribution in pre- and post-menopausal women: metabolic and anthropometric 
variables and their inter-relationships. Int J Obes Relat Metab Disord. 1992 
Jul;16(7):495–504.  
94 
39.  Zamboni M, Armellini F, Harris T, Turcato E, Micciolo R, Bergamo-Andreis IA, et al. 
Effects of age on body fat distribution and cardiovascular risk factors in women. Am 
J Clin Nutr. 1997 Jul;66(1):111–5.  
40.  Schrager MA, Metter EJ, Simonsick E, Ble A, Bandinelli S, Lauretani F, et al. 
Sarcopenic obesity and inflammation in the InCHIANTI study. J Appl Physiol. 
2007;102(3):919–25.  
41.  Florez H, Troen BR. Fat and inflammaging: a dual path to unfitness in elderly people? 
J Am Geriatr Soc. 2008 Mar;56(3):558–60.  
42.  Zamboni M, Mazzali G, Fantin F, Rossi A, Di Francesco V. Sarcopenic obesity: A new 
category of obesity in the elderly. Nutr Metab Cardiovasc Dis. 2008;18(5):388–95.  
43.  Prado CMM, Wells JCK, Smith SR, Stephan BCM, Siervo M. Sarcopenic obesity: A 
Critical appraisal of the current evidence. Clin Nutr. 2012;31(5):583–601.  
44.  Stenholm S, Harris TB, Rantanen T, Visser M, Kritchevsky SB, Ferrucci L. Sarcopenic 
obesity -definition, etiology and consequences.  
45.  Krabbe KS, Pedersen M, Bruunsgaard H. Inflammatory mediators in the elderly. Exp 
Gerontol. 2004;39(5):687–99.  
46.  Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest. 2005 
May;115(5):1111–9.  
47.  Scherer PE. Adipose Tissue: from lipid storage compartment to endocrine organ. 
Diabetes. 2006;55(6).  
48.  Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 
2006 Jul;116(7):1793–801.  
49.  Kern PA, Di Gregorio GB, Lu T, Rassouli N, Ranganathan G. Adiponectin expression 
from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis 
factor-alpha expression. Diabetes. 2003 Jul;52(7):1779–85.  
50.  Greenberg AS, McDaniel ML. Identifying the links between obesity, insulin resistance 
and beta-cell function: potential role of adipocyte-derived cytokines in the 
pathogenesis of type 2 diabetes. Eur J Clin Invest. 2002 Jun;32 Suppl 3:24–34.  
51.  Matsuzawa Y, Funahashi T, Kihara S, Shimomura I. Adiponectin and metabolic 
syndrome. Arterioscler Thromb Vasc Biol. 2004 Jan;24(1):29–33.  
52.  Ridker PM. Inflammatory Biomarkers and Risks of Myocardial Infarction, Stroke, 
95 
Diabetes, and Total Mortality: Implications for Longevity. Nutr Rev. 2007;65(suppl 
3).  
53.  Fain JN, Madan AK, Hiler ML, Cheema P, Bahouth SW. Comparison of the release of 
adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and 
subcutaneous abdominal adipose tissues of obese humans. Endocrinology. 2004 
May;145(5):2273–82.  
54.  Radzuik J, Pye S. The Role of the Liver in Insulin Action and Resistance. In: Reaven 
GM, Laws A, editors. Insulin Resistance, The Metabolic Syndrome X. Totowa: 
Humana Press Inc.; 1999. p. 197–231.  
55.  Reaven GM. The Pathophysiological Consequences of Adipose Tissue Insulin 
Resistance. In: Reaven GM, Laws A, editors. Insulin Resistance, The Metabolic 
Syndrome X. Totowa: Humana Press Inc.; 1999. p. 233–63.  
56.  Kahn SE, Prigeon RL, McCulloch DK, Boyko EJ, Bergman RN, Schwartz MW, et al. 
Quantification of the relationship between insulin sensitivity and beta-cell function 
in human subjects. Evidence for a hyperbolic function. Diabetes. 1993 
Nov;42(11):1663–72.  
57.  Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin 
resistance and type 2 diabetes. Nature. 2006 Dec 14;444(7121):840–6.  
58.  Reaven GM, Hollenbeck C, Jeng C-Y, Wu MS, Chen Y-DI. Measurement of Plasma 
Glucose, Free Fatty Acid, Lactate, and Insulin for 24 h in Patients With NIDDM. 
Diabetes. 1988;37(8).  
59.  Boden G. Role of Fatty Acids in the Pathogenesis of Insulin Resistance and NIDDM. 
Diabetes. 1997;46(1).  
60.  Boden G, Shulman GI. Free fatty acids in obesity and type 2 diabetes: defining their 
role in the development of insulin resistance and beta-cell dysfunction. Eur J Clin 
Invest. 2002 Jun;32(s3):14–23.  
61.  Friedman J. Fat in all the wrong places. Nature. 2002 Jan 17;415(6869):268–9.  
62.  Unger RH. Lipid overload and overflow: metabolic trauma and the metabolic 
syndrome. Trends Endocrinol Metab. 2003;14(9):398–403.  
63.  DeFronzo RA. Glucose Intolerance and Aging: Evidence for Tissue Insensitivity to 
Insulin. Diabetes. 1979;28(12).  
96 
64.  Kim J, Wei Y, Sowers JR. Role of Mitochondrial Dysfunction in Insulin Resistance. 
Circ Res. 2008;102(4).  
65.  Petersen KF, Befroy D, Dufour S, Dziura J, Ariyan C, Rothman DL, et al. 
Mitochondrial Dysfunction in the Elderly: Possible Role in Insulin Resistance. Science 
(80- ). 2003;300(5622).  
66.  Hanson RL, Imperatore G, Bennett PH, Knowler WC. Components of the ‘Metabolic 
Syndrome’ and Incidence of Type 2 Diabetes. Diabetes. 2002;51(10):3120–7.  
67.  Polonsky KS, Given BD, Van Cauter E. Twenty-four-hour profiles and pulsatile 
patterns of insulin secretion in normal and obese subjects. J Clin Invest. 1988 
Feb;81(2):442–8.  
68.  Kahn SE. The Importance of β-Cell Failure in the Development and Progression of 
Type 2 Diabetes. J Clin Endocrinol Metab. 2001 Sep;86(9):4047–58.  
69.  Reaven GM. Compensatory hyperinsulinemia and the development of an atherogenic 
lipoprotein profile: the price paid to maintain glucose homeostasis in insulin-
resistant individuals. Endocrinol Metab Clin North Am. 2005 Mar;34(1):49–62.  
70.  Nathan DM, Davidson MB, DeFronzo RA, Heine RJ, Henry RR, Pratley R, et al. 
Impaired Fasting Glucose and Impaired Glucose Tolerance. Diabetes Care. 
2007;30(3).  
71.  WHO. Expert Committee on Diabetes Mellitus. Second Report. Technical Report 
Series 646. Geneva; 1980.  
72.  WHO. Definition, diagnosis and classification of diabetes mellitus and its 
complications. Report of a WHO consultation. Geneva; 1999.  
73.  The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. 
Report of the Expert Committee on the Diagnosis and Classification of Diabetes 
Mellitus. Diabetes Care. 1997;20(7).  
74.  American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. 
Diabetes Care. 2004;27(Supplement 1):S5–10.  
75.  Abdul-Ghani MA, Jenkinson CP, Richardson DK, Tripathy D, DeFronzo RA. Insulin 
secretion and action in subjects with impaired fasting glucose and impaired glucose 
tolerance: results from the Veterans Administration Genetic Epidemiology Study. 
Diabetes. 2006 May;55(5):1430–5.  
97 
76.  Abdul-Ghani MA, Tripathy D, DeFronzo RA. Contributions of beta-cell dysfunction 
and insulin resistance to the pathogenesis of impaired glucose tolerance and 
impaired fasting glucose. Diabetes Care. 2006 May;29(5):1130–9.  
77.  Hanefeld M, Koehler C, Fuecker K, Henkel E, Schaper F, Temelkova-Kurktschiev T, 
et al. Insulin secretion and insulin sensitivity pattern is different in isolated impaired 
glucose tolerance and impaired fasting glucose: the risk factor in Impaired Glucose 
Tolerance for Atherosclerosis and Diabetes study. Diabetes Care. 2003 
Mar;26(3):868–74.  
78.  Festa A, D’Agostino R, Hanley AJG, Karter AJ, Saad MF, Haffner SM. Differences in 
insulin resistance in nondiabetic subjects with isolated impaired glucose tolerance or 
isolated impaired fasting glucose. Diabetes. 2004 Jun;53(6):1549–55.  
79.  Tabák AG, Herder C, Rathmann W, Brunner EJ, Kivimäki M. Prediabetes: a high-risk 
state for diabetes development. Lancet. 2012 Jun 16;379(9833):2279–90.  
80.  Santaguida P, Balion C, Hunt D, Morrison K, Gerstein H, Raina P, et al. Diagnosis, 
Prognosis, and Treatment of Impaired Glucose Tolerance and Impaired Fasting 
Glucose: Summary. 2005;  
81.  Larsson H, Lindgärde F, Berglund G, Ahrén B. Prediction of diabetes using ADA or 
WHO criteria in post-menopausal women: a 10-year follow-up study. Diabetologia. 
2000 Oct 2;43(10):1224–8.  
82.  Levitan EB, Song Y, Ford ES, Liu S, R C, S A, et al. Is nondiabetic hyperglycemia a risk 
factor for cardiovascular disease? A meta-analysis of prospective studies. Arch Intern 
Med. 2004 Oct 25;164(19):2147–55.  
83.  Meigs JB, Nathan DM, D’Agostino RB, Wilson PWF. Fasting and Postchallenge 
Glycemia and Cardiovascular Disease Risk. Diabetes Care. 2002;25(10).  
84.  Anderson EA, Mark AL. The vasodilator action of insulin. Implications for the insulin 
hypothesis of hypertension. Hypertension. 1993;21(2).  
85.  Tooke JE, Hannemann MM. Adverse endothelial function and the insulin resistance 
syndrome. J Intern Med. 2000 Apr;247(4):425–31.  
86.  Goff DC, Zaccaro DJ, Haffner SM, Saad MF. Insulin Sensitivity and the Risk of 
Incident Hypertension. Diabetes Care. 2003;26(3).  
87.  Salonen JT, Lakka TA, Lakka H-M, Valkonen V-P, Everson SA, Kaplan GA. 
98 
Hyperinsulinemia Is Associated With the Incidence of Hypertension and 
Dyslipidemia in Middle-Aged Men. Diabetes. 1998;47(2).  
88.  Vaccaro O, Imperatore G, Iovino V, Iovine C, Rivellese AA, Riccardi G. Does impaired 
glucose tolerance predict hypertension? Diabetologia. 39(1):70–6.  
89.  Modan M, Halkin H, Almog S, Lusky A, Eshkol A, Shefi M, et al. Hyperinsulinemia. 
A link between hypertension obesity and glucose intolerance. J Clin Invest. 1985 
Mar;75(3):809–17.  
90.  Wassink AMJ, Olijhoek JK, Visseren FLJ. The metabolic syndrome: metabolic changes 
with vascular consequences. Eur J Clin Invest. 2007 Jan;37(1):8–17.  
91.  Kannel WB. Role of blood pressure in cardiovascular disease: the Framingham Study. 
Angiology. 1975;26(1):1–14.  
92.  Andersson OK, Almgren T, Persson B, Samuelsson O, Hedner T, Wilhelmsen L. 
Survival in treated hypertension: follow up study after two decades. BMJ. 
1998;317(7152).  
93.  Murakami T, Michelagnoli S, Longhi R, Gianfranceschi G, Pazzucconi F, Calabresi L, 
et al. Triglycerides are major determinants of cholesterol esterification/transfer and 
HDL remodeling in human plasma. Arterioscler Thromb Vasc Biol. 1995 
Nov;15(11):1819–28.  
94.  Ginsberg HN. Diabetic dyslipidemia: basic mechanisms underlying the common 
hypertriglyceridemia and low HDL cholesterol levels. Diabetes. 1996 Jul;45 Suppl 
3:S27-30.  
95.  Shanmugasundaram M, Rough SJ, Alpert JS. Dyslipidemia in the Elderly: Should it Be 
Treated? Clin Cardiol. 2010 Jan;33(1):4–9.  
96.  Gobal FA, Mehta JL. Management of dyslipidemia in the elderly population. Ther Adv 
Cardiovasc Dis. 2010 Dec;4(6):375–83.  
97.  Reaven GM. Banting Lecture 1988. Role of Insulin Resistance in Human Disease. 
Diabetes. 1988 Dec 1;37(12):1595–607.  
98.  Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus 
and its complications. Part 1: diagnosis and classification of diabetes mellitus 
provisional report of a WHO consultation. Diabet Med. 1998 Jul;15(7):539–53.  
99.  Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. 
99 
Homeostasis model assessment: insulin resistance and beta-cell function from fasting 
plasma glucose and insulin concentrations in man. Diabetologia. 1985 Jul;28(7):412–
9.  
100.  Balkau B, Charles MA. Comment on the provisional report from the WHO 
consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet 
Med. 1999 May;16(5):442–3.  
101.  Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on 
Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult 
Treatment Panel III) final report. Circulation. 2002 Dec 17;106(25):3143–421.  
102.  International Diabetes Federation. The IDF consensus worldwide definition of the 
Metabolic Syndrome. 2005.  
103.  Ford ES, Giles WH, Dietz WH. Prevalence of the Metabolic Syndrome Among US 
Adults. JAMA. 2002 Jan 16;287(3):356.  
104.  Balkau B, Charles M-A, Drivsholm T, Borch-Johnsen K, Wareham N, Yudkin JS, et al. 
Frequency of the WHO metabolic syndrome in European cohorts, and an alternative 
definition of an insulin resistance syndrome. Diabetes Metab. 2002 Nov;28(5):364–
76.  
105.  Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated 
with the metabolic syndrome: A summary of the evidence. Diabetes Care. 
2005;28(7):1769–78.  
106.  Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, et al. National, 
regional, and global trends in fasting plasma glucose and diabetes prevalence since 
1980: systematic analysis of health examination surveys and epidemiological studies 
with 370 country-years and 2·7 million participants. Lancet. 2011;378(9785):31–40.  
107.  International Diabetes Federation. IDF Diabetes Atlas 2015. 2015. 1-144 p.  
108.  Beagley J, Guariguata L, Weil C, Motala AA. Global estimates of undiagnosed diabetes 
in adults. Diabetes Res Clin Pract. 2014;103(2):150–60.  
109.  Whiting DR, Guariguata L, Weil C, Shaw J. IDF Diabetes Atlas: Global estimates of 
the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 2011;94(3):311–
21.  
110.  Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 
100 
2010 and 2030. Diabetes Res Clin Pract. 2010;87(1):4–14.  
111.  Zimmet P, Alberti KGMM, Shaw J. Global and societal implications of the diabetes 
epidemic. Nature. 2001 Dec 13;414(6865):782–7.  
112.  Nolan CJ, Damm P, Prentki M. Type 2 diabetes across generations: from 
pathophysiology to prevention and management. Lancet (London, England). 2011 Jul 
9;378(9786):169–81.  
113.  Diabetesforeningen. Diabetes i Danmark. 2016. Available from: www.diabetes.dk 
114.  Vazquez G, Duval S, Jacobs DR, Silventoinen K. Comparison of body mass index, 
waist circumference, and waist/hip ratio in predicting incident diabetes: a meta-
analysis. Epidemiol Rev. 2007;29(1):115–28.  
115.  Zimmet P, Alberti G, Shaw J. A new IDF worldwide definition of the metabolic 
syndrome: the rationale and the results. Diabetes Voice. 2005;50(3):31–3.  
116.  Lim EL, Hollingsworth KG, Aribisala BS, Chen MJ, Mathers JC, Taylor R. Reversal of 
type 2 diabetes: normalisation of beta cell function in association with decreased 
pancreas and liver triacylglycerol. Diabetologia. 2011 Oct;54(10):2506–14.  
117.  Wilson PWF. Obesity, diabetes, and risk of cardiovascular disease in the elderly. Am 
J Geriatr Cardiol. 2002;11(2).  
118.  Statens Serum Institut. Tal på diabetes 1996-2012. 2013. Available from: 
www.diabetes.dk 
119.  Det Nationale Diabetesregister. Antal diabetikere (prævalens), 1996 – 2012. 2012.  
120.  Green A, Emneus M, Christiansen T, Björk S, Kristensen JK. The societal impact of 
Diabetes mellitus and diabetes care. Report 3: Type 2 diabetes in Denmark year 2001. 
2006.  
121.  Kirkman MS, Briscoe VJ, Clark N, Florez H, Haas LB, Halter JB, et al. Diabetes in older 
adults. Diabetes Care. 2012 Dec 1;35(12):2650–64.  
122.  Davies MJ, Thomas AC. Plaque fissuring - the cause of acute myocardial infarction, 
sudden ischaemic death, and crescendo angina. Br Heart J. 1985 Apr;53(4):363–73.  
123.  Epstein FH, Fuster V, Badimon L, Badimon JJ, Chesebro JH. The Pathogenesis of 
Coronary Artery Disease and the Acute Coronary Syndromes (1). N Engl J Med. 1992 
Jan 23;326(4):242–50.  
101 
124.  Madsen M, Abildstrøm S, Rasmussen S. Folkesundhedsrapporten. In: Hjerte-kar-
sygdom. 2007. p. 73–88.  
125.  Castelli WP. Epidemiology of coronary heart disease: The Framingham study. Am J 
Med. 1984;76(2):4–12.  
126.  Hansen D, Rasmussen N, Munck A. Folkesygdomme i almen praksis. Forekomst og 
forebyggelsesperspek- tiver vurderet i forbindelse med en auditregistrering. Audit 
Projekt Odense, Forskningsenheden for Almen Praksis i Odense, Syddansk 
Universitet. Statens Institut for folkesundhed. 2005.  
127.  Brüünsgaard H, Pedersen BK. Age-related inflammatory cytokines and disease. 
Immunol Allergy Clin North Am. 2003 Feb;23(1):15–39.  
128.  Robins SP. Biochemistry and functional significance of collagen cross-linking. 
Biochem Soc Trans. 2007;35(5).  
129.  Frantz C, Stewart KM, Weaver VM. The extracellular matrix at a glance. J Cell Sci. 
2010;123(24).  
130.  Calleja-Agius J, Muscat-Baron Y, Brincat MP. Skin ageing. Menopause Int. 2007 
Jun;13(2):60–4.  
131.  Freund A, Orjalo A V, Desprez P-Y, Campisi J. Inflammatory networks during cellular 
senescence: causes and consequences. Trends Mol Med. 2010 May;16(5):238–46.  
132.  Sprenger CC, Plymate SR, Reed MJ. Extracellular influences on tumour angiogenesis 
in the aged host. Br J Cancer. 2008 Jan 29;98(2):250–5.  
133.  Wynn TA, Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA, et al. Common 
and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin 
Invest. 2007 Mar 1;117(3):524–9.  
134.  Wynn TA, Barron L. Macrophages: master regulators of inflammation and fibrosis. 
Semin Liver Dis. 2010 Aug;30(3):245–57.  
135.  Wynn T. Cellular and molecular mechanisms of fibrosis. J Pathol. 2008 Jan;214(2):199–
210.  
136.  Pinzani M. Welcome to fibrogenesis & tissue repair. Fibrogenesis Tissue Repair. 
2008;1(1):1.  
137.  Theocharis AD, Skandalis SS, Gialeli C, Karamanos NK. Extracellular matrix 
structure. Adv Drug Deliv Rev. 2016;97:4–27.  
102 
138.  Karsdal MA, Nielsen MJ, Sand JM, Henriksen K, Genovese F, Bay-Jensen A-C, et al. 
Extracellular Matrix Remodeling: The Common Denominator in Connective Tissue 
Diseases. Possibilities for evaluation and current understanding of the matrix as more 
than a passive structure, but a key player in tissue failure. Assay Drug Dev Technol. 
2013 Mar;11(2):70–92.  
139.  Ricard-Blum S. The Collagen Family. Cold Spring Harb Perspect Biol. 2011 Jan 
1;3(1):a004978–a004978.  
140.  Karsdal MA, Leeming DJ, Henriksen K, Bay-Jensen A-C. Type I Collagen. In: 
Biochemistry of Collagens, Laminins and Elastin - Structure, Function and 
Biomarkers. First edit. London: Academic Press; 2016. p. 1–11.  
141.  Niyibizi C, Eyre DR. Structural Characteristics of Cross-Linking Sites in type V 
Collagen of Bone. Chain Specificities and Heterotypic Links to Type I Collagen. Eur J 
Biochem. 1994 Sep;224(3):943–50.  
142.  Henriksen K, Leeming D, Christiansen C, Karsdal M. Use of bone turnover markers 
in clinical osteoporosis assessment in women: current issues and future options. 
Women’s Heal. 2011 Nov;7(6):689–98.  
143.  Vasikaran S, Eastell R, Bruyère O, Foldes AJ, Garnero P, Griesmacher A, et al. Markers 
of bone turnover for the prediction of fracture risk and monitoring of osteoporosis 
treatment: a need for international reference standards. Osteoporos Int. 2011 Feb 
24;22(2):391–420.  
144.  Leeming D, He Y, Veidal S, Nguyen Q, Larsen D, Koizumi M, et al. A novel marker 
for assessment of liver matrix remodeling: An enzyme-linked immunosorbent assay 
(ELISA) detecting a MMP generated type I collagen neo-epitope (C1M). Biomarkers. 
2011 Oct 25;  
145.  Leeming DJ, Sand JM, Nielsen MJ, Genovese F, Martinez FJ, Hogaboam CM, et al. 
Serological investigation of the collagen degradation profile of patients with chronic 
obstructive pulmonary disease or idiopathic pulmonary fibrosis. Biomark Insights. 
2012;7:119–26.  
146.  Siebuhr AS, Petersen KK, Arendt-Nielsen L, Egsgaard LL, Eskehave T, Christiansen C, 
et al. Identification and characterisation of osteoarthritis patients with inflammation 
derived tissue turnover. Osteoarthr Cartil. 2014;22(1):44–50.  
147.  Jenkins RG, Simpson JK, Saini G, Bentley JH, Russell A-M, Braybrooke R, et al. 
103 
Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary 
fibrosis: an analysis from the prospective, multicentre PROFILE study. Lancet Respir 
Med. 2015;3(6):462–72.  
148.  Siebuhr A, Bay-Jensen ACA, Leeming DDJ, Plat A, Byrjalsen I, Christiansen C, et al. 
Serological identification of fast progressors of structural damage with rheumatoid 
arthritis. Arthritis Res Ther. 2013;15(4):R86.  
149.  Stanziano DC, Whitehurst M, Graham P, Roos BA. A review of selected longitudinal 
studies on aging: past findings and future directions. J Am Geriatr Soc. 2010 Oct;58 
Suppl 2(Suppl 2):S292-7.  
150.  Santoro N, Sutton-Tyrrell K, Sutton-Tyrrell K. The SWAN song: Study of Women’s 
Health Across the Nation’s recurring themes. Obstet Gynecol Clin North Am. 2011 
Sep;38(3):417–23.  
151.  Lee C, Dobson AJ, Brown WJ, Bryson L, Byles J, Warner-Smith P, et al. Cohort Profile: 
the Australian Longitudinal Study on Women’s Health. Int J Epidemiol. 2005 
Oct;34(5):987–91.  
152.  Karsdal MA, Leeming DJ, Henriksen K, Bay-Jensen A-C. Biochemistry of Collagens, 
Laminins and Elastin. London: Academic Press; 2016. 1-278 p.  
153.  Dragsbæk K, Neergaard JS, Hansen HB, Byrjalsen I, Alexandersen P, Kehlet SN, et al. 
Matrix Metalloproteinase Mediated Type I Collagen Degradation - An Independent 
Risk Factor for Mortality in Women. EBioMedicine. 2015 Jul;2(7):723–9.  
154.  Siebuhr A, Bay-Jensen AC, Leeming DJ, Plat A, Byrjalsen I, Christiansen C, et al. 
Serological identification of fast progressors of structural damage with rheumatoid 
arthritis. Arthritis Res Ther. 2013;15(4):R86.  
155.  Sarkar D, Fisher PB, Harman D, Riley PA, Farber JL, Kyle ME, et al. Molecular 
mechanisms of aging-associated inflammation. Cancer Lett. 2006 May 8;236(1):13–23.  
156.  Johnson LW, Weinstock RS. The metabolic syndrome: concepts and controversy. 
Mayo Clin Proc. 2006;81(12):1615–20.  
157.  Stern MP, Williams K, González-Villalpando C, Hunt KJ, Haffner SM. Does the 
metabolic syndrome improve identification of individuals at risk of type 2 diabetes 
and/or cardiovascular disease? Diabetes Care. 2004;27(11):2676–81.  
158.  Sundström J, Risérus U, Byberg L, Zethelius B, Lithell H, Lind L. Clinical value of the 
104 
metabolic syndrome for long term prediction of total and cardiovascular mortality: 
prospective, population based cohort study. BMJ. 2006 Apr 15;332(7546):878–82.  
159.  Reaven GM. The metabolic syndrome or the insulin resistance syndrome? Different 
names, different concepts, and different goals. Endocrinol Metab Clin North Am. 
2004;33(2):283–303.  
160.  Meigs JB, Wilson PWF, Fox CS, Vasan RS, Nathan DM, Sullivan LM, et al. Body mass 
index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J 
Clin Endocrinol Metab. 2006 Aug;91(8):2906–12.  
161.  Arnlöv J, Sundström J, Ingelsson E, Lind L. Impact of BMI and the metabolic 
syndrome on the risk of diabetes in middle-aged men. Diabetes Care. 2011 
Jan;34(1):61–5.  
162.  Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, et al. Metabolic 
syndrome and risk of incident cardiovascular events and death: a systematic review 
and meta-analysis of longitudinal studies. J Am Coll Cardiol. 2007 Jan 30;49(4):403–
14.  
163.  Ford ES, Li C, Sattar N. Metabolic syndrome and incident diabetes: current state of 
the evidence. Diabetes Care. 2008 Sep;31(9):1898–904.  
164.  Cameron AJ, Zimmet PZ, Soderberg S, Alberti KGMM, Sicree R, Tuomilehto J, et al. 
The metabolic syndrome as a predictor of incident diabetes mellitus in Mauritius. 
Diabet Med. 2007 Dec;24(12):1460–9.  
165.  Cameron AJ, Magliano DJ, Zimmet PZ, Welborn TA, Colagiuri S, Tonkin AM, et al. 
The metabolic syndrome as a tool for predicting future diabetes: the AusDiab study. 
J Intern Med. 2008 Aug;264(2):177–86.  
166.  Stern MP, Williams K, Haffner SM. Identification of persons at high risk for type 2 
diabetes mellitus: do we need the oral glucose tolerance test? Ann Intern Med. 2002 
Apr 16;136(8):575–81.  
167.  Wijndaele K, Beunen G, Duvigneaud N, Matton L, Duquet W, Thomis M, et al. A 
Continuous Metabolic Syndrome Risk Score. Diabetes Care. 2006;29(10).  
168.  Motta M, Bennati E, Cardillo E, Passamonte M, Ferlito L, Malaguarnera M. The 
metabolic syndrome (MS) in the elderly: Considerations on the diagnostic criteria of 
the International Diabetes Federation (IDF) and some proposed modifications. Arch 
Gerontol Geriatr. 2009;48(3):380–4.  
105 
169.  Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 
European Guidelines on cardiovascular disease prevention in clinical practice. Eur 
Heart J. 2016;  
170.  Chapman IM. Obesity Paradox during Aging. In: Body Composition and Aging. Basel: 
Kager; 2010. p. 20–36.  
171.  Heiat A, Vaccarino V, Krumholz HM, KM F, WC W, M T, et al. An evidence-based 
assessment of federal guidelines for overweight and obesity as they apply to elderly 
persons. Arch Intern Med. 2001 May 14;161(9):1194–203.  
172.  Harrington M, Gibson S, Cottrell RC. A review and meta-analysis of the effect of 
weight loss on all-cause mortality risk. Nutr Res Rev. 2009 Jun;22(1):93–108.  
173.  Fine JT, Colditz GA, Coakley EH, Moseley G, Manson JE, Willett WC, et al. A 
Prospective Study of Weight Change and Health-Related Quality of Life in Women. 
JAMA. 1999 Dec 8;282(22):2136.  
174.  Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to 
the pathophysiology of Type 2 diabetes. Diabetologia. 2003 Jan;46(1):3–19.  
175.  Alexander CM, Landsman PB, Grundy SM. The influence of age and body mass index 
on the metabolic syndrome and its components. Diabetes Obes Metab. 2008 
Mar;10(3):246–50.  
176.  Ruderman N, Chisholm D, Pi-Sunyer X, Schneider S. The metabolically obese, 
normal-weight individual revisited. Diabetes. 1998 May;47(5):699–713.  
177.  Qiao Q, Jousilahti P, Eriksson J, Tuomilehto J. Predictive Properties of Impaired 
Glucose Tolerance for Cardiovascular Risk Are Not Explained by the Development of 
Overt Diabetes During Follow-Up. Diabetes Care. 2003;26(10).  
178.  Glümer C, Jørgensen T, Borch-Johnsen K. Prevalences of Diabetes and Impaired 
Glucose Regulation in a Danish Population. Diabetes Care. 2003;26(8).  
179.  Green A, Sortsø C, Jensen PB, Emneus M. Validation of the danish national diabetes 
register. Clin Epidemiol. 2015 Jan;7:5–15.  
180.  Sun K, Park J, Gupta OT, Holland WL, Auerbach P, Zhang N, et al. Endotrophin 
triggers adipose tissue fibrosis and metabolic dysfunction. Nat Commun. 2014 Mar 
19;5:2094–101.  
181.  Goodwin N, Sonola L, Thiel V. Co-ordinated care for people with complex chronic 
106 
conditions. Key lessons and markers for success. London; 2013.  
182.  Oliver D, Foot C, Humphries R. Making our health and care systems fit for an ageing 
population. London; 2014.  
183.  Smith SM, Soubhi H, Fortin M, Hudon C, O’Dowd T. Managing patients with 
multimorbidity: systematic review of interventions in primary care and community 
settings. BMJ. 2012;345.  
184.  Chatterji S, Byles J, Cutler D, Seeman T, Verdes E. Health, functioning, and disability 
in older adults--present status and future implications. Lancet (London, England). 
2015 Feb 7;385(9967):563–75.  
185. Guralnik, Jack M., et al., eds. The Women's Health and Aging Study: health and social 
characteristics of older women with disability. DIANE Publishing, 1995. 
186. Colditz, GA, Manson, JE, Hankingson, SE. The Nurses' Health Study: 20-Year 
Contribution to the Understanding of Health Among Women. Journal of Women's 
Health. 2009 Apr 6(1): 49-62. 
187. Riis, B. J., K. Overgaard, and C. Christiansen. "Biochemical markers of bone turnover 
to monitor the bone response to postmenopausal hormone replacement therapy." 
Osteoporosis international 1995 5(4): 276-280. 
188. Henriksen, K., Tanko, L. B., Qvist, P., Delmas, P. D., Christiansen, C., Karsdal, M. A. 
Assessment of osteoclast number and function: application in the development of 
new and improved treatment modalities for bone diseases. Osteoporosis 
international, 2007 18(5), 681-685. 
189. Shimokata, H., Muller, D.C., Fleg, J.L., Sorkin, J., Ziemba, A.W., Andres, R., Age as 
independent determinant of glucose tolerance. Diabetes 1991 40, 44–51. 
190. Koda, M., Ando, F., Shimokata, H., Kuzuya, F., 1998. The effects of aging on the 
relationship between changes in body weight, serum lipid levels, and blood pressure. 
Nippon Ronen Igakkai Zasshi 35, 631–636. 
191. Stevic, R., Beljic Zivkovic, T., Erceg, P., Milosevic, D., Despotovic, N., Davidovic, M. 
Oral glucose tolerance test in the assessment of glucose-tolerance in the elderly 
people. Age Ageing 2007 36, 459–462. 
192. Di Bari, M., Lambertucci, L., Pozzi, C., Virgillo, A., Ungar, A., Casotti, G., Marchionni, 
N. Epidemiologic aspects of hypertension in old age. G. Gerontol. 2004 52, 331– 337 
